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AICAR 5-aminoimidazole-4-carboxamide ribonucleoside 
AMBA 2-Amino-3-methylaminobutanoic acid 
ADP adenosine diphosphate 
AMP adenosine monophosphate 
ATP adenosine triphosphate 
BB building block 
BDV borna disease virus 





CC column chromatography 
CF continuous flow 
d doublet 
de diastereomeric excess 




DMP Dess–Martin periodinane 
DMSO dimethyl sulfoxide 
DSC differential scanning calorimetry 
EA ethyl acetate 
ee enantiomeric excess 
EI electron impact 
EICAR 5-ethynylimidazole-4-carboxamide ribonucleoside 
ED50 median effective dose   
equiv. equivalents 
FICAR 5-fluoro imidazole-4-carboxamide ribonucleoside 
FPV influenza virus A  
GC gas chromatography 
GMP guanosine monophosphate 
GTP guanosine triphosphate 
HbHNL Hevea Brasiliensis Hydroxy nitrile lyase 
HBV hepatitis B virus 
HIV human immunodeficiency virus 
HCV hepatitis C virus 
HCN hydrocyanic acid 
HMCV human cytomegalovirus 
HMDS hexamethyldisilazane 
HMPA hexamethylphosphoric acid 
HNL Hydroxynitrile lyase 
HPLC high-performance liquid chromatography 
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HRMS high-resolution mass spectra 
HSV herpes simplex virus 
HWE/aza-DA 4CR Horner-Wadsworth-Emmons/aza-Diels Alder four component reaction 
IC50 concentration at which cell growth is inhibited 50 %   
IMP inosine monophosphate 
IMPDH inosine monophosphate dehydrogenase 
IPCAR methyl-iodo-1-β-D-ribofuranosylpyrazole-3-carboxylate 
IPdR 5-Iodo-pyrimidin-2-one 2’-deoxyribose 
IPN infectious pancreatic necrosis 
IR infrared 
KU kilo unit 
LD50 concentration at which lethality is 50 % 
m medium 
MCR multi component reaction 
MIC minimal inhitory concentration 
MRD mureidomycin 
MS mass spectrum 
MTBE methyl t-butyl ether 
MVV maedi-visna virus 
MW microwave 
NAD nicotinamide adenine dinucleotide 
NaOCl sodium hypochlorite 
NDV newcastle disease virus  
NMP N-methyl-2-pyrrolidone 
NMR nuclear magnetic resonance 
PaHNL Prunus amygdalus Hydroxy nitrile lyase 
PCC pyridinium chlorochromate 
PDC pyridinium dichromate 
PE petroleum ether 
PG protecting group 
PsRV pseudorabies virus 
Rf retardation factor 
RVF rift valley fever 
RSV respiratory syncital virus 
Rt retention time 
s singlet/strong 
SAR structure-activity relationship 
spp species 
SVR sustained viral response 
t triplet 
TBS tert-butyldimethyl silyl 
TEMPO tetramethylpiperidinyloxy free radical 
THF tetrahydrofuran 




UDP uridine 5’-diphosphate 
UPA uridylpeptide antibiotic 
VEE venezuelan equine encephalitis 
VV vaccinia virus 
w weak 
YFV yellow fever virus 
ZMP AICAribotide 
5-AZA-CdR 5-aza-2’-deoxycytidine 
4CR four-component reaction 
3-DC 3-deazacytidine 






















Over the last twenty years the incidence of life-threatening infections has increased while the number of immuno 
compromised persons has also increased. As a consequence the resistance of bacterial strains to current antibiotics 
like penicillins and vancomycin has become a major clinical threat. In the late eighties a family of antibiotics, the 
mureidomycins, has been discovered which act as antibacterial agent via inhibition of MraY, an essential enzyme 
in the peptidoglycan synthesis of bacteria. The mureidomycins have been investigated, but a clear inhibition 
mechanism has not been found. In this chapter a short summary will be given of what is known about the 




Some seventy-five years ago antibiotics became available. When first discovered, 
antibiotics were thought to provide a miracle cure, and they literally were. Infections that 
were fatal before 1900 were tamed to mere inconveniences during the 20th century. 
However, the misuse, overprescription and abuse of antibiotics has allowed resistant strains 
of bacteria to develop and they once again threaten health and life.1 The first example of 
resistance to an antibiotic was observed in the early 1940s. Right after the introduction of 
penicillin, it was found that the Minimal Inhitory concentrations (MICs) for Staphylococcus 
aureus, which can cause severe food poisoning, increased.2 In the period of the 1980s and 
1990s very potent broad-spectrum antibacterials were introduced. However, this led to 
concomitant increase in antibiotic resistance.3 The resistance of bacteria, fungi and yeasts 
against antibiotics can be described with three types of mechanisms: 4  
a) Drug modification or inactivation 
b) Target modification 
c) Modified Cellular Uptake 
The development of resistance against antibiotics is a cause of serious concern and the 
search for new antibacterial agents is a hot topic. The problem adherent to this is that these 
new antibiotic agents will show also resistance leading to the question: when does the next 
generation of resistance factor emerge after new antibacterial agents have been introduced? 
1.2  Targets for antibacterial drugs 
Almost all of the major antibiotics act against three primary processes in the pathogenic 
bacteria: protein biosynthesis, DNA replication and repair, and cell-wall biosynthesis 
(Figure 1.1).5-7 Protein biosynthesis offers many steps where antibiotics could disrupt the 
machinery; examples of these antibiotics are macrolides, tetracyclines, aminoglycosides 
and oxazolidinones.5 The only class of antibiotics in current use that blocks DNA 
replication and repair are the fluoroquinolones that exert their action by blocking the 
enzyme DNA gyrase and a cognate topoisomerase.8 Antibiotics directed against cell-wall 
biosynthesis include the β-lactam group of penicillins and cephalosporins as well as the 
glycopeptide antibiotic class, of which two members, vancomycin and teicoplanin, are 
approved for clinical use in humans.5 However, resistance has been reported against all of 
these antibiotics, which is a cause of concern. One of the possible solutions to overcome 
this problem is to find new biological targets e.g. in the cell-wall biosynthesis on which no 
antibiotic is currently acting.  














Figure 1.1 Bacterial targets of antibiotics 
This thesis focuses on the mureidomycins (MRDs), and this new class of antibiotics has 
been shown to disrupt the bacterial cell wall synthesis. The biosynthesis of peptidoglycan is 
a complex three-stage process. The first stage involves synthesis of N-acetylmuramyl-
pentapeptide by enzymes located in the cytoplasm, or at the inner surface of the 
cytoplasmic membrane. First UDP-N-acetylmuramic acid is formed from UDP-
glycosamine. Then a pentapeptide is built up in a stepwise fashion by specific sequential 
actions of ATP-dependant ligases. (  in Figure 1.2). The second stage occurs on the inner 
surface of the cytoplasmic membrane where N-acetylmuramylpentapeptide is transferred 
from UDP to a lipid carrier, then modified to form a complete nascent peptidoglycan 
subunit. This compound then accepts GlcNAc from UDP-GlcNAc catalysed by transferase 
(  in Figure 1.2). Transglycolase catalyses transfer of the peptidodisaccharide chain 
through the membrane followed by addition of the reducing end of a pre-existing 
peptidoglycan chain on the outside of the cell wall. The lipid pyrophosphate, which is 
released, is hydrolysed to the monophosphate by a lipid pyrophosphorylase, so it can re-
enter the cycle (  in Figure 1.2). In the last stage adjacent chains are cross-linked. This 
involves a transpeptidation reaction, with the cleavage of one peptide bond providing the 
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Figure 1.2 Biosynthesis of cell-wall of bacteria 
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1.3  MraY inhibitors 
Phospho-MurNAC-pentapeptide translocase (MraY) is a catalyst in the peptidoglycan 
synthesis of bacteria (  in Figure 1.2 and Figure 1.3)9 and catalyses the attachment of a 
phospho-lipid carrier to a pentapeptide. There are different inhibitors known that are active 

















































Figure 1.3 Catalysis by translocase I 
Despite the number of inhibitors found active against MraY, it is not the target of any 
antibiotics currently used in the clinic. In general, these type of antibiotics block the 
synthesis of Lipid I, which is the product of the MraY enzyme reaction. However, the 
mechanism of inhibition appears to be different from one class to another. Most of these 
inhibitors have been tested in different assays, which makes it difficult to compare the 
reported  50 % inhibitory concentration (IC50) values. Some of these inhibitors present 
antibacterial activities against Gram-positive bacteria (e.g. tunicamycins,11 riburamycin12 
and amphomycin13), against Mycobacterium spp. (liposidomycins,10 capuramycins14) and 
against Pseudomonas spp. (mureidomycins15 and related compounds). Some are toxic and 
others are devoid of such drawbacks: tunicamycins are known to be highly toxic, while e.g. 
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Figure 1.4 MraY inhibitors and classification 
1.4  Uridyl peptide antibiotics  
Mureidomycins, the molecules of interest in this thesis, belong to the class of uridyl 
peptide antibiotics (UPA) represented also by the pacidamycins17 and napsamycins18 
(Figure 1.4 and Figure 1.5). UPA antibiotics share the same chemical template: a 3’-
deoxyribose sugar is attached via an unusual enamide linkage to a peptide chain and linked 
by a glycosidic bond to a uracil or dihydrouracil. The still unexploited mode of action, their 
favourable toxicological and pharmacokinetic properties, and pharmacodynamic qualities 
against the highly refractory pathogen, Pseudomonas aeruginosa, makes this class of 




















Pacidamycin  R1= alanyl, H or phenyl





















Napsamycin  R1= uracil or dihydrouracil
                       R2= H or CH3  
Figure 1.5 Uridyl-peptide antibiotics (UPAs) 
However, the UPA class has two disadvantages which prohibited the introduction of a 
drug from this class. First, they have a limited spectrum; they are active against P. 
aeruginosa, an organism with high resistance to all current therapeutics, but show no 
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activity against any other significant human pathogen. Second, P. aeruginosa becomes 
resistant to these compounds at a frequency (10-5-10-6) that would restrict the usefulness of 
a UPA-based drug.16c,17c  
1.5  Mureidomycins 
The Mureidomycin family Mureidomycins A-D are isolated from Streptomyces 
flavidovirens SANK 6048615 which show selective anti-pseudomonal activity, while not 
being toxic in mice. Mureidomycin E and F (=napsamycin with R1 = uracil and R2 = H) can 
be isolated from Streptomyces flavidovirens SANK 60486 or synthesised from 
mureidomycin A and formaldehyde via a Pincet-Spengler reaction.19 They showed strong 
anti-pseudomonal activity, but less than mureidomycin A. This family of antibacterial 
agents, above all Mureidomycin A ([IC50] is 0.05 μg/mL), exhibits a strong activity both in 
vitro and in vivo against strains of the difficult pathogen Pseudomonas auruginosa20 and is 
as adequate as cefsoludin21 and ceftazidime21 (antibiotics currently in use) in a in vivo 
model of P. aeruginosa infection in a mouse.22 It is active against isolated translocases 
from both Escherichia coli and Staphylococcus aureus although it lacks whole cell activity 
against these bacteria, indicating that these bacteria are still sensitive to MRDs. The 
resistance may be due to a permeability barrier to these agents. These interesting biological 
properties make the mureidomycin family, and especially mureidomycin A, an attractive 
synthetic target.22  
Mureidomycin A: R1 = uracil, R2 = H
                         B: R1 = dihydro-uracil, R2 = H
                         C: R1 = uracil, R2 = glycol
                         D: R1 = dihydro-uracil, R2 = glycol
Mureidomycin E: R1 = OH, R2 = H















































Mureidomycin A consist of a 3’-deoxyuridine nucleoside linked via an unusual enamide 
linkage to a modified peptide chain, which contains two m-tyrosine residues, one 
methionine residue, an unsymmetrical urea and one N-methyl-2,3-diaminobutyric acid 
residue. The closely related UPAs share the overall skeleton, but show small differences in 
the amino acid composition (Figure 1.7). All contain the pyrimidine nucleoside, the 
enamide linkage, a free amino terminus and the carboxy-terminal aromatic amino acid.  
The molecular mechanism of inhibition of MraY by MRD A has been investigated. 
Brandish et al.9a have reported that MRD A is a slow binding inhibitor (Ki: 36 nM; Ki*: 2 
nM) of solubilised E. coli MraY. Slow-binding inhibition can be rationalised by the 
formation of an initial EI complex, followed by isomerisation to a more tightly binding EI* 
complex, however the molecular basis for the EI to EI* transition during slow-binding 
inhibition is unknown. In the next sub-sections the influence of the different parts of MRD 




















found in MRD E, F and 
Napsamycins MRD A R = H
MRD C R = Gly
pacidamcyins R = H, Gly, Ala
Found as Ala in 
pacidamycins
MRD B amd F contain 
dihydrouracil, rest contain uracil
Pacidamcyins contain 
m-Tyr, Phe or Trp at 
carbonyl terminus
 
Figure 1.7 Relationships between the UPAs. 
1.5.1  Role of enamide linkage on MraY inhibition  
The presence of the enamide function is unusual and suggests that this feature plays an 
important role in the biological activity. Another unusual feature is the presence of a β-
oxygen (the endocyclic oxygen of ribose) which might be expected to increase the 
reactivity of the enamide. There are two things that suggest that this enamide function could 
be important for biological activity of MRD A. First, enamides are able to generate N-
acyliminium ion intermediates, which are readily attacked by a range of nucleophiles.23 
Secondly, the reactions catalysed by translocase I, are believed to occur via a two-step 
mechanism involving the attack of an active site nucleophile onto the β-phosphate of the 
substrate ADP-MurNAC-pentapeptide.24 Gentle et al.25 proposed the hypothesis for slow 
binding inhibition of translocase I by the enamide moiety at the enzyme active site to give 
N-acyliminium ion 2, followed by attack of a nucleophilic amino acid side chain to give 
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covalent adduct 3, as shown in Scheme 1.1. The pyrimidine nucleoside itself appears to be 
































 1 2 3 
Scheme 1.1 Hypothesis for mechanism of slow binding inhibition by Mureidomycin A 
To study the relevance of the enamide linkage and to investigate the mechanistic 
hypothesis several enamide analogues have been synthesised. A simple analogue of MRD 
A (6) has been synthesised and revealed to be quite stable. Aldehyde 4 was coupled to an 

























 4 5 6 
Scheme 1.2 Synthesis of uridine-based enamides 
Enamide 6 and mureidomycin A show similar chemical inertness. The uracil base exerts 
an important influence on the properties of the enamide functionality, resulting in an 
increase in chemical stability. Apparently, a stereoelectronic effect of nitrogen substitution 
at the anomeric centre stabilises the enamide functional group. The lack of reactivity of 
mureidomycin A and 6 under a range of acidic reaction conditions coupled with the lack of 
inhibition shown by 6, does not support the intermediacy of an N-acyliminium ion which is 
formed in the slow-binding inhibition of translocase I. However, it is possible that the 
enamide functional group in mureidomycin A is activated within the confines of the 
translocase I active site. Considering this together with the fact that dihydropacidamycin D, 
which lacks the enamide functionality, showed only slightly reduced activity against 







The solid phase synthesis of MRD analogues lacking the enamide group, the N-methyl 
group and the diaminobutyric acid C-4 methyl function has been accomplished by Bozzoli 
et al.29 These analogues were not biologically active, implying that the methyl groups of the 
N-methyl diaminobutyric acid residue are important for biological activity.  
1.5.3  Derivatisation of Mureidomycin A    
Other traits that MRD A shares with closely related families are the free amino terminus 
and the carboxy-terminal in the aromatic amino acid. Gentle et al. investigated the 
importance of these functional groups for the inhibition of translocase I.30 Mureidomycin A 
contains several functional groups that can be derivatised chemically (Figure 1.8). The 
activity shown by chemical derivatives of Mureidomycin A suggest that the amino terminus 
and the phenolic hydroxyl groups form significant binding interactions with the enzyme 







































Figure 1.8 Derivatisation of mureidomycin A 
1.5.4  C‐ and N‐terminus 
The influence of the carboxy-terminal in the aromatic amino acid was studied by 
synthesis and testing of a C-terminus analogue 7 (Figure 1.9). Modest inhibition of this 
analogue showed that there is some binding interaction for the C-terminal part of MRD A, 
but that it is not strong by itself.30 In order to further assess the role of the free amino 
terminus on the biological activity, a series of 5’-aminoacyluridine derivatives were 
synthesised by Gentle et al., containing a variable alkyl spacer (Figure 1.9). The results 
gave a surprising pattern of inhibition: only the 3-aminopropionyl (8) and 7-
aminoheptanoyl (11) derivatives showed effective enzyme inhibition, but none was 
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observed for the 5-aminopentanoyl and 6-aminohexanoyl analogues, suggesting that there 






















Ph OH OH n=1,3,4,5,6
n = 1:   IC50: 0.26 mM    n = 5:  IC50: 1.5 mMIC50: 1.9 mM  
 7 8-12 
Figure 1.9 C- and N-terminus analogues 
It is known that MraY requires Mg2+ for activity. Gentle et al. suggested that MraY has a 
binding site as shown in Figure 1.10. The Mg2+ cofactor is bound relatively weakly by the 
enzyme, so it is reasonable that the inhibitors could bind to the active site in absence of 
Mg2+. The vacant cation-binding site can now be occupied by the ammonium side chain. 
Gentle et al.30 have suggested that 8 binds via a syn-ester conformation, while 11 binds via 
an anti-ester conformation (Figure 1.10). According to this model, the 5- and 6-
aminoderivatives would be too long to bind in the syn conformation, while too short to bind 
in the anti conformation. Mureidomycin has a 7-carbon spacer between the uridine C-5’ 
position and the amino terminus, consistent with the anti- conformation in Figure 1.10. 
This implies that the N-terminal part binds in the Mg2+ binding site, which brings the m-
tyrosine residue close to the MurNAC binding site of the enzyme. The C-terminal m-
tyrosine may bind instead the co-substrate undecaprenyl phosphate, which is also 



















































Figure 1.10 Proposed model for enzyme inhibition by aminoacyl-uridine models; A. Proposed 
role of Mg2+ cofactor and Asp-Asp pair; B. Proposed inhibition mode of 3’-aminopropionyl 





In addition Howard and Bugg synthesised a series of 5’-uridinyl dipeptides, in which the 
dipeptide is linked to the uridine via either an ester or an amide (Figure 1.11).31 The majority 
of the amide and ester analogues showed only 15-30 % inhibition at 2.35 mM concentration, 
however a few examples showed higher inhibition, especially 14C (Figure 1.11).  
Entry AA R MraY inhibition of amide 13 (%) 
MraY inhibition 









OHH/Me  A L-Tyr H 48 24 
B β-Ala Me 43 33 13 X=NH 
14 X=O C L-Ala Me 14 97 
Figure 1.11 The 5’-uridinyl dipeptides 
Significantly lower activity was observed when either the N-methyl substituent or the 
ester linkage was absent, implying that these functionalities are both important for 
biological activity. This 5’-uridyl peptide was used to confirm the hypothesis that the amino 
terminus binds in place of the Mg2+ cofactor at the MraY active site. The enzyme assay 
used indicated that increasing concentration of Mg2+ reduces the potency of enzyme 
inhibition. In addition to the earlier proposed inhibition models, the model for 14A is 
depicted in Figure 1.12A, where the amide bond has the cis-configuration and the ester 
function is flexible. The less reactive 5’-uridinyl dipeptides have a trans-amide 
conformation resulting in a less potent inhibitor. Mureidomycin A could also adopt a cis-
amide conformation resulting from the enamide, as shown in Figure 1.12B. In this way 

































Figure 1.12 A. Proposed model for enzyme inhibition by 5’-uridinyl dipeptides; B. Proposed binding 
mechanism of MRD to Mg2+ binding site of MraY, via cis-amide linkage. 
In conclusion, the slow binding inhibition by Mureidomycin A is due to several binding 
interactions from different parts of the molecule. More complex synthetic analogues will be 
needed to study more closely the tight binding to the enzyme active site. 
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1.6  Retrosynthetic analysis of Mureidomycin A 
In the preceding section the different approaches to mureidomycin analogues and their 
biological activity have been discussed. In addition the total synthesis of 
dihydropacidamycin D has been reported.28 Although a total synthesis of mureidomycin A 
is not the primary goal of the research described in this thesis, it is useful to draw a 
retrosynthetic analysis at this point. In order to keep the synthesis modular, we would like 
to introduce the enamide as late as possible in the synthesis of mureidomycin A.  
The peptide backbone of mureidomycin A (BB7) consists of three building blocks (BB), a 
protected m-tyrosine (BB1), an amide analogue of AMBA (2-amino-3-
methylaminobutanoic acid) (BB2) and an unsymmetrical urea (BB6). This urea can be 
divided again in three more building blocks, a m-tyrosine (BB1), a methionine (BB3) and 
triphosgene (BB4). The synthesis of unsymmetrical ureas from amino acids is known and  
is an uncomplicated synthesis,32 apart from the synthesis of the m-tyrosine itself. The amide 
building block should be made from AMBA, and AMBA itself has been made before in the 
synthesis of dihydropacidamycin D.28a The synthesis of BB 8 starting from BB 9 can be 
envisioned via a vinyl tin nucleoside. Synthesis of an adenine analogue has been reported 
by Tanaka et al.33 Building block 9 can be synthesised from uridine in four steps of which 
most of the reactions are protection and deprotection reactions.34  
For the total synthesis of MRD A the protecting groups in the different coupling reactions 
have to be chosen wisely. Protecting group 1 (PG1), as in Scheme 1.3, stays during the 
whole synthesis, and has to be removed very mildly, but has to withstand some peptide 
couplings. A Fmoc (9-fluorenylmethoxycarbonyl) protecting group seems to be a good 
choice. This group has to be removed under basic conditions, where enamides are stable. 
The second protecting group (PG2) is an amide-protecting group. Removal of PG2 should 
take place before, or during the iodide coupling reaction. A CBz group could be a good 
choice, because it can be reduced under conditions where the Fmoc group is not. The third 
protecting group (PG3) is on the acid part of the unsymmetrical urea. This part has to be 
protected, because otherwise, it could couple with the AMBA-amide. This protecting group 
has to stay till the vinyl iodide coupling, and selectivity is not a problem, because it is the 









































































































Scheme 1.3 Proposed retrosynthesis mureidomycin A 
1.7  Goal  
In this first chapter the mureidomycins, a class of natural antibiotics were discussed. 
These compounds contain a 3’-deoxy-ribose unit linked to uracil with a peptide backbone 
coupled via an unusual enamide bond (Scheme 1.4). This provides a challenging array of 
functionalities present in many other peptidyl nucleoside antibiotics as well. The methods 
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reported so far for the synthesis of such compounds most often involve a large number of 
steps and lack stereocontrol at some point. In addition only a few examples are known 
which do not use chiral starting materials. This limits the flexibility of the methods and 
makes them not suitable for the synthesis of a library of compounds needed for structure-
activity relationship (SAR) studies. With regard to the synthesis of UPAs and its analogues, 
Boojamra et al. reported the synthesis of dihydropacidamycin D and a series of analogues, 
however, never with the unusual enamide linkage.28a,35 In chapter 2 nucleoside analogues 
will be discussed. A large range of nucleoside analogues exists, but we focus on ribose 
sugars linked to monocyclic five- and six-membered heterocyclic bases that do not 
resemble one of the natural nucleobases in their core structure.  
The combination of these two chapters leads to the goals of this thesis. The primary goal 
of the research is the synthesis of dihydropyrimidine nucleosides A (Scheme 1.4). The 
second goal is the total synthesis of mureidomycin A. In order to prepare A, an approach is 
followed that employs the versatility of a multi component reaction (MCR) in combination 
with the stereoselectivity of a chemo-enzymatic cascade reaction. A disconnection between 
the pyrimidine base and the 3’-deoxyribose moiety seems appropriate resulting in the 3’-
deoxyribose moiety B and dihydropyrimidine (DHPM) C, which later could be combined 
(Scheme 1.4). The synthesis of 3’-deoxyribose moiety B is envisioned via a chemo-

































































Scheme 1.4 Goal of thesis 
Chapter 1 
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In chapter 3 a new approach to dihydropyrimidines C will be discussed. The scope and 
limitations of a new four-component reaction have been explored resulting in 
dihydropyrimidines, phosphoramidates and triazinane diones. Chapter 4 is an extension of 
chapter 3. Here the synthesis of thiazines using a similar four component approach and a 
subsequent rearrangement to the corresponding dihydropyrimidine-2-thiones is described. 
Chapter 5 discusses a mild chemo-enzymatic oxidation-hydrocyanation protocol for the 
synthesis of cyanohydrins. These cyanohydrins are precursors for the 3’-deoxyribose 
moiety (B). In chapter 6 the synthesis of such a 3’-deoxyribose moiety B will be discussed. 
Both a chemical and chemo-enzymatic route are described. Chapter 7 summarises the 
synthetic studies towards mureidomycin A and dihydropyrimidine nucleosides A. The 
synthesis of the several building blocks of the peptide backbone will be discussed.  In 
addition a model study is described about the coupling of dihydropyrimidines to ribose 
sugars. 
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A large range of nucleoside analogues is known with a wide variety of therapeutic actions. In this chapter we 
discuss nucleoside analogues with a 5- or 6-membered monocyclic nucleobase, not having the core heterocyclic 




Nucleosides and nucleotides are an interesting class of compounds, which have gained their 
importance as biopharmaceuticals. Their biological activities range from antiviral, 
antibacterial, antifungal, antitumour, antitrypanosomal, herbicidal, insecticidal to immuno-
stimulating.1 This is not surprising, since nucleosides and nucleotides are precursors of DNA 
and RNA. Nucleosides and nucleotides consist of a sugar moiety attached to a heterocyclic 
base, and in nucleotides the 5’-OH is phosphorylated. The natural bases present in DNA 
and/or RNA have either the purine (15) or the pyrimidine (18) skeleton and are known as 
adenine (16), guanine (17), cytosine (19), thymine (20) and uracil (21). In natural nucleosides 
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Figure 2.1 Bases and sugars in DNA and RNA 
DNA and RNA contain the genetic information of the organism and in replication this 
genetic information is replicated also. Genes in living cells always contain DNA, while 
genes of viruses can consist of DNA or RNA. RNA viruses replicate through DNA 
intermediates. The genetic information goes from RNA to DNA rather than from DNA to 
RNA.  For example, human immunodeficiency virus-1 (HIV-1), the cause of aids, uses this 
pathway and is also known as a retrovirus. Their RNA is transcribed to DNA by reverse 
transcriptase, an RNA-directed DNA polymerase. This implies that viral infections involve 
DNA and RNA.2  
Nucleosides and nucleotides play also an important role in different metabolic processes 
in the human body and are intermediates in many biosyntheses. E.g. ATP is the major 
source of cellular energy and GTP is used as a source of energy in protein synthesis. Also 
nucleoside and nucleotide analogues, modified in either the base and/or the sugar moiety, 
are known to take part in metabolic processes.3 For example, NAD+, which is one of 
Nature’s most important oxidising agents. In Figure 2.2 some examples are shown of other 
biologically active nucleoside analogues. Cis- and trans-N6-(3-hydroxymethylbut-2-enyl)-
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adenosine (24) are cytokinines, which are plant growth substances. Furthermore, 
cordycepin (3’-deoxyadenosine; 25), tubercidin (26) and formycin (27) are all antibiotics.3 
Thus, nucleoside analogues are interesting compounds, either as regulators of, for example 
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Figure 2.2 Several biologically active nucleoside analogues 
Biologically active nucleoside analogues can differ from the natural-nucleosides in 
several ways. Either, the heterocyclic base can have substituents (24), the ribose is modified 
(25) or the base does not resemble the natural base in its core structure (26-27). In this 
chapter, we discuss nucleoside analogues with a 5- or 6-membered monocyclic base not 
having the core heterocyclic skeleton of a natural nucleobase and that is attached to a 5-ring 
sugar (ribose) via a nitrogen atom. We will focus only on biologically relevant nucleoside 
analogues. In section 2.2 the nucleoside analogues with a 5-membered nucleobase will be 
discussed. Here imidazole, imidazolinone, pyrazole, and triazole nucleosides are 
consecutively described. Next section (2.3) will address the nucleoside analogues with a 6-
membered nucleobase, the pyridine, pyridinone, pyrazine, pyrimidinone and azapyrimidine 
nucleosides. 
Mostly, the syntheses of the nucleoside analogues that are discussed in this chapter are 
based on the Silyl-Hilbert-Johnson method, better known as the Vorbrüggen condensation.4 
In this method, first the base is silylated using, for example hexamethyldisilazane (HMDS), 
and then a peracylated ribose together with a Lewis acid (TMSOTf) are added resulting in a 
nucleoside. In this way the β-anomer of the nucleoside is formed selectively (Scheme 2.1).5 
Often additional manipulations are necessary to obtain the desired nucleoside. Further 
synthetic details are only described when the approach significantly differs from the 




































































Scheme 2.1 The Vorbrüggen condensation 
2.2 Nucleoside analogues with a 5‐membered ring nucleobase 
2.2.1 Imidazole nucleosides 
In this class of nucleosides a large range of compounds has been synthesised and 
evaluated for their biological activity. In order of importance the imidazole nucleosides will 
be discussed starting with, bredinin/mizoribine, 5-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR) and 5-ethynylimidazole-4-carboxamide ribonucleoside (EICAR) 
followed by their analogue (Figure 2.3–2.8).  
Mizoribine is an imidazole nucleoside isolated from Eupenicillium brefeldianum M-2166 
and is structurally related to ribavirin (see section 2.2.4).6 In 1984 mizoribine was clinically 
approved as immunosuppressant for renal transplantation, later for lupus nephritis (1990), 
rheumatoid arthritis (1992) and nephrotic syndrome (1995). Combination therapies with 
other immunosuppressive drugs like steroids,7 azathioprine, methotrexate8 or cyclosporin9 
are also in clinical use, because they exhibit excellent synergism. In addition mizoribine 
shows also antiviral activity, e.g. against influenza viruses type A and B,10 bovine diarrhea 
virus (BDV),11 hepatitis C virus (HCV),12 and SARS.13 The biological activities of 
mizoribine are resulting from the ability of its metabolites, the 5’-phosphate nucleotides, to 
inhibit inosine monophosphate dehydrogenase (IMPDH) and guanosine monophosphate 
(GMP) synthetase.14 Mizoribine can be synthesised in different ways, either via enzymatic 
transformation of uridine,15 or via two chemical pathways: Ueda et al. reported the 
synthesis via photolysis of the amine-analogue, resulting in a malonamide, which was 
reacted with ethylorthoformate resulting in mizoribine.16 Shaw et al. reacted a protected 
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ribosylamine with malonic acid and subsequent amination and intramolecular 
cyclocondensation led to mizoribine.17  
AICAR (29 in Figure 2.3) is a good activator of AMP-dependant protein kinase (AMPK) 
when phosphorylated. Activation of AMPK is known to regulate glucose and fatty acid 
metabolism.18 AICAR is phosphorylated by adenosine kinase to AICAR 5’-monophospate 
(ZMP), which mimics AMP and activates AMPK without altering the cellular levels of ATP, 
ADP or AMP.19 ZMP is a key intermediate in purine biosynthesis and is usually immediately 
converted into inosine-5’-monophospate, the precursor of all purine compounds.20 AICAR 
has shown apoptotic and anti-apoptotic effects, either induced by AMPK or not, e.g. in lung 
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Figure 2.3 Mizoribine (28), AICAR (29), EICAR (30) and EICAR-analogues (31) 
EICAR (30 in Figure 2.3) is another imidazole nucleoside, which has been investigated 
extensively. EICAR shows in vitro activity against a range of viruses, such as, respiratory 
syncital virus (RSV), BDV, yellow fever virus (YFV), infectious pancreatic necrosis (IPN), 
measles-, pox-, toga- arena-, reo- orthomyxo- and paramyxoviruses.22 The antiviral potency of 
EICAR is 10- to 100 fold greater than that of ribavirin.23 Furthermore, EICAR exhibits 
antitumour activity and inhibits the growth of various tumour cells in vitro.24,25 The mechanism 
of action is still unclear. Balzarini et al. showed that EICAR inhibits murine leukemia L1210 
cells and human lymphocyte CEM cells.23 This antitumour effect is caused by inhibition of IMP 
dehydrogenase. The 5’-monophosphate of EICAR was found to inhibit L1210 IMP 
dehydrogenase, too.25 Several analogues of EICAR have been synthesised and evaluated for 
their antitumour activity, of which 31a-c were the most profound.25 a 
One of the other more interesting imidazole-4-carboxamide nucleosides is 5-fluoro imidazole-
4-carboxamide ribonucleoside (FICAR (32a); Figure 2.4).26 The antiviral and antimetabolic 
activities of this compound were compared to those of ribavirin and AICAR. The antiviral tests 
showed that ribavirin was generally most active, followed by FICAR and finally AICAR. The 
metabolic experiments revealed that ribavirin and FICAR are both potent inhibitors of cellular 
DNA and RNA synthesis, while AICAR did not show any inhibition; in fact it enhanced 
synthesis at a high dose. In addition, ribavirin and FICAR are both not cytotoxic.  
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Other 5-halogen-substituted (32b-d) and unsubstituted (33a) imidazole-4-carboxamide 
ribonucleosides were also tested and showed lower (32b-d) or comparable (33a) in vitro 
antiviral activity against herpes simplex virus 1 (HSV) and vaccinia virus (VV) than 
FICAR (32a).27 The 5-methylimidazole carboxamide ribonucleoside 33b showed a good 
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Figure 2.4 Imidazole-4-carboxamide analogues 
Robins et al. investigated the antiviral and antimicrobial activity of two 5-
cyanomethylribofuranosyl imidazole-4-carboxamides 34a-b.29 Both show considerable in 
vitro activity against herpes viruses, while negligible activity against RNA viruses is 
observed and no antimicrobial activity. The 5’-monophosphate nucleoside 34b shows also 
inhibition of IMP dehydrogenase, like ribavirin and mizoribine.  
Other brominated imidazole nucleosides (35 and 36, Figure 2.5) have been reported to 
possess cytostatic activity against HeLa cells.30 35a-c showed moderate ED50 values (10-50 
μg/mL) while 36 had an ED50 of 5 μg/mL. In addition, Townsend et al. reported recently two 
tribrominated imidazole ribonucleosides with moderate human cytomegalovirus (HMCV) 
activity (37 and 38; Figure 2.5). However, toxicity of the compounds was higher than the 










































 35 36 37 38 
Figure 2.5 Bromo-imidazole nucleosides 
Some thio-imidazole nucleosides (39-41) showed also activity against distinct viruses 
(Figure 2.6). Nucleoside 39 showed broad spectrum antifungal activity against Candida 
Albicans, Trichophyton, Microsporum and Epidermophyton.27 Nucleosides 40 showed good 
antiviral activity against VV in vitro, however these activities were less than reported for 
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ribavirin, which is not a significant agent against VV.32 Methylsulfonyl nucleoside 41 is in 
vitro active against several RNA viruses, like Rift Valley Fever (RVF) and Venezuelan 
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Figure 2.6 Thio-imidazole nucleosides 
Very recently, an imidazole nucleoside with a triazine substituent (42) has been 
synthesised and evaluated for its inhibitory activity against the West Nile virus 
NTPase/helicase. IC50 values of 3-10 μg/mL were reported.33 Nucleoside 42 was 
synthesised via acidic work-up of 5-diethoxymethyl-imidazole-4-carboxylate riboside. 












Figure 2.7 Triazine-imidazole nucleoside 
Finally, 5’-monophosphate analogues of mizoribine and EICAR have been synthesised and 
evaluated for their antitumour or inhibitory properties of IMP dehydrogenase.34 Nucleosides 
43, 44 and 45a have been evaluated for their inhibitory properties of IMP dehydrogenase of 
human Type I and II and Candida Albicans. Although not nearly as good as the 5’-phosphates 
of ribavirin and mizoribine itself, the activities are reasonable and lie almost all in the range of 
EICAR. 5’-Monophospate nucleosides 45b and c have been tested for their in vivo antitumour 
activity against ip- and sc- implanted tumours in mice and compared to mizoribine. The first 
experiment (ip-implanted tumour) showed that 45b and c had no activity against P338 
leukemia and Ehrlich carcinoma, while significant activity against MethA fibrosarcoma and 
Sarcoma180 was observed, in contrast mizoribine showed no activity against these three 
tumours. In the second experiment (sc-implanted tumour) only 45b and mizoribine were 
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compared. Mizoribine did not show any activity against the tested tumours, while 45b 










































 43 44 45  
Figure 2.8 5’-Phosphate imidazole nucleotides 
2.2.2 Imidazolinone nucleosides 
This class of compounds consists mainly of neopolyoxin A and B, polyoxin N and 
nikkomycins Bx, X and I (Figure 2.9). These are all peptidyl nucleosides that have been 



























































Figure 2.9 Different natural imidazolin-2-one nucleosides 
Neopolyoxins A and B have been discovered by Isono et al. in 1980 and are isolated from 
Streptomyces cacaoi subsp. Asoensis.35 Neopolyoxins are chitin synthetase inhibitors and 
are structurally related to the polyoxins, which have the same activity spectrum. 
Neopolyoxin A shows higher antifungal activity than neopolyoxin B and polyoxins, against 
a range of different fungi like Pyricularia oryzae, Cochliobolus miyabeanus and Botrytis 
cinerea.35b,36 Polyoxin N has been isolated as a minor component from Streptomyces 
piomogenus.37 As neopolyoxin A, it shows good antifungal activity against e.g. Pyricularia 
oryzae, Cochliobolus miyabeanus.38 
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Nikkomycins Bx, X and I are very closely related to the neopolyoxins, in fact 
neopolyoxin A is the same as nikkomycin X. However, the nikkomycins have been isolated 
from different strains, the Streptomyces tendae Tü901.39 Like the neopolyoxins and the 
polyoxins, they are potent chitin synthetase inhibitors, because of their structural similarity 
to UDP-N-acetylglucosamine, the natural substrate of the enzyme. They show good 
fungicidal, insecticidal and acaricidal properties, while their toxicity against mammalian 
cells is low.35,36,40 Combination therapy of nikkomycins X and Z with several azoles like 
clotrimazole (46), miconazole (47) or R3783 (48) (Figure 2.10) resulted in in vitro activity 
against Candida Albicans, which is normally poorly inhibited by these nikkomycins.41  
The nikkomycins, X, I, Z and J show a clear difference in activity: while all are good 
chitin synthetase inhibitors, only dipeptides nikkomycin X and Z exhibit a good in vivo 
effect on Mucor rouxii. It is suggested that the uptake of the nikkomycins involves the 
transpeptidase reaction of the γ-glutamyl cycle, thus the dipeptides can be transported in 
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Figure 2.10 Azoles synergistic with nikkomycin X and Z 
While nikkomycin Bx has not been studied as extensively as the other nikkomycins 
regarding its activity, much is known about the synthesis of this nucleoside. In 1987 Konig 
et al. reported the synthesis of nikkomycin Bx, its enantiomer and a p-methoxy analogue, 
nikkomycin X and its enantiomer. Only the natural occurring nikkomycins showed 
fungicidal activity, while the p-methoxy analogue showed activity against yeasts.43 The 
nikkomycins were synthesized via coupling of the C-terminal nucleoside amino acid with 
the dipeptide resulting in the nikkomycins.  
Rudd et al. reported in 1995 the biosynthesis of nikkomycin X from histidine in 
Streptomyces tendae.44 L-Histidine is the source in S. tendae for the imidazolin-2-one 
moiety. In 2004 Tan et al. reported the enhanced production of nikkomycin X by over-
expression of a non-ribosomal peptide synthetase in Streptomyces ansochromogenes, SanO. 
Twice as much nikkomycin X was produced compared to the wild type strain.45 The 
biosynthesis of nikkomycins has been explored by Bormann et al, they report that 6 genes 
are involved in the synthesis; nikU and nikV are required for the synthesis of 
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hydroxypyridyl homothreonine, nikP1, nikP2 and nikS for the assembly of nikkomycins 
and nikT for both pathways.46   
Besides these peptidyl imidazolin-2-one nucleosides also one example of a non-peptidyl 
imidazolin-2-one nucleoside is known with biological activity. Imidine (49) is a 5-
membered ring isomer of thymidine and its triphosphate competes with thymidine 
triphosphate for incorporation into DNA. The triphosphate is shown to be a potent inhibitor 
of HIV reverse transcriptase and causing premature termination of DNA synthesis and 









Figure 2.11 Imidine (49), non-peptidyl imidazolin-2-one nucleoside 
2.2.3 Pyrazole nucleosides 
In contrast to the triazole (see section 2.2.4) and imidazole nucleosides no pyrazole 
nucleoside is clinically in use. However, a series of pyrazole nucleosides (50) have interesting 
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Figure 2.12 Pyrazole nucleosides with cytostatic activity 
Pyrazole nucleosides 50a-f showed good cytostatic activity against HeLa cells,48 while 50g-
m showed moderate activity (Figure 2.12).48,49 In addition compound 50m showed good 
antiproliferative activity against T-cell lines.50 Several analogues of 50m (51-52) showed 
comparable or even better antiproliferative activity against several lymphoblastic cell lines. 
While 50m showed no effect on the proliferation of solid tumour-derived and embryonal cell 
lines, 51a-c showed moderate (51b) and good (51a and c) activity (see also Figure 2.13).51  
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Figure 2.13 Iodo-pyrazole nucleosides and fluoro pyrazole nucleoside 
Pyrazole nucleoside 51a (IPCAR) has been tested for its cytotoxicity against proliferating 
and resting human PBL cells. Although non-cytotoxic to resting PBL-cells, IPCAR is 
cytotoxic to stimulated PBL-cells. Furthermore, IPCAR was found to promote the activity of 
ddI, an antiretroviral agent for the treatment of HIV-1. In conclusion, IPCAR seems to be a 
promising candidate for antitumour chemotherapy. Especially, the low toxicity for resting 
PBL cells and the promotion of the anti HIV-1 activity of ddI, makes this compound a 
potential candidate for the therapy of AIDS-associated neoplasias.51 Although structurally 
related to ribavirin, La Colla et al. proposed that IPCAR does not inhibit IMPDH of the de 
novo purine biosynthesis. However, the exact mode of action remains unclear.52 Finally, Coe 
et al. reported the anti-influenza activity of 4-fluoropyrazole nucleoside 52, while no activity 
against several RNA and DNA viruses was observed.53 This is in line with the other halogen 
substituted pyrazole nucleosides discussed above. 
2.2.4 Triazole nucleosides 
Triazole nucleosides consist of a sugar- and a triazole moiety. A triazole is a 5-membered 
ring that contains three nitrogen atoms. Depending on the position of the N-atoms in the ring, 
different types of triazoles are identified. Consequently, different types of triazole nucleosides 























Figure 2.14 Possible triazole nucleosides 
From a pharmacological perspective most potent and therefore interesting are the 1,2,4-
triazole nucleosides. Ribavirin is such a 1,2,4-triazole nucleoside and has been discovered by 
Witkowski and Robins in 1972 (Figure 2.15).54,55 Since the discovery of ribavirin a large 
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range of analogues has been synthesised. However only a few display a similar biological 
activity as ribavirin, which is still the most potent one. 
2.2.4.1  1,2,4‐triazole nucleosides 
Ribavirin is a broad-spectrum antiviral drug active against a number of DNA and RNA 
viruses. It is one of the few antiviral drugs in clinical use effective against viruses other 
than HIV and herpes.56 First, ribavirin was approved in its aerosol form for the treatment of 
respiratory syncital virus infection in children with respiratory distress.57,58 Later ribavirin, 
in combination with interferon-α, was also approved for the treatment of chronic HCV, 
however the success rate of this therapy is limited.59,60 Although use of pegylated interferon 
in combination with ribavirin improved the treatment considerably,61 clinical use of 
ribavirin has been overshadowed by its side-effect: haemolytic anemia upon long-term 
administration.62  
Ribavirin mimics the configuration of e.g. adenosine or guanosine. This makes it possible 
to target viral and host enzymes that utilise these natural nucleosides as target or co-factor. 
In addition, indirect effects like inhibition of IMPDH resulting in a decrease of the guanine 
nucleotide pool,63 may account for the activity of ribavirin as well. Ribavirin acts as a 
prodrug, which after entering the cell, is phosphorylated by deoxyadenosine kinase and/or 
adenosine kinase resulting in the active ribavirin 5’-phosphate.64 The ribavirin 5’-
monophoshate analogue shows a similar in vitro broad-spectrum antiviral activity 
compared to the parent compound. The ribavirin di- and tri-phosphate analogues only 
showed activity against Type 1 HSV.65 Ribavirin can be synthesised via reaction of 1,2,4-
triazole-3-carboxylate with tetra-O-acetyl-β-ribofuranose at 160°C in the presence of bis(p-
nitrophenyl)phosphate and subsequent reaction with ammonia in methanol resulting in 
ribavirin in 70 % yield.54 In addition enzymatic syntheses are known for ribavirin, where a 
natural nucleoside with the help of an enzyme is transformed into ribavirin. The natural 
nucleosides that can be used are orotidine,66 uridine or cytidine,67 inosine68 or guanosine.69  
The only two 1,2,4-triazole nucleosides that show similar activity as ribavirin are 
levovirin70 and viramidine71 (Figure 2.15). Levovirin is the L-enantiomer of ribavirin 
(Figure 2.15) and has been synthesised in 2000 by Averett and co-workers.70 It has similar 
immunological properties (type 1 cytokine-enhancing activity)70 as ribavirin, but showed no 
in vitro antiviral activity and no toxicity. This may be explained by the fact that levovirin is 
not efficiently phosphorylated.72 The immunomodulatory properties however, seem 
important as potential HCV drug and therefore Levovirin is now in phase II clinical trials.73 
A disadvantage is that levovirin is only partially absorbed, which results in relatively poor 
oral bioavailability. Levovirin valinate hydrochloride (R1518), a 5’-valine derivative 
Biologically Active Nucleoside Analogues with 5- or 6-Membered Monocyclic Nucleobases 
43 
addresses this problem. After uptake, R1518 is almost quantitatively hydrolysed to 
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Figure 2.15 Biologically active 1,2,4-triazole nucleosides 
Viramidine is the carboxamidine analogue of ribavirin and has been discovered and 
synthesised in 1973 by Witkowski and Robins.71 Viramidine acts primarily as prodrug of 
ribavirin and is converted to ribavirin by adenosine deaminase.75 Viramidine has some 
advantages, first it is not taken up by red blood cells like ribavirin, which decreases the 
potential to cause haemolytic anemia.76 Second, viramidine is better liver-targeting than 
ribavirin,77 while the liver is the main viramidine to ribavirin conversion site. These two 
advantages make viramidine interesting for the treatment of HCV for which it is currently 
in phase III of clinical trials.78 Furthermore, viramidine has been tested for the treatment of 
human influenza virus infections, while being as active as ribavirin, the toxicity of 
viramidine is much lower.79  
Many other analogues have been synthesised, however only a few showed similar 
bioactivities as ribavirin, viramidine or Levovirin. Sidwell et al. synthesised the thio-
analogue of ribavirin (56), however this compound showed only good activity against Type 
I HSV.71 Robins et al. published in 1992 the synthesis of some N-carboxamidine 
substituted analogues of viramidine. Some of these exhibit interesting in vitro activities 
(Figure 2.16).80 1,2,4-Triazole 57 showed significant in vivo activity against murine 
leukemia L1210,81 although its in vitro activity was restricted to the bunyaviruses PT and 
SF and dengue-4-virus. The observed IC50 values were comparable to those of ribavirin. 
1,2,4-Triazole 58, dimethylated viramidine, showed similar activity as ribavirin, except that 




















































 56 57 58 59a-h 
Figure 2.16 Tested viramidine analogues 
Other analogues of viramidine, the 1,2,4-triazole nucleosides 59b-h showed a range of 
antiviral activities. In general these analogues showed no activity against flaviviruses, an 
alphavirus or HIV-1. The most potent antiviral nucleoside is 59d with comparable activity 
to viramidine against bunyaviruses PT and SF.80  
Nikolova et al. reviewed the antiviral activity of some 5’-amino acid esters of ribavirin 
(60).82 The activity of these amino acid esters 60 was tested against FPV (influenza virus 
A), NDV (Newcastle disease virus) and PsRV (pseudorabies virus). Compound 60a showed 
activity against FPV and 60b and c against NDV, however these amino acid esters are not 
as potent as ribavirin. The lower antiviral activity may be related to incomplete hydrolysis 

















Figure 2.17 Amino acid esters of ribavirin 
Recently, Cui et al. published the synthesis and antiviral activity of 5’-modified 1,2,4-
triazole nucleosides with a 5’-azide, amine, hydrogen or iodine functionality.83 However, 
only one compound (61; Figure 2.18) demonstrated a weak protection against viral 
infection (IC25=0.4 μmol/mL). No cytotoxicity was observed at this concentration. In 
addition, Keithly reported antiparasitic activity of some sulfamoyl triazole nucleosides 62a-
c (Figure 2.18).84 All compounds have been evaluated in vitro against five organism, L. 
donovani, T. cruzi, T. gambiense, G. lamblia, T. vaginalis. Sulfamoyl triazole nucleoside 
62a proved most active and showed good ED50 against L. donovani and T. gambiense. 
Because of its good in vitro activity against T. gambiense, 62a was tested in vivo against T. 
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brucei, however only moderate activity was observed. In addition 62a showed good activity 























 61 62 
Figure 2.18 5’-Iodo analogue and sulfamoyl nucleosides 
2.2.4.2  1,2,3‐Triazole nucleosides 
1,2,3-Triazole nucleoside 63 and 64 (Figure 2.19) have been prepared and tested for their 
biological activity.85,86 The 1,2,3-triazole nucleoside 63 exhibited interesting cell growth 
inhibition against leukemia K562 and HL-60 cells with comparable activity to ribavirin.85 
Furthermore, the TSAO-triazole nucleosides (64) gained interest because of their anti HIV-
1 activity.86 TSAO stands for the modified ribose ring with two TBS groups and one spiro 
group. 1,2,3-Triazole-TSAO nucleosides 64a-e showed good anti HIV-1 activity 



































 63 64 
Figure 2.19 1,2,3-Triazole nucleoside  
Finally, de las Heras et al. reported good cytostatic activity of some N-ribosyl-
halomethyl-1,2,3-triazoles 65-67 (Table 2.1).87 The cytostatic activity increased with –
CH2X alkylating ability, i.e. –CH2OH < CH2Cl < CH2Br < CH2I. The in vitro experiments 
revealed that the type of the sugar ring (furan or pyran), its size (pentose or hexose), or its 
stereochemistry (ribo or gluco) are not of great importance. The cytostatic activities are 
similar having the same halomethyl moiety and protecting group. The protecting group is 
important, e.g. the cytostatic activities of acetyl protected sugars are at least 10 times less 
than benzoyl protected sugars. These triazole nucleosides can be synthesised via the click 
reaction using the ribosylazide and the appropriate acetylene.   
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Only a limited number of biologically active pyridine nucleosides have been described in 
literature. Perhaps, the most interesting one is nicotinamide riboside (68), which is a 
precursor of nicotinamide mononucleotide. Nicotinamide ribotide is a component for both 
chemical88 and enzymatic89 preparation of nicotinamide adeninedinucleotide (NAD+, 69) 
(Figure 2.20). The importance of NAD is well known; NAD is a co-factor in numerous 
enzyme-catalysed redox reactions in living organisms and plays a fundamental role in 
cellular metabolic processes. Therefore, it is of great importance that the level of NAD is 
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Figure 2.20 Nicotinamide and NAD+ 
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Another important pyridine nucleoside is 3-aminopyridine riboside (70). This compound 
in contrast to other nicotinamide ribose analogues, like 3-acetylpyridine riboside, 3-
thionicotinamide and 3-pyridine-aldehyde riboside inhibits Haemophilus influenza.91 
Compound 70 is taken up by its NAD-processing and nicotinamide riboside route and in 
this way inhibits H. influenza. Compound 70 was also tested in other species of the family 
Pasteurellaceae, Pasteurella multocida and Actinobacillus actinomycetemcomitans. 
However no inhibitory activity was observed, which makes 70 an anti-infective agent with 








Figure 2.21 3-aminopyridine riboside 
3-Aminopyridine nucleoside (70) is synthesised via a two-step enzymatic degradation 
starting with the corresponding dinucleotide. The dinucleotide is treated with a snake 
venom nucleotide pyrophosphatase resulting in the mononucleotide and subsequently 
converted into the nucleoside with a prostatic acid phosphatase.93   
Finally, related to NAD 69 is isoniazid-NAD complex (Figure 2.22). This complex has 
been proposed as the metabolite responsible for antituberculosis activity of isoniazid (INH; 
71 in Figure 2.22).94 It structure results from binding of the isonicotinoyl radical at C4 of 
the nicotinamide moiety of NAD (72)95 with further possible debated cyclisation to form a 
cyclic hemiamidal derivative (73).96 It still unclear whether 72 or 73 is responsible for its 
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A benzoylhydrazide (BH) can form the same complex (BH-NAD; 74 in Figure 2.23) and 
in this way was shown to have the same activity.97 On this basis, Bernadou et al. 
synthesised benzoyl-1,4-dihydronicotinamide ribonucleoside 75 and reported that this 
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Figure 2.23 BH-NAD and benzoyl-1,4-dihydronicotinamide riboside (75) 
2.3.2  Pyridinone nucleosides 
Pyridinone nucleosides can have two different nucleobases, a pyridine-2-one or a pyridine-
4-one. Pyridine-4-one nucleosides are scarce and do not show much interesting activities, 
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Figure 2.24 Different pyridinone nucleosides 
2.3.2.1  Pyridin‐2‐one nucleosides 
The most interesting pyridin-2-one nucleoside is 3-deazauridine (3-DU; 78).99 This is a 
broad-spectrum therapeutic, showing in vitro activity against several tumour cells, like 
leukemia L1210 and L1210/AraC (also in vivo activity), Ehrlich ascites and Gross 
leukemia, several RNA viruses, e.g. Rhinovirus 1A and 13, coxsachievirus type A21, PR-8 
influenza virus, reoviruses type 1, 2 and 3 and SA11 virus, E. Coli and Streptococcus 
faecium.100 Biochemical studies show that 3-DU, after its uptake and intracellular 
conversion to 3-DU triphosphate, competitively (with uridine triphosphate) inhibits cytidine 
triphosphate synthetase. This enzyme catalyses the formation of cytidine 5’-triphosphate 
from uridine-5’-triphosphate.100c,101 Since 3-DU as a single agent showed only minimal 
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clinical effectiveness on acute leukemia, there was a lack of interest in clinical 
investigations using this drug. However, combination therapy drew more attention, 
resulting in synergistic effects with e.g. cytosine arabinoside102 or 5-aza-2’-
deoxycytidine.103  
Another interesting pyridine-2-one nucleoside, 3-deazacytidine (3-DC; 79), was found to 
be active against L1210 leukemia, E. coli, Streptococcus faecium, Ehrlich ascites 
carcinoma, rhino virus 1A, 13 and 56, influenza A & B, parainfluenza virus 1 and vesicular 
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Figure 2.25 3-deazauridine (3-DU; 78) and 3-deazacytidine (3-DC; 79) 
A few other pyrimidin-2-one nucleosides showed interesting activities. The 5-carboxylic 
acid pyridin-2-one nucleoside 80 showed significant success in the treatment of adjuvant-
induced arthritis in rats.105 3-Nitro-3-deazauridine (81) showed a much broader spectrum of 
activity. It is active against a range of RNA virus families, paramyxoviruses, 
picornaviruses, rhabdoviruses, togaviruses, bugaviruses and rhinovirus type 34.106 4-
Adamantoyl-3-deazauridine (82) showed antitumour activity against leukemia L1210 both 
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Figure 2.26 Different other pyridin-2-one nucleosides 
Finally, three 3-fluoro-3-deazacytidine derivatives (83a-c) have been reported by Cook et 
al. in 1987, which all show in vitro activity against L1210 leukemia tumour cells in the 
same range as 3-DC. 83a-b have been shown to possess also in vivo activity.107 Later Teepe 
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et al. reported the in vivo activity of 83a against P338 leukemia tumour cells and the in 
vitro activity against rhinovirus type 34.106b 
2.3.2.2  Pyridin‐4‐one nucleosides 
Only two biologically active pyridin-4-one nucleosides have been reported (84 and 85; 
Figure 2.27). In 1984 Marquez et al. reported the synthesis and the in vitro activity of 84 
against P338 leukemia tumour cells, while in vivo a low activity was observed.108 Recently, 











 84 85 
Figure 2.27 Several pyridin-4-one nucleosides 
2.3.3  Pyrazine nucleosides 
Interesting pyrazine nucleosides are limited to only a few examples. Three biologically 
active pyrazine nucleosides are the ribose analogues (87a-c) of emimycin (86), which is a 
natural antibiotic that was isolated from Streptomyces No. 2020-I.110 Emimycin nucleoside 
87a has shown to possess only moderate antibacterial activity against S. faecium and E. 
Coli, while being a good anticoccidial agent against several species of chicken Eimeria.111 
2’-Deoxyriboside 87b shows the reverse activity. While a 100.000 times higher activity 
against S. feacium and E. Coli is found, the anticoccidial activity is very low.111c,112 5-
Methyl emimycin 2’-deoxyriboside 87c showed low antibacterial activity, while good anti- 
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Figure 2.28 Emimycin nucleosides 
A further example of pyrazine nucleosides is, N-aminopyrazinonium nucleoside 88, 
which showed moderate activity as a cytotoxic agent.114 Finally, triphoshate pyrazine 
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nucleotide 89 has been found to exhibit potent inhibition of influenza viral polymerase. 
However, this triphosphate has not been synthesised chemically, but was found to be 
formed intracellular from the nucleoside by phosphorylation of nucleotidase.115    
2.3.4 Pyrimidin‐2‐one nucleosides 
Pyrimidinone nucleosides draw considerable attention as potential anti-cancer drugs. 
Especially, zebularine (pyrimidin-2-one riboside; 90a in Figure 2.29), which was originally 
discovered in 1969 as antibacterial agent, has drawn a lot of attention the last five years as 
anti-cancer drug.116 Zebularine (90a) targets DNA methyltransferase (DNA Mtase)117 and 
cytidine deaminase.118 DNA Mtases take care of the methylation pattern of DNA and 
maintain it during every round of DNA replication. Hypermethylation of tumour suppressor 
genes caused by aberrant activity of DNA Mtase is an important mechanism that 











































 90 91 92 
Figure 2.29 Pyrimidine nucleosides 
The mechanism by which DNA Mtase acts, involves the addition of a protein thiol group 
(from a cysteine residue) to the C6 position of the target cytidine, which activates the 
carbon atom at the 5 position allowing reaction with S-adenosyl-L-methionine.117 This 
results, after abstraction of the C5-proton, in methylated DNA and free enzyme (Scheme 
2.2; path a). The proposed inhibition mechanism of zebularine is depicted in Scheme 2.2 
(path b). The absence of the amino group on C4 enhances the nucleophilic attack of the 
cysteine residue at C6 of the base resulting in a very stable covalent complex. Although a 




















































































Scheme 2.2 Chemical structure of covalent adduct between DNA Mtase and zebularine 
Zebularine preferentially inhibits tumour cells over normal fibroblasts.119 Furthermore, 
the response in DNA, RNA, proteins, and cellular growth of tumour cells is higher 
compared to normal cells. In addition, zebularine is very stable unlike 5-Aza-2’-
deoxycytidine (5-Aza-CdR), making oral administration possible. However, a poor 
bioavailability of zebularine is reported, which can be due to rapid metabolism of absorbed 
zebularine to uridine and further degradation to uracil. Therefore large doses of zebularine 
are necessary.120 A combination therapy with 5-azacytidine (see section 2.3.5.1), which is 
deactivated by cytidine deaminase and inhibited by zebularine, showed better results than 
the monotherapy with either of these therapeutics. This makes this approach a serious 
candidate for clinical use.121 The mechanism of this drug interaction may involve inhibition 
of cytidine deaminase by zebularine and inhibition of DNA Mtase by both agents.  
Reduction of one of the double bonds of zebularine results in nucleosides 91 and 92a, 
which are as potent as zebularine in cytidine deaminase activity. When at C4 a hydromethyl 
group was introduced (92b in Figure 2.29) a 5-fold increase in activity was observed.118b 
Introduction of several other functional groups at C5 resulted in some interesting 
compounds (Figure 2.29). E.g. a SCH3, ethynyl or propargyl group at C5 resulted in a 
HSV-1 and/or HSV-2 active compound.122 The 5-halogen pyrimidinone nucleosides 90b-e 
showed all HSV-1 and -2 activity comparable to zebularine or even higher.118a,123 Barchi et 
al. reported also anti-leukemia activity for 5-fluoro-pyrimidin-2-one nucleoside 90b.118d 5-
Iodo-pyrimidin-2-one 2’-deoxyribose (IPdR), the 2’-deoxy analogue of 90c, is also HSV-1 
and -2 active.124 IPdR is now under preclinical evaluation as prodrug of 5-iodo-2’-
deoxyuridine, which is a radiosensitizer.125   
 




5-Azapyrimidine nucleosides consist mainly of 5-azacytidine (93a) and analogues (Figure 
2.30), which are all DNA methyltransferase (DNA Mtase) inhibitors. As with zebularine, 5-
azacytidine (93a) and analogues can form similar covalent complexes with DNA Mtase and 
in this way inhibit DNA Mtase (Scheme 2.3).126 The nucleophilic attack of a cysteine 
residue on C6 is enhanced, because the C6 position is more electrophilic due to the 
presence of a nitrogen atom at position 5. Due to the absence of a proton on N5 the last step 





































Scheme 2.3 Inhibition of DNA Mtase by 5-azacytidine 
5-Azacytidine (93a) and 5-aza-2’-deoxycytidine (decitabine; 93b) were originally tested 
for their anti-leukemia activity,127 and were during the 1970s and 1980s used in high, and 
most of the time toxic, doses to treat leukemia. At that time, 5-azacytidine and decitabine 
were not recognised as hypomethylating agents yet. It was only in the mid 1990s that 5-
azacytidine (93a) and decitabine (93b) were recognised as DNA MTase inhibitors.128,129,130 
5-Azacytidine (93a) can be incorporated both in DNA and RNA after it is activated to its 
triphosphate and leads to inhibition of DNA, RNA and protein synthesis.131 In contrast, 
decitabine (93b), which is a 10-fold more cytotoxic than 93a, is only incorporated into 
DNA.132  
A hydrolytically stable analogue of 5-azacytidine133 is dihydro-5-azacytidine (94a) and 
shows antitumour activity against L1210 leukemia cells, Friend leukemia, human MX-1 
mammary xenograft, murine CD8F mammary tumour, implanted colon 38 tumour and 
malignant mesothelioma.134 Dihydro-5-azacytidine (94a) targets besides DNA Mtase also 
RNA synthesis. It is less effective than 5-azacytidines 93a-b in DNA Mtase inhibition, and 
a 25-fold higher dose is necessary to obtain the similar therapeutic effects as with 93a.135 
Phase I and II clinical trials for the treatment of malignant mesothelioma have revealed that 
94a is not effective enough and further clinical research has ceased.136 The 2’-deoxy 
analogue 94b has recently been discovered for the treatment of HIV, however not via 
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inhibition of DNA Mtase. Compound 94b uses a different strategy of mutation of the viral 
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Figure 2.30 5-Azacytidine and analogues 
Fazarabine, 1-β-D-arabinofuranosyl-5-azacytosine (95), has been synthesised in the late 
1970s138 and has been shown active against L1210 leukemia cell lines,139 P-338 cell 
lines,140 and several human tumor xenografts.141 Despite, this broad spectrum of activity, 
clinical trials showed no potent antitumour activity.142 
L-nucleoside analogs of 5-azacytidine (96a-e) have been synthesised and tested for their 
ability to inhibit HIV, hepatitis B virus (HBV) and Maedi-visna virus (MVV).  Only 96a 
showed a good anti-HBV activity but no anti-HIV activity,143 while 96b-e showed a 
moderate MVV activity.144  
2.3.5.2  6‐Azapyrimidine nucleosides 
This class of nucleoside analogues is dominated by 6-azauridine (97a; Figure 2.31). 
While this compound has been extensively studied, only a few related compounds have 
shown biological activity. Already in the beginning of the sixties it was shown that 6-
azauridine is an anti-psoriasis145 and anti-neoplastic drug.146 2’,3’,5’-Triacetyl-6-azauridine 
(97b) is the orally active prodrug of 6-azauridine.147 It can chemically and enzymatically be 
deacetylated and subsequently metabolised to its 5’-monophosphate nucleotide, which 
inhibits orotidine 5’-phosphate decarboxylase, an essential enzyme in the biosynthesis of 
pyrimidines.148 Although 6-azauridine showed promising cytostatic properties and very low 
toxicity in animals, only a small effect was observed on human leukemia.149 In addition a 
large range of side-effects was observed, e.g. fever or joint pain were observed in cases of 
rheumatoid arthritis.149a More recent, 6-azauridine has been evaluated for several viruses, 
which caused severe outbreaks in the past. 6-Azauridine was proven to be active against 
yellow fever virus,150 sandfly fever Sicilian virus,151 West Nile virus,152 pathogenic 
flaviviruses,153 Chikungunya and Semliki Forest viruses,154 and HIV-1.155  
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Figure 2.31 Different 6-azapyrimidine nucleosides 
In addition, a few reports on biologically active analogues of 6-azauridine (97) have 
appeared. Olin and co-workers reported the in vitro and in vivo activity of 2-thio-6-
azauridine (98) against L1210 leukemia cells.156 Furthermore, 98 shows also in vitro and/or 
in vivo antiviral activity against five RNA viruses,157 and in vitro activity against the West 
Nile virus.152 6-Azacytidine (99) was shown to be an antiviral agent too, with a broad 
spectrum of activity, for example several adeno-, herpes- and influenza- viruses are 
inhibited.158 Finally, Scopes et al. reported two 6-aza analogues of (E)-5-(2-Bromovinyl)-
2’-deoxyuridine (BVDU). BVDU is one of the most potent in vitro herpes simplex virus 
type 1 (HSV-1) inhibitors. Although a 500-fold lower activity is observed for 100a-b 
compared to BVDU, it is still of  significance.159  
2.4  Conclusion 
The nucleoside analogues discussed in this chapter show a broad spectrum of activity, 
different classes show different activities. Table 2.2 summarises the potential therapeutic 
areas of these nucleoside analogues. The discovery of a new clinical therapeutic application 
boosts often synthesis of analogues. In this way even more interesting nucleosides have 
been found; e.g. ribavirin used for the treatment of hepatitis C was overtaken by viramidine, 
because the side-effects were reduced and viramidine was a better liver targeting antibiotic.  
In this context, our goal to synthesise dihydropyrimidine nucleosides, as discussed in 
chapter 1, is relevant for the development of new therapeutics. The related pyrimidine 
nucleosides (see section 2.3.4) show a broad range of therapeutic action: antitumour, 
antiviral and antibacterial activity. In order to get dihydropyrimidine nucleosides, first 








Table 2.2 Overview of nucleoside analogues and their therapeutic activity 
























- chitin synthetase inhibitor 
- antifungal 
- anti-yeast 

























- immunomodulatory properties 
- antiparasitic  
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Continuation of Table 2.2 
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A broad range of differently substituted dihydropyrimidines can be efficiently prepared using a four-component 
reaction between phosphonates, nitriles, aldehydes and isocyanates. The scope and limitations of this 
multicomponent reaction are fully described. Variation of all four components was investigated. The nitrile and 
aldehyde inputs can be varied extensively but variation of the phosphonate input remains limited. An interesting 
rearrangement leading to phosphoramidates has been observed. Furthermore, the multicomponent reaction seems 
to be restricted to the use of isocyanates with strongly electron-withdrawing substituents, but an interesting 
additional exchange reaction under microwave conditions leads to dihydropyrimidines with less electron-
withdrawing substituents at N3. In addition, a diastereoselective formation of dihydropyrimidines has been 
observed when using a chiral aldehyde as the input.  
 




Structurally diverse libraries of small molecules are conveniently generated by 
combinatorial assembly of different types of building blocks onto a common scaffold. Most 
approaches rely on a stepwise protocol, but for more complicated skeletons such sequential 
re-iteration of individual reactions becomes a limiting factor. A more convergent approach 
is desired that ideally provides the suitably decorated scaffold in a single synthetic 
operation. Procedures that yield complex molecules by performing multiple reaction steps 
in which several bonds are formed without isolation of intermediates are commonly 
referred to as tandem reactions.1 An important subclass of tandem reactions are the multi-
component reactions (MCRs), which are defined as one-pot processes in which at least 
three easily accessible components are combined to form a single product.2 In this regard, 
MCRs are receiving ever-increasing attention as useful tools for parallel syntheses of arrays 
of structurally diverse products with considerable complexity.3,4  
Many small synthetic organic molecules with high medicinal potential contain 
heterocyclic rings. Also, the most potent ligand systems in (transition) metal-mediated 
(asymmetric) catalysis are often based on heterocyclic cores. The range of easily accessible 
and suitably functionalised heterocyclic building blocks is, however, surprisingly limited 
and the construction of even a small array of, for example, 500 relevant heterocyclic 
compounds is far from trivial. Heterocyclic chemistry therefore continues to attract the 
attention of medicinal and synthetic chemists,5 and the development of novel methodologies 
allowing efficient access to heterocycles efficiently is still highly appreciated. Traditionally, 
methods based on MCRs have proven quite efficient for the construction of many different 
types of heterocycles.4b For example, the Hantzsch four-component pyridine synthesis, the 
Bucherer–Bergs three-component thiazole synthesis, and the Biginelli three-component 
reaction for the preparation of dihydropyrimidines (DHPMs) are all well-known MCRs for 
the construction of heterocyclic species.4b Recently, we have also contributed with several 
examples in this area.6,7  
DHPMs are versatile heterocyclic 6-membered ring scaffolds with remarkable 
pharmacological activities.8 They are widely used in medicinal chemistry. For example, 
antiviral, antitumour, antibacterial and anti-inflammatory activities have been reported and 
DHPMs are also used as calcium channel modulators, α1a-adrenoceptor-selective 
antagonists and anti-hypertensive agents.9 The methods hitherto used for the preparation of 
biologically active DHPMs all involve multi step processes.10-13 An interesting approach 
was reported by Elliott and co-workers during their work on the synthesis of Batzelladine 
A,14 for which they developed an aza-DA reaction between a dihydro-oxazole and 
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isocyanates resulting in oxazolopyrimidines.15 Other well-known approaches to DHPMs 
use the classical Biginelli 3CR.8a,16 In the past decade, a series of procedures has been 
developed to overcome the relatively harsh conditions (EtOH, HCl, Δ) of the original 
reaction.17 A serious drawback of these protocols is that only the pharmacologically less 
important N1-substituted and N3-unsubstituted DHPM derivatives can be obtained. 
Additional synthetic manipulations are needed to obtain the biologically active N3-
substituted DHPMs.8,18    
The four-component reaction (4CR) depicted in Scheme 3.1 offers an alternative, which 
largely overcomes these problems and produces the desired N3-substituted DHPMs 106 in 
a single step. In this chapter the tolerance of this reaction to a broad range of nitrile 102 and 
aldehyde 103 inputs are presented. In addition, an extensive scope study is reported that 
addresses the influence of the phosphonate (101) and the isocyanate (105) components on 
the four component assembly of DHPMs 106. Steric and electronic factors that direct this 
MCR are discussed in detail in order to fully define its exploratory power EN. Also, the use 
of optically active input has been explored in order to obtain the desired DHPMs 106 




















 101 102 103 104 105 106 
Scheme 3.1 Multi component approach to DHPMs. 
101a R1 = H 102a R2 = Ph 103a R3 = 4-MeOPh 105a R4 = Ts 
101b R1 = Me 102b R2 = iPr 103b R3 = 4-ClPh 105b R4 = 4-NO2Ph 
101c R1 = Ph 102c R2 = 2-Furyl 103c R3 = Ph 105c R4 = Ph 
101d R1 = CH=CH2 102d R2 = CHMe(Et) 103d R3 =4-NMe2Ph 105d R4 = C(O)Ph 
101e R1 = PO(OEt)2 102e R2 = tBu 103e R3 = 3-NO2Ph 105e R4 = CO2Me 
101f R1 = CO2Me 102f R2 = nPr 103f R3 = 4-NO2Ph 105f R4 = CH(Me)Ph 
  103g R3 = iPr   
  103h R3 = PhOCH2OCH2  
  103i R3 = Me  






The reaction for the synthesis of DHPMs of type 106 as depicted in Scheme 3.1 is in fact 
a combination of a Horner-Wadsworth-Emmons reaction and an aza-Diels-Alder reaction 
(HWE/aza-DA 4CR) and most likely proceeds via 1-azadiene intermediates 104. These 
species are conveniently generated by mixing a phosphonate (101) with a base (e.g. nBuLi) 
at –78 °C, followed by nucleophilic addition to a nitrile (102). The intermediate ketimine is 
more nucleophilic at carbon than at nitrogen, resulting in a Horner-Wadsworth-Emmons 
reaction with a third component, an aldehyde (103),7,19 to give 1-azadiene 104. The mixture 
is then allowed to warm to room temperature, whereupon addition of an isocyanate (105) 
induces a formal Diels-Alder cycloaddition to give 106 (Scheme 3.1).  
3.2.1  Scope study of nitrile, aldehyde and isocyanate inputs 
Reaction of diethyl methylphosphonate (101a) and tosylisocyanate (105a) with aromatic 
nitriles 102 and aromatic aldehydes 103 proceeds smoothly and efficiently affords the 
corresponding DHPMs 106a–106f (entries 1–6; Table 3.1) efficiently.  
 
Table 3.1 HWE/aza-DA 4CR of phosphonate 101a and isocyanate 105a with nitriles 102 and 
aromatic aldehydes 103.  
Entry Nitrile R2 Aldehyde R3 Yield (%) DHPM 
1 102a Ph 103a 4-MeOPh 65 106a 
2 102a Ph 103b 4-ClPh 80 106b 
3 102a Ph 103c Ph 71 106c 
4 102a Ph 103d 4-Me2NPh 54 106d 
5 102a Ph 103e 3-NO2Ph 38 106e 
6 102c 2-furyl 103a 4-MeOPh 61 106f 
7 102b iPr 103a 4-MeOPh 73 106g 
8 102b iPr 103b 4-ClPh 65 106h 
9 102b iPr 103c Ph 55 106i 
10 102b iPr 103d 4-Me2NPh 49 106j 
11 102b iPr 103e 3-NO2Ph 60 106k 
12 102b iPr 103f 4-NO2Ph 55 106l 
13 102d CH(Me)Et 103a 4-MeOPh 49 106m 
14 102e tBu 103a 4-MeOPh 15 106n 
15 102f nPr 103b 4-ClPh < 5 106o 
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Aliphatic nitriles 102 in combination with aromatic aldehydes 103, 101a and 105a gave 
modest to good yields of the corresponding DHPMs 106g–106o (entries 7–15; Table 3.1). 
When secondary nitriles 102b and 102d were used (entries 7–13; Table 3.1) the yields of 
the corresponding DHPMs 106g–106m were still satisfying. However, when the sterically 
more demanding pivalonitrile (102e) was used as input (entry 14; Table 3.1) the yield of 
106n was rather poor. Also, use of the primary nitrile 102f resulted in only traces of the 
desired DHPM 106o (entry 15; Table 3.1). In a related study toward the synthesis of α,β-
unsaturated ketones via in situ generated 1-azadienes, it was reported that primary nitriles 
are quite prone to dimerisation and polymerisation,19,20 which may account for the 
diminished yield of DHPM 106o. 
Besides aromatic aldehydes, aliphatic aldehydes were also used as inputs in the MCR. 
When these aliphatic aldehydes (103g, 103h, and 103i) were allowed to react with nitriles 
102a–c, 101a and 105a only moderate yields of the corresponding DHPMs 106p–106t 
could be isolated (Table 3.2). 
 
Table 3.2. HWE/aza-DA 4CR of phosphonate 101a and isocyanate 105a with nitriles 102 and 
aliphatic aldehydes 103.  
Entry Nitrile R2 Aldehyde R3 Yield (%) DHPM 
1 102a Ph 103g iPr 35 106p 
2 102a Ph 103i Me 15 106q 
3 102c 2-furyl 103g iPr 36 106r 
4 102b iPr 103g iPr 40 106s 
5 102b iPr 103h PhOCH2OCH2 21 106t 
 
In order to further explore the scope of the HWE/aza-DA 4CR for the synthesis of 
DHPMs 106 the isocyanate input 105 was also varied (Figure 3.1). Isocyanates are versatile 
starting materials, which are used in other MCRs as well.21 Thus, next to 105a, also 
isocyanates 105b, 105d and 105e proved successful when reacted with 101a, 102a, and 
103a in the presence of nBuLi and afforded DHPM 106u–106x in modest to good yield. 
Several pharmacological studies show that an ester or amide function at N3 or C5 in 
DHPMs like 106 are required for biological activity.8c To our satisfaction isocyanate 105e 
afforded in this way, pharmaceutically more relevant DHPMs 106v and 106w in 70% and 































 106u (26%) 106v (70%) 106w (29%) 106x (70%) 
Figure 3.1 DHPMs 106 formed with various isocyanates 105. 
The synthesis of 106 most likely starts with abstraction of the α-H of 101 by nBuLi, 
followed by nucleophilic addition to the nitrile 102 (Scheme 3.2). The intermediate ketimine 
A is more nucleophilic at carbon than at nitrogen, resulting in a Horner-Wadsworth-Emmons 
reaction with the third component, the aldehyde 103, to give 1-azadiene 104. Efficient 
generation of the resonance stabilised A is crucial and strongly depends on the type of nitrile 
used. The use of nitriles with poorly accessible α-hydrogens as well as aromatic nitriles 













































 104 B 106 
Scheme 3.2 Horner-Wadsworth Emmons aza Diels-Alder four component reaction 
Although, a nitrogen at the 1-position of 104 creates a π-deficient diene, which usually 
shows much lower reactivity towards dienophiles, 1-azadiene 104 must undergo a formal DA 
reaction with the electron-deficient N=C π-bond of isocyanate 105 in order to afford the 
observed DHPMs 106. Normal aza-DA reactions, where an electron-rich (aza)diene reacts 
with an electron deficient (aza)dienophile, are well-known using 2-azadienes.22 Similar DA-
reactions with 1-azadienes, however often proceed sluggish and are of limited synthetic 
significance.23 Usually, the thermodynamic driving force for an (concerted) aza DA reaction 
of 1-azadienes is, compared to butadienes and 2-azadienes about 200 kcal/mol lower resulting 
in a much lower reactivity toward dienophiles.23,24 On the other hand, cycloaddition reactions 
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involving isocyanates are reported to proceed via a polar stepwise mechanism in almost all 
cases.25 In our study a stepwise mechanism for the cyclocondensation to generate 106 is 
supported by isolation of triazinane dione 107a and non-cyclised 108, where 101a, 102a, and 
103a were used in combination with isocyanate 105c (Scheme 3.3). The isolation of the non-
cyclised linear precursor 108 strongly supports a stepwise cycloaddition of the corresponding 
1-azadiene intermediate with 105c.26 These observations suggest that the final 
cyclocondensation proceeds through stabilised intermediates B although a concerted DA 
cyclisation for the MCRs using more electron-deficient TsNCO cannot be excluded.27 Thus, 
non-cyclised 108 can be formed from intermediate B via a 1,3-H-shift. Formation of 
triazinane dione 107a can be rationalised by addition of a second equivalent of PhNCO to B 
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Scheme 3.3 Synthesis of DHPMs 109 with less electron withdrawing R4-substituents 
The HWE/aza-DA approach to form DHPMs 106 directly, seems confined to the use of 
isocyanates with relatively strongly electron-withdrawing substituents R4. Strong electron 
withdrawing groups R4 on the isocyanate favour aza-DA of the initially formed 1-azadiene 
104 to form the corresponding DHPM 106. However, the application of 105 with less 
electron-withdrawing R4 can successfully lead to DHPMs using microwave (MW) conditions. 
To our satisfaction, 108 could be cyclised under MW-conditions at 120 °C in THF as the 
solvent and the desired DHPM 109 could be isolated in 38% yield (Scheme 3.3). Moreover, 
we also observed an interesting exchange reaction under MW-irradiation. When DHPM 106a 
(R4=Ts, y = 65%) is heated together with isocyanate 105c (R4=Ph) at 190 °C in dioxane for 




Another point of diversity in the DHPM-scaffold (106) is R1, which is introduced via the 
phosphonate input 101. Therefore, we decided to investigate the application of different 
phosphonates in the HWE/aza-DA 4CR. Phosphonates 101 were prepared by way of the 
Michaelis−Arbuzov reaction.28 Thus, reaction of triethyl phosphite with appropriate halides 
under controlled microwave heating in a monomode reactor afforded phosphonates 101a–d 
in very good yields.29 
 
Table 3.3. HWE/aza-DA 4CR of phosphonates 101a and 101b, nitriles 102a-c, aldehyde 103 and 
isocyanate 105a. 
Entry Phosphonate R1 Nitrile R2 Yield (%) DHPM 
1 101a H 102a Ph 65 106a 
2 101a H 102c 2-furyl 61 106f 
3 101a H 102b iPr 73 106h 
4 101b Me 102a Ph 35 106y 
5 101b Me 102c 2-furyl 90 106z 
6 101b Me 102b iPr -- -- 
 
Phosphonates 101a–d were used in combination with a small set of nitriles (102a–c), 
anisaldehyde (103a) and tosylisocyanate (105a). The results are summarised in Table 3.3 
and Table 3.4.  The use of phosphonate 101b instead of 101a in combination with aromatic 
nitriles 102a/102c, 103a and 105a results in moderate to good yields of the corresponding 
DHPMs 106y and 106z (entries 4 and 5, Table 3.3), although the yield of 106y is 
considerably lower than that of 106z. Moreover, when the aliphatic nitrile 102b is reacted 
with 101b, 103a and 105a no DHPM could be detected (entry 6; Table 3.3). The other two 
synthesised phosphonates 101c and 101d also failed to give DHPMs in the HWE/aza-DA 
4CR. To clarify the course of the reaction, the consumption of phosphonates 101b, 101c 
and 101d by either 102a or 102b was studied in more detail using 31P NMR spectroscopy. 
For the reaction involving 101b, this revealed that although initial deprotonation with 
nBuLi proceeds smoothly, the resulting anion reacts rather slowly with 102b. Even after 
stirring the reaction mixture at room temp. overnight, considerable amounts of unreacted 
101b were still detected. Nevertheless, formation of the corresponding intermediate of type 
A (Scheme 3.2) most likely took place. When the reaction mixture was quenched with MeI 
(no products could be identified with H2O) the intermediate was indeed trapped. A mixture 
of products was formed; the main products were identified as the phosphoramidates (E)- 
and (Z)-110a (37%, entry 1; Table 3.4). 
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Table 3.4. Reaction of phosphonates 101b-d with nitriles 102a and b.a 
Entry Phosphonate  Nitrile  Quench 
method 
Products  Recovery of 101 















(Z)-110b (100%) -- 

























(Z)-110c (20%) 7%c 






(Z)-111b (25%)d 7%c 
















(E)- 113 (63%) 
-- 
a) After reaction with nitrile was complete (entries 2, 3 and 6) or after stirring at room temp. overnight (entries 1, 4 
and 5), the reactions were quenched by either MeI or H2O and the product composition was analysed with 1H and 
31P NMR, see experimental for more details; b) A third phosphoramidate (6%) was identified as well, see 
reference 30; c) Another phosphonate (10-20%) was identified next to residual 101c, see reference 31; d) 






Also, when phosphonate 101c was used in combination with 102a, 103a and 105a in the 
4CR, no corresponding DHPM was formed at all. However, if after initial deprotonation 
and addition of 102a the reaction was quenched using MeI, the sole identifiable product 
was phosphoramidate 110b (quant., entry 2; Table 3.4). On the other hand, when the same 
reaction mixture was quenched with water instead of MeI (entry 3; Table 3.4) the 
phosphoramidates (E)- and (Z)-111a (58%) together with the imine 112 (42%) were found, 
as concluded on the basis of the NMR data. Next, the reaction of 101c with isobutyronitrile 
(102b) was investigated (entries 4 and 5; Table 3.4). Although initial deprotonation seemed 
to proceed smoothly, the resulting anion reacted only relatively slowly with 102b. After 
stirring at room temperature overnight, 7% of unreacted 101c remained. Additionally, some 
20-25% of the corresponding phosphoramidates (Z)-110c and (Z)-111b were identified 
when MeI and water, respectively, were used to quench the reaction. Finally, when 
diethylallyl phosphonate 101d was deprotonated in a similar fashion as above with nBuLi, 
the resulting anion was found to react with benzonitrile 102a. After quenching with MeI 
two main products, (E)-110d and 113 were identified in a 1:2 ratio, respectively (entry 6; 
Table 3.4). The process depicted in Scheme 3.4 can rationalise the formation of 
phosphoramidates 110 and 111 as well as the formation of imine 112. After initial 
deprotonation of the phosphonates 101b–d, the resulting anions react with nitriles 102a or 
102b to form the corresponding stabilised intermediates A. Then, A rearranges to D, which 
is also stabilised by resonance. Ultimately, the observed rearranged products are formed by 
reaction of D with MeI (110) or water (111 and 112). The rearrangement of A → D may 
proceed via C, which is a four-membered N,P-containing ring analogous to the 
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 C D 110 (R3=Me) 112 (R1, R2=Ph, R3=H) 
  111 (R3=H) 
Scheme 3.4 Mechanism for formation of phosphoramidates 110–112. 
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Efficient formation of A depends on the stability of the initial anion in combination with 
the accessibility of the α-proton of the nitrile input. Furthermore, the intermediate A 
derived from 101b is less stable than the corresponding anion derived from 101c or 101d.33 
Consequently, DHPMs 106 can still be formed upon reaction of the anion of 101b with 
aromatic nitriles 102 followed by a quick HWE/aza-DA process with 103a and 105a 
(entries 4 and 5; Table 3.3). On the other hand, after deprotonation of the phosphonates 
101c and 101d the anion reacts smoothly with the nitrile input to form A but then fast 
rearrangement to D is preferred, which ultimately leads to products 110, 111 and 112. Only 
one precedent for a similar rearrangement exists in literature.34 Two commercially available 
phosphonates 101e and 101f were treated with nBuLi and a nitrile in a similar manner as 
described above. Deprotonation was successful in both cases, but resulted in a very stable 
anion that did not react with benzonitrile 102a at all and no rearranged products were 
observed. Also, one-pot reaction of either 101e or 101f with 102a, 103a and 105a did not 
give the corresponding DHPM as a product. Addition of crown ethers or the use of HMPA 
as co-solvent did not result in reaction of the anion. Also, the use of alternative bases, like 
KOtBu or LDA did not result in any reaction of the anion A of 101e or 101f with 102a. 
3.2.3  Chiral starting materials as input in MCR 
The biological activity of DHPMs depends on the absolute configuration at the C4 centre, 
whereby the orientation of the substituent acts as a molecular switch between agonist and 
antagonist activities.9c A stereoselective synthesis of optically pure DHPMs is therefore of 
great relevance for medicinal applications of these compounds. Although not comparable to 
the HWE/aza-DA 4CR, stereoselective formation of DHPMs via the classical Biginelli-
3CR has been reported. Dondoni and co-workers achieved good de values by using C-
glycosylated inputs,35 and very recently an enantioselective Biginelli 3CR was reported 
using a chiral Ytterbium catalyst.36 In order to induce chirality in our HWE/aza-DA 4CR, 
three reactions were performed with different optically pure inputs (Scheme 3.5). First, a 
reaction was performed with the commercially available optically pure nitrile (S)-(+)-102d 
in combination with 101a, 103a and 105a. This gave a 1:1 diastereomeric mixture of 114a 
in 60% yield. When optically pure isocyanate (R)-105f was combined with 101a, 102a, and 
103a, the corresponding DHPM was not formed. Instead triazinane dione 107b was isolated 
in 42 % yield and a 1:1.5 mixture of diastereomers. Formation of triazinane diones has been 
observed previously for less reactive isocyanate inputs (Scheme 3.3) This interesting 
reaction will be further explored and will be subject of a forthcoming paper. However, 
when the commercial (-)-myrtenal 103j was used as the aldehyde input (with 101a, 102a 
and 105a) the corresponding DHPM 114b was formed in 80% yield as a 11:1 
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diastereomeric mixture, which is comparable to what Dondoni et al.35 found when they 



















 (S)-102d 114a (R)-102f 107b 
  yield: 60 %  yield:42 % 










  103j 114b 
 (-)-myrtenal yield: 80% 
  de: 83 % 
Scheme 3.5 Use of chiral inputs in the HWE/aza-DA 4CR. 
3.2.4  Application of ketones in HWE/aza‐DA 4CR 
In order to further explore the scope of the four-component HWE/aza-DA reaction some 
ketones were also used as inputs instead of aldehydes. When cyclohexanone (115) or 
benzophenone (117) was combined with 101a, 105a and either 102a or 102b, the 
corresponding DHPM was not formed (Scheme 3.6). However, when the reactions were 
quenched with sulphuric acid prior to addition of 105a, the α,β-unsaturated ketones 116 
and 118 were detected.37 This indicates that the HWE-process took place and that the 
corresponding 1-azadiene intermediates did form. Apparently, these are not reactive enough 
to undergo subsequent cycloaddition upon in situ treatment with 105a to give the desired 























 101a 102a-b 115 104 116 





















 101a 102a-b 117 104 118 
Scheme 3.6 Use of ketones in the HWE/aza-DA 4CR. 
3.3 Conclusions 
The four component HWE/aza-DA approach to synthesise a variety of DHPMs has been 
extensively explored. A broad range of different R2 (nitrile) and R3 (aldehyde) substituents 
can be introduced on the DHPM scaffold via this procedure. However, variation of R1 
(phosphonate) remains limited. Next to R1=H, R1=Me is tolerated depending on the type of 
nitrile applied, but with other R1 groups in the phosphonate input a rearrangement reaction 
is observed that results in phosphoramidates as the main product. The R4 substituent can be 
varied, although direct formation of DHPMs is restricted to the use of isocyanates that bear 
a strongly electron-withdrawing R4 substituent. However, less electron-withdrawing R4 
substituents can be easily introduced by heating the initially formed DHPM with 
appropriate isocyanates under microwave conditions. Furthermore, we have demonstrated 
that, in particular, the use of optically pure aldehydes as input results in diastereoselective 
formation of the corresponding DHPM. 
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All reactions were carried out under dry nitrogen or argon. 1H, 13C and 31P nuclear magnetic 
resonance (NMR) spectra were recorded on a Bruker AC 200 (200.13 and 50.32 MHz, respectively), 
a Bruker Avance 250 (250.13, 62.90 and 101.25 MHz, respectively) or a Bruker MSL 400 (400.13, 
100.61 and 161.98 MHz respectively) spectrometer; chemical shifts (δ) are given in ppm, internally 
referenced to residual solvent resonances (1H: δ 7.29 ppm, 13C: δ 77.0 ppm). Column chromatography 
was performed on Baker 7024-02 silica gel (40 μ, 60 Å) with petroleum ether (PE, boiling range 40-
60 °C) and ethyl acetate (EA) as eluents. Thin-layer chromatography (TLC) was performed using 
silica plates from Merck (Kieselgel 60 F254 on aluminium with fluorescence indicator). Compounds 
on TLC plates were visualised under UV light or by treatment with an anisaldehyde solution (6 ml p-
anisaldehyde, 7 ml acidic acid and 7 ml sulphuric acid in 120 ml ethanol). High-resolution mass 
spectra (HRMS, EI) were recorded on a Finnigan Mat 900 spectrometer at 70 eV. IR spectra were 
recorded on a Mattson 6030 Galaxy spectrophotometer and are reported in cm-1. Melting points were 
measured on a Stuart Scientific SMP3 melting point apparatus and are uncorrected. Diastereomeric 
excess (de) was determined on a Shimadzu Prominence, equipped with a DAD detector and a 
Shimadzu SIL-20A auto-injector. Optical rotation was determined with an AA-10 automatic 
polarimeter from Optical Activity Ltd. Microwave reactions were performed in a monomode 
microwave (MW) reactor equipped with an autosampler (CEM explorer). The temperature was 
controlled throughout the reaction and was assessed by measuring the surface temperature at the 
bottom of the reaction vessel  by means of an infrared sensor. In all cases capped vessels were used, 
allowing a pressure to build-up. The pressure was evaluated by measuring the bulging of the septum, 
but never exceeded 20 bars. Tetrahydrofuran (THF) was dried and distilled from sodium 
benzophenone prior to use. PE was distilled prior to use. Benzonitrile (102a), isobutyronitrile (102d) 
and benzaldehyde (103c) were dried, distilled, and stored under a dry nitrogen atmosphere. Other 
commercially available chemicals were used as purchased.  
3.5.2  Synthetic procedures and physical data 
Diethyl methylphosphonate (101a) 
Triethyl phosphite (3.0 mL, 17.5 mmol) and methyl iodide (1.95 mL, 31.3 mmol) were 
heated in a microwave oven (Power max: 50 W, ramp time: 10 min, hold time 5 min at 
130°C). The ethyl iodide formed as a side product was distilled off at 40°C and 10 
mbar. Yield: 97 %; 1H NMR (250.13 MHz, CDCl3): δ=1.34 (t, J=7.0 Hz, 6H; CH3CH2), 1.48 (d, 
J=17.5 Hz, 3H; CH3), 4.04–4.10 (m, 4H; CH2); 13C NMR (50.32 MHz, CDCl3): δ=10.4 (d, J=144.2 
Hz), 15.7 (d, J=6.2 Hz), 60.6 (d, J=6.2 Hz); 31P NMR (101.25 MHz, CDCl3): δ=29.7.29 
  
Diethylethylphosphonate (101b) 
Triethyl phosphite (1.0 mL, 5.83 mmol) and ethyl bromide (0.44 mL, 5.83 mmol) were 
heated in a microwave oven (Power max. 50 W, ramp time 10 min, hold time 15 min at 
200°C and 10 min at 180°C). Ethyl bromide was distilled off from the resulting 
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J=7.7 Hz, 3H; CH3CH2P), 1.00 (t, J=7.1 Hz, 6H; CH3CH2O), 1.32–1.49 (m, 2H; CH2P), 3.70–3.83 
(m, 4H; CH2O); 13C NMR (50.32 MHz, CDCl3): δ=6.3 (d, J=6.8 Hz), 16.2 (d, J=6.0 Hz), 18.5 (d, 
J=142.6 Hz), 61.1 (d, J=6.5 Hz); 31P NMR (101.25 MHz, CDCl3): δ=34.4.29  
 
Diethylbenzylphosphonate (101c) 
Triethyl phosphite (3.0 mL, 17.5 mmol) and benzyl bromide (2.71 mL, 22.75 
mmol) were heated in a microwave oven (Power max. 200 W, ramp. time 10 min, 
hold time 15 min at 140°C). Ethyl bromide (40°C and 100 mbar) and 
diethylethylphosphonate (90°C and 20 mbar) were distilled off to leave the pure product. Yield: 98 %; 
1H NMR (250.13 MHz, CDCl3): δ=1.26 (t, J=7.0 Hz, 6H; CH3), 3.18 (d, J=21.7 Hz, 2H; CH2Ph), 
3.97–4.10  (m, 4H; CH2), 7.25–7.34 (m, 5H; Ph-H); 13C NMR (50.32 MHz, CDCl3): δ=16.1 (d, J=6.0 
Hz), 33.5 (d, J=138.0 Hz), 61.9 (d, J=6.8 Hz), 126.6 (d, J=3.6 Hz), 128.3 (d, J=3.1 Hz; 2C), 129.6 (d, 
J=6.5 Hz, 2C), 131.4 (d, J=9.1 Hz); 31P NMR (101.25 MHz, CDCl3): δ=27.6.29 
 
Diethylallylphosphonate (101d) 
Triethyl phosphite (1.0 mL, 5.83 mmol) and allylbromide (0.6 mL, 6.93 mmol) 
were heated in a microwave oven (Power max. 250 W, ramp time 10 min, hold 
time 5 min at 180°C). Ethyl bromide was distilled off from the resulting solution at 
40°C and 100 mbar. Yield: 94 %; 1H NMR (250.13 MHz, CDCl3): δ=1.35 (t, J=7.1 Hz, 6H; CH3), 
2.64 (dd, J=7.4 Hz, J=21.9 Hz, 2H; PCH2), 4.08-4.20 (m, 4H; CH2CH3), 5.22-5.29 (m, 2H; 
CH2=CH), 5.77-5.88 (m, 1H; CH); 13C NMR (50.32 MHz, CDCl3): δ= 16.0 (d, J=6.0 Hz), 31.4 (d, 
J=139.3 Hz), 61.5 (d, J=6.6 Hz), 119.5 (d, J=14.4 Hz), 127.2 (d, J=11.2 Hz); 31P NMR (101.25 MHz, 
CDCl3): δ=27.9. 29 
 
General procedure for the synthesis of 106, 107, 108, 114, 116 and 118 via the HWE/aza-DA 
reaction. 
nBuLi (1.6 M in hexane; 1.2 equiv) was added dropwise to a stirred solution of phosphonate 101 (0.2 
M in dry THF) at –78°C. The resulting solution was stirred for 1.5 h and then nitrile 102 (1.1 equiv) 
was added. The reaction mixture was allowed to warm to –5°C over 1.5 h and then aldehyde 103 (1.1 
equiv) was added. The mixture was stirred for a further 0.5 h at –5°C and thereafter for 1.5 h at room 
temperature. Isocyanate 105 (1.1 equiv) was then added dropwise over 10 min and the resulting 
solution was stirred overnight. The solvent was removed under reduced pressure and the crude 
product was purified by crystallisation, column chromatography (PE/EA 4/1 → 1/1) or column 




The product was crystallised from THF. Yield: 65%; m.p.179–182°C [THF]; 1H 
NMR (250.13 MHz, CDCl3): δ=2.32 (s, 3H; CH3Ph), 3.83 (s, 3H; CH3O), 5.51 
(d, J=6.1 Hz, 1H; CHC), 6.15 (d, J=6.1 Hz, 1H; CHN), 6.88 (d, J=8.6 Hz, 2H; 
Ph-H), 6.99 (d, J=8.3 Hz, 2H; Ph-H), 7.34–7.53 (m, 9H; Ph-H), 7.93 (s, 1H; NH); 13C NMR (50.32 
MHz, CDCl3): δ=21.4, 55.3, 59.1, 101.7, 114.2 (2C), 125.2 (2C), 125.3 (2C), 128.5 (2C), 128.7 (2C), 
128.9 (2C), 129.3, 132.9 (2C), 134.0, 136.0, 143.9, 150.5, 159.6; IR (KBr): ν˜=3243 (m), 3125 (m), 






















The product was crystallised from THF. Yield: 80%; m.p. 186–189°C [THF]; 1H 
NMR (200.13 MHz, CDCl3): δ=2.35 (s, 3H; CH3Ph), 5.39 (d, J=6.1 Hz, 1H; 
CHC), 6.05 (d, J=6.1 Hz, 1H; CHN), 7.00 (d, J=8.5 Hz, 2H; Ph-H), 7.24–7.45 
(m, 12H; Ph-H and NH); 13C NMR (50.32 MHz, CDCl3): δ= 21.4, 58.8, 100.8, 
125.2, 128.5 (2C), 128.7 (2C), 128.9 (6C), 129.5 (2C), 132.6, 134.2, 134.6, 
135.7, 139.2, 144.4, 150.3; IR (KBr): ν˜=3239 (m), 3122 (m), 1693 (s), 1681 (s), 1360 (s), 1171 (s); 
HRMS (EI): m/z=438.0809 [M]+, calc. for C23H19ClN2O3S=438.0805. 
 
4,6-diphenyl-3-tosyl-3,4-dihydropyrimidin-2(1H)-one (106c) 
The product was purified by column chromatography and recrystallised from 
THF/pentane. Yield: 71%; m.p.183–185°C [THF]; 1H NMR (250.13 MHz, 
CDCl3): δ=2.33 (s, 3H; CH3Ph), 5.52 (d, J=6.1 Hz, 1H; CHC), 6.17 (d, J=6.1 Hz, 
1H; CHN), 7.00 (d, J=8.2 Hz, 2H; Ph-H), 7.29–7.48 (m, 12H; Ph-H), 7.65 (s, 1H; 
NH); 13C NMR (50.32 MHz, CDCl3): δ=21.4, 59.6, 101.4, 125.2 (2C), 127.2 (2C), 128.4, 128.5 (2C), 
128.8 (2C), 128.9 (4C), 129.4, 132.8, 134.3, 135.8, 140.7, 144.0, 150.5; IR (KBr): ν˜=3242 (m), 2986 




one (106d)  
The product was purified by column chromatography. Yield: 54%; m.p. 187–
189°C [EA]; 1H NMR (250.13 MHz, CDCl3): δ=2.28 (s, 3H; CH3Ph), 2.94 (s, 
6H; (CH3)2N), 5.45 (d, J=6.1 Hz, 1H; CHC), 6.03 (d, J=6.1 Hz, 1H; CHN), 6.68 
(d, J=8.8 Hz, 2H; Ph-H), 7.00 (d, J=8.2 Hz, 2H; Ph-H), 7.28–7.40 (m, 10H; Ph-H 
and NH); 13C NMR (100.61 MHz, CDCl3): δ=21.4, 40.6 (2C), 59.5, 102.3, 112.5 (2C), 125.3 (2C), 
128.4, 128.6 (4C), 129.0 (2C), 129.1 (2C), 129.3, 133.3, 133.8, 136.5, 143.7, 150.6, 150.8; IR (KBr): 
ν˜=3208 (m), 3108 (m), 2926 (m), 1674 (s), 1522 (s), 1350 (s), 1169 (s); HRMS (EI): m/z=447.1621 
[M]+, calc. for C25H25N3O3S=447.1617. 
 
4-(3-nitrophenyl)-6-phenyl-3-tosyl-3,4-dihydropyrimidin-2(1H)-one (106e) 
The product was purified by column chromatography. Yield: 38%; m.p. 195–
197°C [EA]; 1H NMR (200.13 MHz, CDCl3): δ=2.30 (s, 3H; CH3Ph), 5.47 (d, 
J=6.1 Hz, 1H; CHC), 6.27 (d, J=6.1 Hz, 1H; CHN), 7.07 (d, J=8.4 Hz, 2H; m-CH 
(Ts)), 7.42–7.54 (m, 7H; Ph-H), 7.73 (d, J=7.8 Hz, 1H; Ph-H), 8.00 (s, 1H, NH), 
8.14–8.17 (m, 2H; Ph-H)); 13C NMR (100.61 MHz, CDCl3): δ=21.6, 59.7, 99.9, 121.9, 123.3, 125.3 
(2C), 129.0 (4C), 129.2 (2C), 130.0, 130.1, 132.5, 133.0, 135.7, 135.8, 142.9, 145.0, 148.6, 149.8; IR 
(KBr): ν˜=3217 (m), 3106 (m), 1694 (s), 1676 (s), 1528 (s), 1348 (s), 1169 (s); HRMS (EI): 




The product was crystallised from DEE. Yield: 61%; m.p. 114°C (decomp) 
[DEE]; 1H NMR: (400.13 MHz, CDCl3): δ=2.26 (s, 3H; CH3Ph), 3.74 (s, 3H; 
CH3O), 5.56 (dd, J=1.2 Hz, J=6.1 Hz, 1H; CHC), 6.04 (d, J=6.1 Hz, 1H; CHN), 
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Hz, 2H; m-CH (PhOMe)), 6.99 (d, J=8.1 Hz, 2H; m-CH (Ts)), 7.25 (d, J=8.6 Hz, 2H; o-CH 
(PhOMe)), 7.32–7.34 (m, 3H; CH (Furan) and o-CH (Ts)), 7.71 (s, 1H; NH); 13C NMR (100.61 MHz, 
CDCl3): δ=21.9, 55.8, 59.5, 100.0, 107.7, 112.1, 114.7 (2C), 126.1, 129.2 (2C), 129.3 (4C), 133.3, 
136.7, 143.4, 144.6, 146.5, 150.8, 160.2; IR (KBr): ν˜=3243 (w), 3121 (w), 1697 (s), 1684 (s), 1510 




The product was crystallised from THF. Yield: 73%; m.p. 178–179°C [THF]; 1H 
NMR (200.13 MHz, CDCl3): δ=1.01 (d, J=6.9 Hz, 6H; (CH3)2CH), 2.15-2.26 (m, 
1H; CH(CH3)2), 2.26 (s, 3H; CH3Ph), 3.76 (s, 3H; CH3O), 4.84 (d, J=5.7 Hz, 1H; 
CHC), 5.83 (d, J=5.7 Hz, 1H; CHN), 6.82 (d, J=8.7 Hz, 2H; Ph-H), 7.01 (d, J=8.4 Hz, 2H; Ph-H), 
7.22–7.30 (m, 4H; Ph-H), 7.61 (s, 1H; NH); 13C NMR (100.61 MHz, CDCl3): δ=19.1, 19.2, 20.5, 
29.9, 54.4, 58.1, 97.7, 113.1 (2C), 127.6 (2C), 127.8 (2C), 127.9 (2C), 132.8, 135.6, 138.9, 142.9, 
149.8, 158.7; IR (KBr): ν˜=3223 (m), 3111 (m), 2969 (m), 1676 (s), 1510 (s), 1343 (s), 1169 (s); 
HRMS (EI): m/z=400.1444 [M]+, calc. for C21H24N2O4S=400.1457. 
 
4-(4-chlorophenyl)-6-isopropyl-3-tosyl-3,4-dihydropyrimidin-2(1H)-one (106h) 
The product was crystallised from THF. Yield: 65%; m.p. 186–187°C [THF]; 1H 
NMR (400.13 MHz, CDCl3): δ=1.08 (d, J=6.8 Hz, 6H; (CH3)2CH), 2.20–2.30 (m, 
1H; CH(CH3)2), 2.33 (s, 3H; CH3Ph), 4.87 (d, J=5.3 Hz, 1H; CHC), 5.9 (d, J=5.3 
Hz, 1H; CHN), 7.03–7.35 (m, 8H; Ph-H), 7.90 (s, 1H; NH); 13C MR (100.61 MHz, 
CDCl3): δ=20.1 (2C), 21.5, 30.6, 58.8, 97.9, 128.7 (4C), 128.9 (2C), 129.0 (2C), 134.1, 136.3, 140.2, 
140.7, 144.3, 155.0; IR (KBr): ν˜=3225 (m), 3117 (m), 2962 (m), 1705 (s), 1676 (s), 1344 (s), 1169 
(s); HRMS (EI): m/z=404.0961 [M]+, calc. for C20H21ClN2O3S=404.0961. 
 
6-isopropyl-4-phenyl-3-tosyl-3,4-dihydropyrimidin-2(1H)-one (106i) 
The product was purified by column chromatography. Yield: 55%; m.p. 178–
180°C [EA]; 1H NMR (200.13 MHz, CDCl3): δ=1.05 (d, J=6.8 Hz, 6H; 
(CH3)2CH), 2.15–2.30 (m, 1H; CH(CH3)2), 2.29 (s, 3H; CH3Ph), 4.91 (d, J=5.7 Hz, 
1H; CHC), 5.91 (d, J=5.7 Hz, 1H; CHN), 6.98 (d, J=8.3 Hz, 2H; Ph-H), 7.21–7.30 
(m, 8H; Ph-H), 7.97 (s, 1H; NH); 13C NMR (50.32 MHz, CDCl3): δ=19.9, 20.0, 21.4, 30.8, 59.5, 98.2, 
127.2 (2C), 128.2, 128.4 (2C), 128.7 (2C), 128.8 (2C), 136.2, 140.1, 141.5, 143.8, 151.1; IR (KBr): 
ν˜=3219 (m), 3107 (m), 2962 (m), 1705 (s), 1678 (s), 1356 (s), 1169 (s); HRMS (EI): m/z=370.1358 




The product was crystallised from THF. Yield: 49%; m.p. 178–180°C [THF]; 1H 
NMR (200.13 MHz, CDCl3): δ=1.05 (d, J=6.8 Hz, 6H; (CH3)2CH), 2.20–2.29 (m, 
1H; CH(CH3)2), 2.29 (s, 3H; CH3Ph), 2.94 (s, 6H; (CH3)2N), 4.88 (d, J=5.7 Hz, 
1H; CHC), 5.83 (d, J=5.7 Hz, 1H; CHN), 6.62 (d, J=8.8 Hz, 2H; Ph-H), 6.99 (d, J=8.2 Hz, 2H; Ph-
H), 7.15–7.29 (m, 4H; Ph-H) 7.40 (s, 1H; NH); 13C NMR (100.61 MHz, CDCl3): δ=20.6 (2C), 21.9, 
31.0, 41.0 (2C), 59.8, 99.3, 112.9 (2C), 128.9 (2C), 129.0 (2C), 129.3 (2C), 129.6, 137.2, 139.9, 
143.9, 151.1, 151.3; IR (KBr): ν˜=3230 (m), 2971 (m), 1676 (s), 1350 (s), 1169 (s); HRMS (EI): 



































The product was purified by column chromatography. Yield: 60%; m.p. 155–
157°C [EA]; 1H NMR (250.13 MHz, CDCl3): δ=1.14 (d, J=6.1 Hz, 6H; 
(CH3)2CH), 2.25–2.35 (m, 1H; CH(CH3)2), 2.33 (s, 3H; CH3Ph), 4.97 (d, J=5.3 Hz, 
1H; CHC), 6.11 (d, J=5.3 Hz, 1H; CHN), 7.07 (d, J=8.0 Hz, 2H; m-CH (Ts)), 
7.49–7.57 (m, 4H; Ph-H), 7.67 (d, J=7.7 Hz, 1H; CH (3-NO2Ph)), 8.14–8.18 (m, 2H; Ph-H and NH); 
13C NMR (100.61 MHz, CDCl3): δ=20.1 (2C), 21.5, 30.7, 58.5, 96.9, 122.0, 123.1, 128.8 (2C), 128.9 
(2C), 130.0, 133.1, 136.0, 141.9, 143.6, 144.7, 148.5, 150.7; IR (KBr): ν˜=3243 (m), 2967 (m), 1676 




The product was purified by column chromatography and recrystallised from 
THF/pentane. Yield: 55%; m.p. 170–171°C [THF]; 1H NMR (400.13 MHz, 
CDCl3): δ=1.07 (d, J=6.5 Hz, 6H; (CH3)2CH), 2.11–2.28 (m, 1H; CH(CH3)2), 2.35 
(s, 3H; CH3Ph), 4.91 (d, J=5.4 Hz, 1H; CHC), 6.05 (d, J=5.4 Hz, 1H; CHN), 6.91 
(s, 1H; NH), 7.10 (d, J=8.2 Hz, 2H; m-CH (Ts)), 7.44–7.47 (m, 4H; o-CH (Ts) and o-CH (4-NO2Ph)), 
8.16 (d, J=8.2 Hz, 2H; m-CH (4-NO2Ph)); 13C NMR (100.61 MHz, CDCl3): δ=20.0, 20.1, 21.6, 30.7, 
58.7, 97.0, 124.2 (2C), 127.7 (2C), 128.9 (4C), 135.9, 141.4, 144.9, 147.7, 148.4, 150.2; IR (KBr): 
ν˜=3211 (w), 3113 (w), 2963 (w), 1709 (m), 1680 (s), 1522 (s), 1346 (s), 1171 (s); HRMS (EI): 




The product was crystallised from THF and was thereby obtained as a 1:1 mixture 
of diastereomers. Yield: 49%; m.p. 170–171°C [THF]; 1H NMR (250.13 MHz, 
CDCl3): δ= 0.78 (t, J=8.0 Hz, 6H; CH3CH), 1.09 (d, J=8.2 Hz, 6H; CH3CH), 1.18–
1.49 (m, 4H; CH2CH), 2.01–2.17 (m, 2H; CHCH3), 2.36 (s, 6H; CH3Ph), 3.73 (s, 6H; CH3O), 4.90 (d, 
J=5.8 Hz, 2H; CHC), 5.87 (dd, J=5.8 Hz, J=3.2 Hz, 2H; CHN), 6.53 (s, 2H; NH), 6.82 (d, J=8.7 Hz, 
4H; o-CH (PhOMe)), 7.09 (d, J=8.4 Hz, 4H; m-CH (Ts)), 7.28–7.41 (m, 8H; NH); 13C NMR (100.61 
MHz, CDCl3): δ=10.8 (2C), 17.1, 17.4, 20.8 (2C), 26.1, 26.3, 36.8, 36.9, 54.7 (2C), 58.3, 58.4, 98.3, 
98.6, 113.3 (4C), 127.9 (4C), 128.0 (4C), 128.2 (4C), 133.3, 133.4, 136.0 (2C), 138.6 (2C), 143.1 
(2C), 149.6 (2C), 158.8 (2C); IR (KBr): ν˜=3239 (m), 2962 (m), 1681 (s), 1509 (m), 1345 (s), 1167 




The product was purified by column chromatography. Yield: 16%; m.p. 197–
202°C [EA]; 1H NMR (200.13 MHz, CDCl3): δ=1.10 (s, 9H; (CH3)3C), 2.31 (s, 
3H; CH3Ph), 3.81 (s, 3H; CH3O), 4.95 (d, J=5.9 Hz, 1H; CHC), 5.89 (d, J=5.9 Hz, 
1H; CHN), 6.82 (d, J=8.7 Hz, 2H; o-CH (PhOMe)), 7.03 (d, J=8.2 Hz, 2H; m-CH (Ts)), 7.15–7.26 
(m, 5H, Ph-H and NH); 13C NMR (100.61 MHz, CDCl3): δ=21.5, 27.7 (3C), 33.2, 55.4, 58.9, 98.4, 
114.1 (2C), 128.6 (2C), 128.8 (4C), 133.7, 136.5, 142.0, 143.8, 150.8, 159.7; IR (KBr): ν˜=3435 (m), 
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4-(4-chlorophenyl)-6-propyl-3-tosyl-3,4-dihydropyrimidin-2(1H)-one (106o) 
The product was purified by column chormatography; Yield: < 5%; m.p. 144–
147°C [EA]; 1H NMR (200.13 MHz, CDCl3): δ=0.90 (t, J=7.3 Hz, 3H; CH3CH2), 
1.43–1.57 (m, 2H; CH2CH3), 2.03 (t, J=7.4 Hz, 2H; CH2C), 2.34 (s, 3H; CH3Ph), 
4.90 (d, J=5.8 Hz, 1H; CHC), 5.90 (d, J=5.8 Hz, 1H; CHN), 7.05–7.39 (m, 9H; Ph-
H and NH); 13C NMR (62.90 MHz, CDCl3): δ=13.3, 19.7, 21.5, 33.8, 59.0, 100.2, 
127.8 (2C), 128.5 (2C), 128.7 (2C), 128.9 (2C), 134.1, 134.8, 136.2, 140.1, 144.4, 150.4; IR (KBr): 
ν˜=3223 (m), 3113 (m), 2961 (m), 1709 (s), 1680 (s), 1356 (s), 1167 (s), 1088 (s); HRMS (EI): 
m/z=404.0940 [M]+, calc. for C20H21ClN2O3S=404.0961. 
 
4-isopropyl-6-phenyl-3-tosyl-3,4-dihydropyrimidin-2(1H)-one (106p) 
The product was purified by column chromatography. Yield: 35%; m.p. 170–
171°C [THF]; 1H NMR (400.13 MHz, CDCl3): δ=0.88 (d, J=6.8 Hz, 3H; 
CH3CH), 0.96 (d, J=6.8 Hz, 3H; CH3CH), 2.18–2.31 (m, 1H; CH(CH3)2), 2.34 (s, 
3H; CH3Ph), 4.99–5.02 (m, 1H; CHC), 5.23 (dd, J=6.1 Hz, J=1.4 Hz, 1H; CHN), 6.68 (s, 1H; NH), 
7.32 (s, 3H; Ph-H), 7.82–7.84 (m, 4H; Ph-H), 7.83 (d, J=8.2 Hz, 2H; Ph-H); 13C NMR (100.61 MHz, 
CDCl3): δ=16.1, 18.7, 22.0, 35.7, 61.9, 98.2, 125.6 (2C), 129.3 (2C), 129.5 (2C), 129.6 (2C), 129.9, 
133.7, 136.9, 137.0, 144.8, 151.2; IR (KBr): ν˜=3238 (m), 2965 (m), 1693 (s), 1674 (s), 1344 (s), 
1171 (s); HRMS (EI): m/z=369.1280 [M]+, calc. for C20H22N2O3S=369.1273. 
 
4-methyl-6-phenyl-3-tosyl-3,4-dihydropyrimidin-2(1H)-one (106q) 
The product was purified by column chromatography and recrystallised from 
THF/pentane. Yield: 15%; m.p. 177–179°C [THF]; 1H NMR: (200.13 MHz, 
CDCl3): δ=1.45 (d, J=6.5 Hz, 3H; CH3CHN), 2.40 (s, 3H; CH3Ph), 5.21–5.35 (m, 
1H; CHCH3), 5.40 (dd, J=6.2 Hz, J=1.9 Hz, 1H; CHC), 6.89 (s, 1H; NH), 7.26 (d, J=8.2 Hz, 2H; o-
CH (Ts)), 7.38 (s, 5H; Ph-H), 7.93 (d, J=8.2 Hz, 2H; m-CH (Ts)); 13C NMR: (250.13 MHz, CDCl3): 
δ=22.0, 22.7, 52.6, 102.9, 125.5 (2C), 129.3 (2C), 129.4 (2C), 129.6 (2C), 129.9, 133.5, 135.7, 137.1, 
144.9, 150.6; IR (KBr): ν˜=3236 (m), 3116 (m), 1693 (s), 1678 (s), 1409 (s), 1345 (s), 1162 (s); 
HRMS: (EI): m/z=342.1062 [M]+, calc. for C18H18N2O3S=342.1038. 
 
6-(furan-2-yl)-4-isopropyl-3-tosyl-3,4-dihydropyrimidin-2(1H)-one (106r) 
The product was purified by column chromatography. Yield: 36%; m.p. 90°C 
(decomp.) [EA]; 1H NMR: (400.13 MHz, CDCl3): δ=0.92 (d, J=6.8 Hz, 3H; 
CH3CH), 1.01 (d, J=6.9 Hz, 3H; CH3CH), 2.24–2.29 (m, 1H; CH(CH3)2), 2.39 (s, 
3H; CH3Ph), 5.05–5.09 (m, 1H; CHN), 5.47 (dd, J=6.2 Hz, J=1.9 Hz, 1H; CHC), 6.44 (dd, J=1.6 Hz, 
J=3.5 Hz, 1H; CHCHO (furan)), 6.51 (d, J=3.5 Hz, 1H; CHC (furan)), 7.08 (s, 1H; NH), 7.26 (d, 
J=8.1 Hz, 2H; m-CH (Ts)), 7.40 (d, J=1.6 Hz, 1H; CHO (furan)), 7.88 (d, J=8.1 Hz, 2H; o-CH (Ts)); 
13C NMR (100.61 MHz, CDCl3): δ=15.7, 18.2, 21.5, 35.3, 61.4, 95.6, 106.6, 111.6, 127.6, 128.7 (2C), 
129.2 (2C), 136.5, 142.8, 144.4, 146.1, 150.5; IR: ν˜=3243 (w), 2967 (w), 1696 (s), 1684 (s), 1177 (s); 
HRMS: m/z=360.1184 [M]+, calc. for C18H20N2O4S=360.1143. 
 
4,6-diisopropyl-3-tosyl-3,4-dihydropyrimidin-2(1H)-one (106s) 
The product was crystallised from THF. Yield: 40%; m.p. 177–181°C [THF]; 1H 
NMR (400.13 MHz, CDCl3): δ=0.82 (d, J=6.9 Hz, 3H; CH3CH), 0.91 (d, J=6.9 
Hz, 3H; CH3CH), 1.04 (d, J=6.8 Hz, 6H; CH3CH), 2.08–2.25 (m, 2H; CH(CH3)2), 








































m-CH (Ts)), 7.85 (d, J=8.1 Hz, 2H; o-CH (Ts)); 13C NMR (100.61 MHz, CDCl3): δ=15.7, 18.5, 20.7, 
20.9, 22.0, 31.1, 35.3, 61.5, 94.0, 129.1 (2C), 129.5 (2C), 137.4, 142.8, 144.6, 151.8; IR (KBr): 





The product was purified by column chromatography. Yield: 21%; m.p. 148–
149°C [EA]; 1H NMR (400.13 MHz, CDCl3): δ=1.09 (d, J=6.9 Hz, 6H; 
(CH3)2CH), 2.14–2.29 (m, 1H; CH(CH3)2), 2.42 (s, 3H; CH3Ph), 3.42–3.53 (m, 
2H; CH2CH), 4.51 (s, 2H; CH2Ph), 4.87 (d, J=5.2 Hz, 1H; CHC), 5.11–5.19 (m, 1H; CHN), 6.45 (s, 
1H; NH), 7.22–7.98 (m, 9H; Ph-H); 13C NMR (62.90 MHz, CDCl3): δ=20.2 (2C), 21.6, 30.6, 55.1, 
72.0, 73.1, 95.1, 127.4 (2C), 127.6, 128.0 (2C), 128.9 (2C), 129.0 (2C), 136.9, 138.0, 143.1, 144.2, 
150.8; IR (KBr): ν˜=3221 (w), 3115 (w), 2963 (w), 1699 (s), 1670 (s), 1348 (s), 1167 (s); HRMS (EI): 




The product was crystallised from THF/pentane. Yield: 26%; m.p. 211–214°C 
[THF]; 1H NMR (250.13 MHz, CDCl3): δ=3.77 (s, 3H; CH3O), 5.34 (d, J=5.1 
Hz, 1H; CHC), 5.45 (d, J=5.1 Hz, 1H; CHN), 6.79–8.14 (m, 14H; Ph-H and 
NH); 13C NMR (100.61 MHz, CDCl3): δ=55.3, 63.8, 100.1, 114.5 (2C), 124.2 (2C), 125.1 (2C), 127.4 
(2C), 127.8 (2C), 129.0 (2C), 129.5, 133.1, 133.6, 134.7, 145.4, 147.1, 152.4, 159.6; IR (KBr): 





The product was purified by column chromatography. Yield: 70%; m.p: 147–150°C 
[EA]; 1H NMR (400.13 MHz, CDCl3): δ=3.68 (s, 3H; CH3), 3.80 (s, 3H; CH3), 5.49 
(dd, J=6.4 Hz, J=1.5 Hz, 1H; CHC), 5.87 (d, J=6.4 Hz, 1H; CHN), 6.80 (d, J=8.6 
Hz, 2H; Ph-H), 7.00 (s, 1H; NH), 7.29–7.41 (m, 7H; Ph-H); 13C NMR (100.61 MHz, CDCl3): δ=54.6, 
55.7, 57.2, 102.2, 114.6 (2C), 125.6 (2C), 128.6 (2C), 129.5 (2C), 129.9, 132.6, 133.6, 135.6, 150.7, 
155.0, 159.9; IR (KBr): ν˜=3259 (m), 2910 (m), 1734 (s), 1694 (s), 1408 (s), 1268 (s); HRMS: 




The product was purified by column chromatography and isolated as a light-yellow 
oil. Yield: 29%; 1H NMR (200.13 MHz, CDCl3): δ=1.06 (d, J=6.9 Hz, 6H; 
(CH3)2CH), 2.20–2.36 (m, 1H; CH(CH3)2), 3.71 (s, 3H; CH3), 3.76 (s, 3H; COOCH3), 
4.92 (d, J=6.1 Hz, 1H; CHC), 5.65 (d, J=6.1 Hz, 1H; CHN), 6.76 (d, J=8.8 Hz, 2H; m-CH (PhOMe)), 
7.22 (d, J=8.8 Hz, 2H; o-CH (PhOMe)), 7.58 (s, 1H; NH); 13C NMR (100.61 MHz, CDCl3): δ=20.4, 
20.8, 20.9, 54.3, 55.6, 57.0, 99.0, 114.5 (2C), 128.5 (2C), 133.4, 141.7, 151.7, 155.1, 159.7; IR (KBr): 




































The product was crystallised from THF. Yield: 70%; m.p. 186–187°C (decomp) 
[THF]; 1H NMR (400.13 MHz, CDCl3): δ=3.78 (s, 3H; CH3), 5.74 (d, J=6.3 Hz, 
1H; CHC), 6.01 (d, J=6.3 Hz, 1H; CHN), 6.87 (d, J=8.8 Hz, 2H; o-CH (PhOMe)), 
7.35–7.46 (m, 10H; Ph-H), 7.57–7.59 (m, 2H; o-CH (COPh)); 13C NMR (100.61 
MHz, CDCl3): δ=55.3, 55.9, 102.9, 114.1 (2C), 125.1 (2C), 127.8 (2C), 128.0 (2C). 128.4 (2C), 129.1 
(2C), 129.5, 131.2, 132.0, 133.0, 135.4, 136.3, 152.3, 159.4, 171.7; IR (KBr): ν˜=3282 (s), 2968 (w), 





The product was crystallised from ethyl acetate. Yield: 35%; m.p. 194–195°C 
[EA]; 1H NMR: (400.13 MHz, CDCl3): δ=1.65 (s, 3H; CH3C), 2.32 (s, 3H; 
CH3Ph), 3.83 (s, 3H; CH3O), 5.75 (s, 1H; CHN), 6.28 (s, 1H; NH), 6.85 (dd, 
J=6.7 Hz, J=2.0 Hz, 2H; m-CH (Ph)), 7.04 (d, J=8.3 Hz, 2H; m-CH (Ts)), 7.28–7.40 (m, 9H; Ph-H); 
13C NMR: (100.61 MHz, CDCl3): δ=15.7, 21.5, 55.4, 63.9, 109.8, 114.2 (2C), 128.5 (2C), 128.7 (2C), 
128.8, 128.9 (2C), 129.0 (2C), 129.1 (3C), 132.2, 133.8, 136.4, 144.0, 149.6, 159.9; IR (KBr): 
ν˜=3208 (m), 3102 (m), 2932 (m), 1680 (s), 1511 (m), 1351 (m), 1167 (s); HRMS (EI): m/z=448.1465 




The product was crystallised from ethyl acetate. Yield: 90%; m.p. 202–204°C 
(decomp) [EA]; 1H NMR (200.13 MHz, CDCl3): δ=1.89 (s, 3H; CH3C), 2.32  (s, 
3H; CH3Ph), 3.81 (s, 3H; CH3O), 5.77 (s, 1H; CHN), 6.45–6.48 (m, 2H; CH 
(Furan)), 6.78 (s, 1H; NH), 6.82 (d, J=8.8 Hz, 2H; m-CH (PhOMe)), 7.06 (d, J=8.2 Hz, 2H; m-CH 
(Ts)), 7.31 (d, J=8.8 Hz, 2H; o-CH (PhOMe)), 7.39 (d, J=8.2 Hz, 2H; o-CH (Ts)), 7.41–7.45 (m, 1H; 
CHO (furan)); 13C NMR (50.32 MHz, CDCl3): δ=16.1, 21.4, 55.2, 64.0, 109.9, 110.0, 111.6, 114.0 
(2C), 120.5, 128.6 (2C), 128.8 (2C), 129.0 (2C), 131.5, 136.1, 142.0, 144.0, 145.8, 149.5, 159.7; IR 
(KBr): ν˜=3225 (m), 3116 (m), 2925 (w), 1688 (s), 1674 (s), 1510 (s), 1258 (s); HRMS (EI): 
m/z=438.1261 [M]+, calc. for C23H22N2O5S=438.1249. 
 
(E)-6-(4-methoxystyryl)-1,3,6-triphenyl-1,3,5-triazinane-2,4-dione (107a) 
The general HWE/aza-DA procedure was followed using 101a, 102a, 103a and 105c. 
The product was purified via column chromatography and afforded 107a as a sticky 
oil. Yield: 32%; 1H NMR (400.13 MHz, CDCl3): δ= 3.82 (s, CH3, 3H), 6.25–7.65 (m, 
Ph-H and C=CH, 21H); 13C-NMR (100.6 MHz, CDCl3): δ= 55.3, 75.8, 114.3 (2C), 
125.6, 127.5 (2C), 127.6, 127.9, 128.2, 128.4 (2C), 128.6 (2C), 128.7 (2C), 128.8 
(2C), 129.2 (2C), 129.3, 129.7 (2C), 132.2, 135.0, 137.7, 140.3, 152.6, 153.3, 160.2; IR (KBr): 
ν˜=3441 (w), 3088 (w), 1723 (s), 1684 (s), 1516 (s), 1439 (s), 1260 (s); HRMS (EI): m/z=475.1893 







































The general HWE/aza-DA procedure was followed using 101a, 102a, 103a and 
(S)-105f. The product was purified by column chromatography to afford 107b in 
20% de. Yield: 42%; Diastereomeric excess was determined by HPLC analysis 
(Pathfinder 100PS_5.0μm, methanol/0.02 M ammonium acetate buffer pH=4.5 
70/30, 1mL/min); tr=70.88 min (minor), tr=63.73 min (major); R=2.22, α=1.12; m.p. 66–69°C [EA]; 
[α]20D= –72.0 (c=1.0 in CHCl3); 1H NMR: (400.13 MHz, CDCl3): δ=1.72 (d, J=7.0 Hz, 3H; CH3CH), 
1.73 (d, J=7.0 Hz, 3H; CH3CH), 1.75 (d, J=7.0 Hz, 3H; CH3CH), 1.78 (d, J=7.0 Hz, 3H; CH3CH), 
3.81 (s, 3H; CH3O), 3.85 (s, 3H; CH3O), 4.44 (q, J=7.0 Hz, 1H; CH3CH), 4.61 (br s, 1H; CH3CH), 
5.61–5.66 (m, 2H; CH3CH), 6.15 (d, J=15.9 Hz, 1H; CHCH), 6.29 (d, J=15.6 Hz, 1H; CHCH), 6.30 
(d, J=15.9 Hz, 1H; CHCH), 6.63 (d, J=15.6 Hz, 1H; CHCH), 6.81 (d, J=8.7 Hz, 2H; Ph-H), 6.91 (d, 
J=8.7 Hz, 2H; Ph-H), 7.00–8.01 (m, 34H; Ph-H); 13C NMR: (100.61 MHz, CDCl3): δ=16.5, 16.6, 
19.9, 20.2, 51.1 (2C), 55.3, 55.4, 56.4, 57.5, 76.1, 76.6, 114.0 (2C), 114.2 (2C), 125.3, 125.5, 126.2, 
126.3, 126.7, 126.9 (4C), 127.0 (2C), 127.1, 127.7 (6C), 127.8 (6C), 128.0 (2C), 128.2 (2C), 128.4 
(4C), 128.6 (2C), 129.0 (2C), 129.4, 129.7, 132.3, 132.5, 140.3, 140.5, 141.2 (2C), 142.0, 142.3, 
152.2, 152.5, 152.6, 153.1, 160.0, 160.2; IR (KBr): ν˜=3027 (w), 1711 (s), 1698 (s), 1512 (s), 1446 
(s), 1250 (s), 1028 (s); HRMS (EI): m/z=531.2522 [M]+, calc. for C34H33N3O3=531.2522. 
 
1-(3-(4-methoxyphenyl)-1-phenylallylidene)-3-phenylurea (108a) 
The general HWE/aza-DA procedure was followed using 101a, 102a, 103a and 
105c. After purification by column chromatography 108a was isolated as sticky oil. 
Yield: 40%; 1H NMR (250.13 MHz, CDCl3): δ=3.82 (s, 3H; CH3O), 5.19 (s, 1H; 
NH), 6.81–7.72 (m, 16H; Ph-H and CH); 13C NMR (100.61 MHz, CDCl3): δ=55.4, 
114.1 (2C), 118.9, 119.0 (2C), 123.8, 127.2, 128.4 (2C), 129.0 (2C), 129.3 (2C), 
129.9 (2C), 130.7, 137.3, 137.9, 145.5, 161.1 (2C), 172.3; IR (KBr): ν˜=3380 (w), 3017 (w), 1580 (s), 
1254 (m), 1173 (m); HRMS (EI): m/z=356.1523 [M]+, calc. for C23H20N2O2=356.1525. 
 
4-(4-methoxyphenyl)-3,6-diphenyl-3,4-dihydropyrimidin-2(1H)-one (109) 
DHPM 109 was prepared under MW conditions from 106b (procedure A) or from 
108a (procedure B). 
Procedure A: DHPM 106b (23 mg, 0.053 mmol) and phenylisocyanate (1.2 equiv) 
were dissolved in dry dioxane (1 mL) and heated in a microwave oven (Power max. 
300 W, ramp. time 30 min, hold time 60 min at 190°C). The solvent was then 
evaporated and the crude product was purified by column chromatography using PE/EA (4/1)→ EA. 
DHPM 109 was isolated in 58% yield. 
Procedure B: urea 108a (47 mg, 0.13 mmol) was dissolved in toluene (2.5 mL) and heated in a 
microwave oven (Power max. 300W, ramp. time 20 min, hold time 75 min at 120°C). The solvent 
was then evaporated and the crude product was purified by column chromatography using PE/EA 
(3/1)→ EA. DHPM 109 was isolated in 38% yield. m.p. 139–142°C [EA]; 1H NMR (400.13 MHz, 
CDCl3): δ=3.81 (s, 3H; CH3O), 5.28 (dd, J=2.1 Hz, J=4.9 Hz, 1H; CHC), 5.34 (d, J=4.9 Hz, 1H; 
CHN), 6.80 (d, J=8.7 Hz, 2H; m-CH (PhOMe)), 6.93 (s, 1H; NH), 7.07–7.51 (m, 12H; Ph-H); 13C 
NMR (100.61 MHz, CDCl3): δ=55.2, 64.6, 99.9, 114.0 (2C), 125.0 (2C), 127.0, 128.0 (2C), 128.5 
(2C), 128.9 (4C), 129.1, 134.1, 134.2, 134.9, 141.0, 153.0, 159.4; IR (NaCl): ν˜=2902 (w), 2839 (w), 
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General procedure for the trapping experiments with MeI and H2O 
nBuLi (1.6 M in hexane; 1.2 equiv) was added dropwise to a stirred solution of phosphonate 101 (0.2 
M in dry THF) at –78 °C. The resulting solution was stirred for 1.5 h and then nitrile 102 (1.1 equiv) 
was added. The reaction mixture was allowed to warm to –5 °C over 1.5 h. After completion or 
overnight stirring at room temperature MeI or H2O (1.1 equiv) was added. The solvent was then 
removed from the reaction mixture under reduced pressure at room temperature. The crude product 
was purified by column chromatography. The composition of the product was analysed by applying 
various NMR techniques (see below). 
 
Trapping experiments with MeI 
Application of the general procedure (see above) using 101b and 102b with overnight stirring gave 
110a. 
(E,Z)-Diethyl N-methyl-N-((Z)-(2-methylpent-3-en-3-yl)) phosphoramidate (110a) 
Yield: 37%; E:Z = 1:6; (Z)-110a: 1H NMR (400.13 MHz, CDCl3): δ=1.02 (d, J=6.8 Hz, 
6H; (CH3)2CH), 1.25–1.29 (m, 6H; CH3CH2), 1.60–1.64 (m, 3H; =CHCH3), 2.43–2.50 
(m, 1H; CH(CH3)2), 2.76 (d, J=9.0 Hz, 3H; NCH3), 3.97–4.13 (m, 4H; OCH2CH3), 5.5 
(q, J=6.8 Hz, 1H; =CH); 31P NMR (161.98 MHz, CDCl3): δ=7.2; (E)-110a: 1H NMR (400.13 MHz, 
CDCl3): δ=1.07 (d, J=7.0 Hz, 6H; (CH3)2CH), 1.25–1.29 (m, 6H; CH3CH2), 1.60–1.64 (m, 3H; 
=CHCH3), 2.74 (d, J=9.9 Hz, 3H; NCH3), 2.78–2.87 (m, 1H; CH(CH3)2), 3.97–4.13 (m, 4H; 
OCH2CH3), 5.46 (dq, J=2.7 Hz, J=7.1 Hz, 1H; =CH); 31P NMR (161.98 MHz, CDCl3): δ=7.8. 
Besides 110a, 6% of another phosphoramidate was identified.30 
 
Application of the general procedure (see above) using 101c and 102a with overnight stirring gave 
110b. 
(Z)-Diethyl-1,2-diphenylvinyl-(methyl)phosphoramidate (110b) 
Yield: 100%; 1H NMR (400.13 MHz, CDCl3): δ=1.24 (t, J = 7.1 Hz, 6H; CH3CH2), 2.62 
(d, J=9.1 Hz, 3H; NCH3), 4.06–4.18 (m, 4H; CH2), 6.49 (s, 1H; =CHPh), 6.82–7.25 (m, 
10H; Ph-H); 13C NMR (100.61 MHz, CDCl3): δ=16.1 (d, J=7.2 Hz), 35.5 (d, J=5.7 Hz), 
64.0 (d, J=6.2 Hz), 123.0 (d, J=3.2 Hz), 126.5 (s), 127.9 (s, 2C), 128.5 (s, 3C), 129.0 (s, 2C), 129.8 (s, 
2C), 135.3 (d, J=5.1 Hz), 136.0 (d, J=1.2 Hz), 141.0 (d, J=3.3 Hz); 31P NMR (101.25 MHz, CDCl3): 
δ=6.0. 
 
Application of the general procedure (see above) using 101c and 102b with overnight stirring gave 
110c. 
(Z)-diethyl methyl(3-methyl-1-phenylbut-1-en-2-yl)phosphoramidate (110c)  
Yield: 20%; 1H NMR (400.13 MHz, CDCl3): δ=1.18 (d, J=6.8 Hz, 6H; (CH3)2CH), 1.28 
(td, J=7.1 Hz, J=0.7 Hz, 6H; CH3CH2O), 2.72 (d, J=8.8 Hz, 3H; NCH3), 2.73–2.81 (m, 
1H; CH(CH3)2), 3.96–4.14 (m, 4H; CH2O), 6.05 (s, 1H; =CHPh), 7.16–7.31 (m, 5H; Ph-
H); 31P NMR (101.25 MHz, THF): δ=4.0. Besides 101c and 110c, 10–20% of another phosphonate 























Application of the general procedure (see above) using 101d and 102a with overnight stirring gave 
110d and 113.  
(E)-Diethyl N-(methyl)-N-( 1-phenylbuta-1,3-dienyl) phosphoramidate (110d)  
 (110d): Yield: 37%; 1H NMR (400.13 MHz, CDCl3): δ=1.16–1.20 (m, 6H; CH3CH2O), 
2.62 (d, J=8.9 Hz, 3H; NCH3), 3.94–4.04 (m, 4H; OCH2), 4.86 (d, J=9.4 Hz, 1H; =CH2), 
5.11 (d, J=16.0 Hz, 1H; =CH2), 6.10–6.38 (m, 2H; =CHCH=), 7.16–7.53 (m, 5H; Ph-H); 
31P NMR (101.25 MHz, THF): δ=6.2. 
 
(E)-Diethyl 1-(methylamino)-1-phenylbuta-1,3-dien-2-ylphosphonate (113): Yield: 
63%; 1H NMR (400.13 MHz, CDCl3): δ=1.16–1.20 (m, 6H; CH3CH2O), 2.89 (d, J=6.5 
Hz, 3H; NCH3), 3.73–4.04 (m, 4H; OCH2), 5.35 (d, J=6.8 Hz, 1H; =CH2), 5.62–5.69 
(m, 1H; =CH2), 6.98–7.14 (m, 1H; CH=CH2), 7.17–7.53 (m, 5H; Ph-H); 31P NMR 
(101.25 MHz, THF): δ=22.1. 
 
Trapping experiment with H2O 
Application of the general procedure (see above) using 101c and 102a with overnight stirring gave 
111a and 112. Three products were identified (E)- and (Z)-111a (Yield: 58%; E:Z = 1:1.5) and 112 
(Yield: 42%). 
(Z)-Diethyl N-1,2-diphenylvinyl)phosphoramidate (111a): 1H NMR (400.13 MHz, 
CDCl3): δ=1.10 (dt, J=0.9 Hz, J=7.1 Hz, 6H; CH3), 3.86–3.96 (m, 4H; CH2), 5.91 (s, 1H; 
CHPh), 7.16–7.57 (m, 10H; Ph-H); 31P NMR (101.25 MHz, CDCl3): δ=3.7. 
(E)-Diethyl N-1,2-diphenylvinyl)phosphoramidate (111a): 1H NMR (400.13 MHz, 
CDCl3): δ=1.32 (dt, J=0.7 Hz, J=7.1 Hz, 6H; CH3), 4.11–4.16 (m, 4H; CH2), 6.32 (s, 1H; 
CHPh), 6.82–7.01 (m, 5H; Ph-H), 7.16–7.57 (m, 5H; Ph-H); 31P NMR (101.25 MHz, CDCl3): δ=10.4. 
 
Diethyl N-1,2-diphenylethylidenephosphoramidate (112): 1H NMR (400.13 MHz, 
CDCl3): δ=1.24 (dt, J=0.7 Hz, J=7.1 Hz, 6H; CH3), 3.98–4.04 (m, 4H; CH2O, 4H), 4.20 
(s, 2H; CH2Ph), 7.16–7.57 (m, 8H; Ph-H), 7.93–7.95 (m, 2H; Ph-H); 31P NMR (101.25 




The general HWE/aza-DA procedure was followed using 101a, (S)-102d, 103a and 
105a. The product was purified by column chromatography to afford 114a in a 
1:1.01 mixture of diastereomers. Yield: 60%; Diastereomeric ratio was determined 
by HPLC analysis (LiChroCART 250-4 Whelk-O 1, nhexane/2-propanol 90:10, 
1mL/min); tr=9.33 min (minor), tr=10.88 min (major); R=2.19, α =1.26; m.p. 149–153°C [EA]; 1H 
NMR: (400.13 MHz, CDCl3): δ=0.88 (t, J=7.3 Hz, 6H; CH3CH2), 1.10 (dd, J=1.1 Hz, J=5.8 Hz, 6H; 
CH3CH), 1.41–1.52 (m, 4H; CH2CH3), 2.02–2.08 (m, 2H; CHCH3), 2.35 (s, 6H; CH3Ph), 3.85 (s, 6H; 
CH3O), 4.90 (d, J=4.5 Hz, 2H; CHC), 5.82–5.90 (m, 2H; CHN), 6.86 (d, J=8.2 Hz, 4H; o-CH 
(PhOMe)), 7.06 (d, J=8.1 Hz, 4H; m-CH (Ts)), 7.24–7.29 (m, 10H; Ph-H); 13C NMR: (100.61 MHz, 
CDCl3): δ=11.5, 11.6, 17.9, 18.0, 21.5, 21.5, 26.8, 26.9, 37.9, 38.1, 55.4, 55.4, 59.1, 59.2, 100.0, 
100.1, 114.0 (2C), 114.1 (2C), 128.6 (4C), 128.8 (8C), 133.8, 133.9, 136.4 (2C), 138.2, 138.3, 143.9 
(2C), 151.0 (2C), 159.6 (2C); IR: (KBr): ν˜=3239 (m), 2962 (m), 1681 (s), 1509 (m), 1345 (s), 1167 
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(1S,4R/S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)-6-phenyl-3-tosyl-
3,4-dihydropyrimidin-2(1H)-one (114b)  
The general HWE/aza-DA procedure was followed using 101a, 102a, (-)-
myrtenal (103j) and 105a. The product was purified by column chromatography 
to afford 114b in a 10.8:1 mixture of diastereomers (de = 83%). Yield: 80%; 
Diastereomeric excess was determined by HPLC analysis (LiChroCART 250-4 Whelk-O 1, 
nhexane/2-propanol 95:5, 1mL/min); tr=13.39 min (minor), tr=16.12 min (major); R=2.92, α=1.25; 
m.p.: 76–79°C; [α]20D= +118 (c=1.0 in CHCl3); 1H NMR: (400.13 MHz, CDCl3): peaks of the major 
isomer are reported δ=0.76 (s, 3H; CH3 myrtenal), 1.13 (s, 3H; CH3 myrtenal), 1.96–2.27 (m, 6H; 2 X 
CH2, 2 X CH (myrtenal)), 2.34 (s, 3H; CH3Ph), 5.15 (d, J=6.2 Hz, 1H; CHC), 5.50–5.53 (m, 2H; 
CHN and CHCH2), 6.69 (s, 1H; NH), 7.17–7.34 (m, 7H; Ph-H), 7.89 (d, J=8.1 Hz, 2H; Ph-H); 13C 
NMR: (100.61 MHz, CDCl3: δ=21.6, 22.0, 26.5, 31.2, 31.6, 38.6, 40.9, 42.5, 60.1, 99.6, 121.3, 125.6 
(2C), 129.4 (2C), 129.5 (2C), 129.7 (2C), 129.9, 133.8, 136.1, 137.0, 144.8, 145.4, 150.9; IR (KBr): 
ν˜=3259 (m), 2912 (m), 1689 (s), 1669 (s), 1357 (s), 1171 (s), 1089 (m); HRMS (EI): m/z=448.1813 
[M]+, calc. for C26H28N2O3S=448.1821. 
 
α,β-unsaturated ketones (116a-b and 118a-b) 
The general HWE/aza-DA procedure was followed, but instead of isocyanate 105, 5N sulfuric acid (1 
mL) was added and the reaction mixture was stirred for 1 hour. The mixture was then extracted with 
diethyl ether (3×20 mL). The combined organic layer was washed with water (20 mL) and dried over 
Na2SO4. 1H NMR analysis of the crude reaction mixture revealed that the α,β-unsaturated ketones 
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When instead of isocyanates, isothiocyanates are used in the HWE/aza-DA 4CR, thiazines are formed. These 
thiazines can be converted into dihydropyrimidinethiones via the Dimroth rearrangement. This rearrangement was 
investigated with a set of substituted 2-amino-6H-1,3-thiazines. The rearrangements were carried out under 
microwave irradiation conditions in batch or continuous flow format, employing either toluene or 1-methyl-2-
pyrrolidone as solvent. Thiazines bearing an ester group at the C5 position rearranged at a considerably higher 
temperature than derivatives without substituent at this position into the corresponding dihydropyrimidinethiones. 
This strictly thermal rearrangement was studied in detail using differential scanning calorimetry and density 
functional theory computational methods. The reaction pathway involves a zwitterionic intermediate.  
 




DHPM-2-thiones have an interesting scaffold as is displayed by some biologically active 
examples (Figure 4.1).1 DHPM-thione 119 shows colchicine-like properties like 
destabilising microtubules,2 while 120 exhibits calcium channel blocking activity, without 
antihypertensive activity, probably due to rapid metabolism.3 Further development of the 
DHPM-2-thiones scaffold led to an orally active long-lasting antihypertensive agent 121.4 
More recent, monastrol (122) has been discovered as cell-permeable molecule that blocks 
mitosis by specifically inhibiting the motor activity of mitotic kinesin, Eg5, which mediates 

































 119 120 121 122 
Figure 4.1 Biologically active DHPM-thiones 
DHPM-2-thiones like 119-121 can be synthesised via the Biginelli 3CR and as with 
DHPMs, additional manipulations are necessary to functionalise N3.4-6 A large range of 
variations of the original Biginelli 3CR using several catalysts, solid phase chemistry, neat 
conditions or microwave irradiation are known to overcome the relatively low yields of the 
original 3CR.7 Obviously, a more direct synthetic route to generate DHPM-2-thiones 123 
with the desired substitution pattern would greatly facilitate further pharmacological 
studies, e.g. SAR studies.    
In the former chapter the synthesis of DHPMs via a HWE/aza-DA 4CR has been 
described. The related dihydropyrimidine-2-thiones (DHPM-2-thione; 123) should become 










Figure 4.2 DHPM-2-thione scaffold 
 




Thus, we decided to explore the reactivity of isothiocyanates (124) in the HWE/aza-DA 
4CR. The reaction of phosphonates, nitriles, aldehydes and isothiocyanates did not result in 
the formation of DHPM-2-thiones 123. Instead thiazines 125 were formed (Scheme 4.1 and 
Table 4.1).  
(R1=H)
a R4 = Ph
b R4 = Et

















 101 102  104 124 125 
Scheme 4.1 Synthesis of thiazines 
The procedure proved quite general and a number of differently substituted thiazines 125 
could be synthesised in reasonable to good yields by combining the appropriate inputs 
(Table 4.1). By simply changing the nature of the fourth component in our MCR from 
isocyanate to isothiocyanate the course of the final cyclocondensation is altered. 
Interestingly, not only electron withdrawing but also alkyl R4-substituents are tolerated in 
the formation of thiazines 125, which is in contrast to the 4CR towards DHPMs.  
 
Table 4.1. HWE/aza-DA 4CR of phosphonate 101a with nitriles 102, aldehydes 103 and 
isothiocyanates 124.  
Entry Nitrile R2 Aldehyde R3 Isothio-
cyanate 
R4 Thiazine Yield (%) 
1 102a Ph 103c Ph 128a Ph 125a 74 
2 102a Ph 103a 4-MeOPh 128a Ph 125a 58 
3 102b iPr 103c Ph 128a Ph 125c 61 
4 102a Ph 103a 4-MeOPh 128b Et 125d 56 
5 102a Ph 103a 4-MeOPh 128c CH(Me)Ph 125e 64 
 
Thiazines are scarcely described in literature,8,9 and not much is known on their biological 
activities.10,11 Our synthetic approach facilitates access to 125 and should promote further 
studies toward their biological relevance. In general thiazines 125 are rather stable 
compounds and they can be easily purified by CC, however, in the case of 125b (entry 2; 
Table 4.1) a rearrangement to the corresponding DHPM-2-thione was observed upon 
standing at room temperature for a couple of hours in CDCl3. 
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These results in relation to the earlier work by Kappe et al.9 prompted us to explore the 
rearrangement of thiazines to DHPM-2-thiones in more detail and to investigate its scope as 
preparative route to N3-substituted DHPM-2-thiones.12,13 In the remainder of this chapter 
we present our computational, mechanistic and experimental results on this so-called 
Dimroth rearrangement of two series of 2-amino-1,3-thiazines.  
The Dimroth rearrangement is an isomerisation process whereby exo- and endocyclic 
heteroatoms are translocated on a heterocyclic ring. In general, it involves the translocation 
of exo- and endocyclic heteroatoms (most commonly nitrogen) on a single heterocyclic 
ring, and has been referred to as an exoannular rearrangement (Scheme 4.2a)14,15 The 
isomerisation process is usually promoted by the presence of base or acid in solution, but 
may also be performed under strictly thermal or photochemical conditions. Many factors 
such as the nature and number of heteroatoms in the ring, or the presence of electron-
withdrawing substituents on the heterocycle influence the Dimroth rearrangement.14,15 
Although early reports of the Dimroth rearrangement date back to as early as 1888,16,17 it 
was only recognised as a general phenomenon in heterocyclic chemistry in the 1950’s and 
has since been reviewed several times.14 Although the Dimroth rearrangement is most 
commonly associated with all-nitrogen heterocycles such as aminoazoles (imidazoles, 
triazoles) and aminoazines (pyridines, pyrimidines),14,15 there are a few examples of 
Dimroth rearrangements known involving the transformation of amino-1,3-thiazines to 
pyrimidinethiones.18-20 A particularly interesting example involves the thermal 
rearrangement of 2-amino-1,3-thiazine A to 3,4-dihydropyrimidine-2-thione B reported by 
Zigeuner and co-workers in 1975 (Scheme 4.2b).19,20 Simply heating above its melting 
point at 145°C resulted in Dimroth rearrangement of thiazine A to the corresponding 




























Scheme 4.2 a) Translocation of exo- and endocyclic heteroatoms in a heterocyclic ring. b) Dimroth 
rearrangement of 2-amino-1,3-6H-thiazine A to 3,4-dihydropyrimidine-2-thione B. 
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To investigate the Dimroth rearrangement of thiazines an additional series of thiazines 
125g–l was synthesised according to the method outlined in Scheme 4.3. These thiazines 
having an ester group at C5 of the thiazine nucleus could be rapidly prepared by 
















 126 127 125 
Scheme 4.3 Second pathway to 2-amino-1,3-6H-thiazines 
In this second protocol also sometimes the formation of the corresponding rearranged 
DHPMs as by-product was observed upon careful investigation of the crude reaction 
mixtures. We therefore investigated this isomerisation in more detail employing several 
isolated and purified thiazine derivatives 125 as model compounds. Since some of the 
Dimroth rearrangements performed in organic solvents required quite high temperatures 
(see below) we employed controlled microwave heating under sealed vessel conditions to 
rapidly attain those temperatures.21 It quickly became evident that thiazines 125a–f, lacking 
an ester functionality at C5, required considerably lower temperatures for rearrangement 
than thiazines 125g–l that have the electron-withdrawing ester group. This was confirmed 
by Differential Scanning Calorimetry (DSC) experiments and also substantiated by 
computational methods (see below).  
For preparative purposes three different rearrangement protocols were developed that lead 
to DHPMs 123a–l in 55-95 % isolated yields (Table 4.2). After some experimentation with 
a variety of different solvent systems and microwave irradiation conditions it became clear 
that these monomolecular rearrangements are best conducted in either toluene or 1-methyl-
2-pyrrolidone (NMP) at a concentration level of ca 100 mmol/L. As indicated, thiazines 
125a–f without an ester group at C5 rearrange at considerably lower temperatures (120°C) 
than thiazines 125g–l in a variety of different solvents. For consistency, all experiments 
were repeated in toluene, which allowed clean rearrangement of 125a–f at 120°C within 60 
minutes. For N-substituted thiazines 125g–j (R4 = alkyl or aryl) NMP at 200°C proved to 
yield the corresponding thiones 123g–j more efficiently, while thiazines 125k,l (R4 = H) 







Table 4.2 Microwave-assisted rearrangement of 2-amino-1,3-6H-thiazines 125 to 3,4-dihydropyrimi-
dine-2-thiones 123.a 
NMP or toluene

















 125a–l 123a–l  
Thiazine R1 R2 R3 R4 Methodb Yield (%)c 
125a H Ph Ph Ph A 74 
125b H Ph 4-MeOPh Ph A 67 
125c H iPr Ph Ph A 59 
125d H Ph 4-MeOPh Et A 70 
125e H Ph 4-MeOPh CH(Me)Ph A 55 
125f H Ph Ph Et A 72 
125g CO2Et Ph Ph Et B 87 
125h CO2Et Me Ph Me B 93 
125i CO2Et Me 4-MePh Me B 95 
125j CO2Et Me Ph Ph B 61 
125k CO2Et Me Ph H C 67 
125l CO2Et Ph Ph H C 63 
a) Single mode microwave heating (MW) under sealed vessel conditions, 0.08 – 0.20  mmol scale; b) Method A: 
toluene, MW, 120°C, 45-60 min; Method B: NMP, 200°C, 35 min; Method C: toluene, MW, 210 °C, 40 min; c) 
Isolated yield of pure compound. See Experimental Section for more details. 
4.2.2  Kinetic and Differential Scanning Calorimetry investigations 
As mentioned above, it became apparent early on in our investigations that thiazines 125 
without an ester group at C5 (125a–f, R1 = H) rearrange at distinctly lower temperature 
than the C5-substituted analogues (125g–l, R1 = CO2Et). In order to determine and compare 
the exact rearrangement temperatures, we compared two model thiazines that had an 
identical substitution pattern for R2 (Ph), R3 (Ph) and R4 (Et), but differed in the R1 
substituent: 125f (R1 = H) and 125g (R1 = CO2Et). Then both thiazines 125f and 125g were 
subjected to the microwave-assisted rearrangement conditions in NMP for a fixed time of 
30 min at variable temperatures (Table 4.3). By HPLC-monitoring of the formation of 
DHPMs 123f and 123g, respectively, it was found that thiazine 125f completely rearranges 
at 120°C within the 30 min timeframe of the experiment. On the other hand, thiazine 125g 
bearing the ester group at C5 required a significantly higher reaction temperature (ca 
200°C) for full conversion to the corresponding DHPM-2-thione 123g (Table 4.3). 
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 Table 4.3 Comparison of Rearrangement Temperatures for Thiazine 125f (R1=H) and 125g 
(R1=CO2Et).a 
Thiazine Temp (oC) Conversion (%)b 
 80 0 
125f 100 16 
 120 100 




 200 100 
a) Conditions: NMP, MW, 30 min, 80-200 °C, 100 mmol/L thiazine; b) HPLC conversion (254 nm, peak area percent). 
 
To further support these data, DSC measurements on selected thiazines were performed. The 
DSC technique, widely used in material science and process research, has recently also emerged 
as useful tool for synthetic organic chemists.22 It provides information on the expected 
temperature, at which a reaction will take place, especially in the case of monomolecular 
transformations such as ring closure or rearrangement reactions. Of particular interest to us was 
the direct comparison of the DSC plots of thiazines 125f and 125g shown in Figure 4.3.  
 
Figure 4.3 Comparison of differential scanning calorimetry (DSC) plots of thiazines 125f and 125g. The 
onset point for the solid-state rearrangement of thiazines 125f and 125g are 142 and 197 °C, respectively.  




The DSC curve of the solid thiazine compound 125g exhibited a sharp endothermic peak 
at 130°C (peak maximum) marking the melting point of the thiazine, followed by an 
exothermic peak, which had a maximum at 214°C. This latter peak marked the 
rearrangement of the thiazine 125g to the corresponding DHPM 123g (onset point of the 
rearrangement at 197°C) and corresponded well with the data obtained in NMP solution 
(Table 4.3). In contrast, the DSC curve of thiazine 125f (oil) showed no melting point and 
displayed an exothermic peak marking rearrangement to 123f at 152°C (peak maximum, 
onset point at 142°C), again nicely matching the data obtained in NMP solution (Table 4.3). 
Similar DSC diagrams were obtained from thiazines 125a, 125h, 125j and 125k further 
corroborating the differences in rearrangement temperatures between thiazines 125 with 
and without ester substitution at C5.  
4.2.3  Mechanism of Rearrangement ‐ Computational Studies 
In order to rationalise the difference in rearrangement temperatures and to gain further 
insight into the mechanism of this particular type of Dimroth rearrangement a 
computational investigation was carried out on the 2-amino-1,3-6H-thiazine to 3,4-
dihydropyrimidine-2-thione rearrangement. After initial geometry optimisations of 125f, 
125g and 125l and rearranged products 123f, 123g, and 123l it became clear that both the 
thiazines 125 as well as the DHPM-2-thiones 123 can exist in various conformations. The 
different conformers originate from different orientations of the ester and/or amino/imino 
groups, which are characterised by the respective dihedral angles τ1=τ(C6–C5–C7–O8) and 
τ2=τ(N1–C2–N10–C11). Representative structures of 125l and 123l and atom numbering 
are displayed in Figure 4.4 (Note that S3 and N10 of the reactants correspond to S10 and 
N3 in the products). The computed structures agree well with X-ray data on related 
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 Thiazine 125l Dihydropyrimidine 123l 
Figure 4.4 Selected optimised geometries (B3LYP/6-31G(d)) of thiazine 125l and DHPM 123l 
Next to the different conformations the amino-imino (for 125) and thion-thiol (for 123) 
tautomerism was taken into account. Clearly, for 125f, 125g and 125l the amino tautomers 
are more stable than the corresponding imino forms with an exocyclic C2=N10 double 
bond. In contrast, for 123f, 123g, and 123l the thione tautomers with an exocyclic C2=S10 
double bond are more favourable than thiols. Furthermore, the thiol tautomer of 123l that 
bears a proton at N3 is favored. Also, calculations show that in some cases the s-trans ester 
conformer is more stable (125l and 123l) whereas in other derivatives (e.g., those with R2 = 
i-propyl) the s-cis rotamer is favoured. Indeed for similar systems,24 both the s-cis and the 
s-trans rotamer are reported. From the computational data it is evident that rearrangement 
products 123 are considerably more stable than the respective thiazines 125. Thus the 
described Dimroth-type rearrangement is exothermic and exergonic, as also confirmed by 
the DSC measurements. However, product stability arguments alone cannot explain the 
differences in rearrangement temperatures observed for the two series of compounds. To 
clarify the influence of substituents, especially the ester group at C5 of the heterocyclic ring 
on the rearrangement process, detailed calculations (B3LYP/6-31G(d)) on model systems 
(aminothiazines 128a–d, their imino tautomers 128a–1, 128b–1, 128c–1, 128d–1, and the 

























 128 129 
128/129 R1 R2 R3 R4 
a H H H H 
b CO2Et H H H 
c H H Ph H 
d CO2Et H Ph H 
Figure 4.5 Structures of model compounds 128a – d and 129a – d. 
In the following, a purely thermal reaction path for the transformation 2-aminothiazine → 
pyrimidine-2-thione, i.e. without the involvement of any nucleophile or electrophile, is 
described. Relative energies of reactants, transition states, intermediates, and products for 
the transformations 128a–128d → 129a–129d have been calculated (B3LYP/6-31G(d)) and 
the reaction paths for the rearrangements 128c→129c and 128d→129d are shown in Figure 
4.6. From the computational results it was not possible to locate a mechanistic pathway for 
direct rearrangement of 128 to 129. Instead, rearrangement seems to proceed via the 
corresponding imino tautomers of 128. Thus, after initial tautomerisation of 128a–128d → 
128a-1–128d-1, rearrangement commences by rotation of the thioimide group S3–C2=N10 
around the N1–C2 bond to give, via TS1a–TS1d, the intermediates Int-a–Int-d. 
Subsequent ring closure of these intermediates via TS2a–TS2d leads to the rearranged 
products, 129a–129d. Activation energies are in the range 35–40 kcal mol-1 and thus, can 
easily overcome the energy requirements for the necessary tautomerisation prior to 
rearrangement. Careful analysis of the computational data reveals that an ethoxycarbonyl 
group at C5 raises the activation energies for rearrangement by ca. 3 kcal mol-1 compared to 
those with a H-atom at C5. The ethoxycarbonyl group at C5 raises both activation energies, 
especially that of TS1. Thus, for the rearrangement 128a→129a the second step is rate 
determining, for 128b→129b both steps have almost equal activation energies, and for 
reactions 128c→129c and 128d→129d ring opening of the imino tautomers of the thiazines 
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 128c,d 128c-1, 128d-1 TS1c,d Intc,d TS2c,d 129c,d  
Figure 4.6 Calculated reaction paths for the thermal aminothiazine – pyrimidinethione rearrangements 
128c→129c and 128d→129d (energies in kcal mol-1). 
Most importantly, the sum of the activation energies for the rearrangement of derivatives 
with an ester group at C5 is higher by ca. 3 kcal mol-1 compared to rearrangement of 
derivatives lacking this substituent. Isodesmic/homodesmotic reactions (1) and (2) and 
analogous ones for the respective transition states TS1, TS2, intermediates and products 
were used to estimate the effect of introducing the ethoxycarbonyl group. From the 
computational data it may be concluded that the increased activation energy for 
rearrangement of 5-ethoxycarbonylthiazines as compared to their C5–unsubstituted deriva-
tives results both from a stabilisation of the reactant as well as a destabilisation of the 
transition states by CO2Et. 
 
128a-1 + ethyl acrylate (s-cis and s-trans) → 128b-1 + ethylene  (1) 





The question now remains whether the influence of the ester group on reactant and 
transition state energies can account for the different rearrangement temperatures found for 
the two series of compounds. For this purpose it is useful to consider the geometric and 
electronic features of the transition states involved in this purely thermal rearrangement. 
The electronic structures have been analysed with the NBO method.25 Ring opening of the 
2-iminothiazine by rotation of the thioimide moiety results in a substantial structural and 
electronic change: r(N1–C2) and r(C5–C6) are significantly longer in TS1, Int and TS2 
than in the starting 2-iminothiazine and the rearranged pyrimidine-2-thione, whereas r(N1–
C6) and r(C4–C5) are shorter. In line with these geometrical changes, the NBO analysis 
indicates the presence of double bonds between N1=C6 and C4=C5, and single bonds 
between N1–C2 and C5–C6. Figure 4.7 gives a pictorial representation of the bonding 












Figure 4.7 Charge distribution (NPA charges) and bonding pattern (NBO analysis) for transition 
states TS1a–d (an analogous representation of the charge distribution is also indicated for the 
intermediates Int and the second transition states, TS2). 
As a consequence, both transition states TS1 and TS2 as well as the intermediate Int, 
have a pronounced zwitterionic character. For instance, in the C5-unsubstituted derivatives 
(R3 = H), the negative charge on the S3-C3=N10H fragment is ca. –0.40 (Mulliken) and –
0.46 (NPA); in contrast, in the reactants this moiety bears a small positive charge (ca. + 
0.1). Conversely, the R1–C4–C5–C6–N1 fragment is positively charged in TS1, Int, and 
TS2, and negatively charged in the reactants. This means that introduction of an electron–
withdrawing substituent will stabilise/destabilise a negatively/positively charged moiety. 
Hence, the C5-located ester group (CO2Et) lowers the energy of the reactant and increases 
that of the transition states, leading to higher rearrangement temperatures for the ester 
substituted derivatives. 
4.3 Conclusions 
A range of differently substituted 2-amino-6H-1,3-thiazines were efficiently transformed 
into 3,4-dihydropyrimidine-2-thiones via a Dimroth-type rearrangement. Isolated yields of 
DHPM-thiones 123 were reasonable to good. In principle, arrays of privileged scaffolds are 
now accessible in only two steps, taking into account that the starting thiazines 125 can be 
prepared by highly versatile multicomponent reactions. DSC measurements can be used to 
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determine the optimal temperature at which Dimroth rearrangement takes place. This 
temperature seems to depend mainly on the C5 substituent. Thiazines with an ester at C5 
rearrange at significantly higher temperatures then thiazines with a proton at C5. The 
described rearrangement is a strictly thermal process that most likely proceeds via a 
zwitterionic intermediate as was corroborated by DFT calculations. 
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4.5 Experimental Section 
4.5.1  General  
1H and 13C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AC 200 (200.13 
and 50.32 MHz, respectively), a Bruker Avance 250 (250.13 and 62.90, respectively) or a Bruker 
MSL 400 (400.13 and 100.61 MHz respectively) spectrometer; chemical shifts (δ) are given in ppm, 
internally referenced to residual solvent resonances (1H: δ 7.29 ppm, 13C: δ 77.0 ppm). Column 
chromatography was performed on Baker 7024-02 (40 μ, 60 Å) or Merck 60H silica gel with 
petroleum ether (PE, boiling range 40-60 °C), ethyl acetate (EA) and cyclohexane (c-hexane) as 
eluents. Thin-layer chromatography (TLC) was performed using silica plates from Merck (Kieselgel 
60 F254 on aluminium with fluorescence indicator). Compounds on TLC plates were visualised under 
UV light or by treatment with an anisaldehyde solution. IR spectra (KBr or NaCl) were recorded on a 
Mattson 6030 Galaxy spectrophotometer and are reported in cm-1. High-resolution mass spectra were 
measured at 70 eV with a Finnigan MAT900 spectrometer. Low-resolution mass spectra were 
obtained in the atmospheric pressure chemical ionisation (positive or negative APCI mode). 
Analytical HPLC analysis was carried out on a LiChrospher 100 C18 reversed-phase analytical 
column (119 × 3 mm, 5µm particle size) at 25 °C, using mobile phase A (water/MeCN 9:1 (v/v) + 
0.1% TFA) and phase B (MeCN + 0.1% TFA), with linear gradient from 30% B to 100% B in 8 min 
and 2 min with 100% phase B. Melting points were measured on a Stuart Scientific SMP3 melting 
point apparatus and are uncorrected. Calorimetric (DSC) data were obtained on a Rheometric 
Scientific DSC-Plus instrument (software - Orchestrator v.6.5.8) using thiazines 125 in 1.5 – 3 mg 
amounts in closed crucibles. The DSC plots were taken in the range of 30 – 350 °C at heating rate 10 
°C/min. Tetrahydrofuran (THF) was dried and distilled from sodium benzophenone prior to use. PE 
was distilled prior to use. Benzonitrile (102a), isobutyronitrile (102d) and benzaldehyde (103c) were 
dried, distilled, and stored under a dry nitrogen atmosphere. Other commercially available chemicals 





Microwave-assisted reactions were performed in either an Initiator 8 (Biotage AB) or Discover 
(CEM Corporation) single-mode microwave instrument at 2450-MHz controlled irradiation using 
standard sealed microwave glass vials. Reaction temperatures were monitored by an IR sensor on the 
outside wall of the reaction vials. Reaction times refer to hold times at the selected set temperature, 
not to total irradiation times.  
4.5.3  Calculations 
All calculations were done with the aid of the Gaussian G03 program suite.26 Geometries were 
completely optimised by Becke’s three-parameter hybrid HF – density functional theory27 method in 
combination with the Lee-Yang-Parr correlation functional28 and the 6-31G(d) basis set. All 
structures were characterised as true minima or transition states by vibrational frequency calculations. 
For transition states, in addition, intrinsic reaction coordinate calculations were performed. The 
electronic structures were analysed with the NBO method.25,29 
4.5.4   Synthetic Procedures and Physical Data 
General procedure for the synthesis of thiazines 125a-f 
nBuLi (1.6 M in hexane; 1.2 equiv) was added dropwise to a stirred solution of phosphonate 101a 
(0.2 M in dry THF) at –78°C. The resulting solution was stirred for 1.5 h and then nitrile 102 (1.1 
equiv) was added. The reaction mixture was allowed to warm to –5°C over 1.5 h and then aldehyde 
103 (1.1 equiv) was added. The resulting mixture was stirred for a further 0.5 h at –5°C and thereafter 
for 1.5 h at room temperature. Isothiocyanate 128 (1.1 equiv) was then added dropwise over 10 min 
and the resulting solution was stirred overnight. The solvent was removed under reduced pressure and 
the crude product was isolated by column chromatography (PE/EA 10/1 → 3/1).  
 
N-4,6-triphenyl-6H-1,3-thiazin-2-amine (125a)  
Yield: 74%; m.p. 128–129 °C [EA]; 1H NMR (200.13 MHz, CDCl3): δ=5.03 (d, 
J=5.6 Hz, 1H; CHC), 5.76 (d, J=5.6 Hz, 1H; CHS), 7.11 (t, J=7.3 Hz, 1H; Ph-H), 
7.29–7.57 (m, 12H; Ph-H), 7.79 (d, J=6.9 Hz, 2H; Ph-H); 13C NMR (100.61 MHz, 
CDCl3): δ=44.5, 101.1, 120.9 (2C), 123.7, 125.9 (2C), 127.9 (2C), 128.1, 128.4, 
128.5 (2C), 128.9 (4C), 138.2, 140.7, 141.5, 145.6, 150.0; IR (KBr): ν˜=1574 (s), 1493 (w), 1292 (w), 
1205 (w), 756 (m), 692 (m); HRMS (EI): m/z=342.1187 [M]+, calc. for C22H18N2S=342.1191. 
 
 6-(4-methoxyphenyl)-N,4-diphenyl-6H-1,3-thiazin-2-amine (125b) 
The product was isolated as a yellow-brown oil. Yield: 58%; 1H NMR (400.13 
MHz, DMSO): δ=3.70 (s, 3H; CH3), 5.11 (d, J=6.5 Hz, 1H; CHC), 5.91 (d, J=6.5 
Hz, 1H; CHS), 6.88 (d, J=8.6 Hz, 2H; m-CH (PhOMe)), 6.96-6.99 (m, 1H; p-CH 
(NHPh)), 7.25–7.40 (m, 7H; Ph-H), 7.78–7.81 (m, 4H; o-CH (NHPh and Ph)), 9.32 
(s, 1H; NH); 13C NMR (100.61 MHz, DMSO): δ=42.0, 55.1, 101.1, 114.0 (2C), 119.5 (2C), 122.3, 
125.3 (2C), 127.7, 128.3 (2C), 128.5 (2C), 128.6 (2C), 133.6, 139.1, 140.5, 146.2, 148.4, 158.7; IR 
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4-isopropyl-N,6-diphenyl-6H-1,3-thiazin-2-amine (125c)  
Yield: 61 %; m.p. 124–128 °C [EA]; 1H NMR (200.13 MHz, CDCl3): δ=1.20 (d, 
J=6.9 Hz, 6H; CH3), 2.40–2.61 (m, 1H; CH(CH3)2), 4.77 (d, J=4.9 Hz, 1H; CHC), 
4.99 (d, J=4.9 Hz, 1H; CHS), 7.01–7.29 (m, 10H; Ph-H); 13C NMR (100.61 MHz, 
CDCl3): δ=21.5, 21.6, 34.3, 44.3, 97.7, 121.6, 123.8, 128.2 (2C), 128.3 (2C), 129.1 (2C), 129.2 (2C), 
139.3, 141.2, 149.9, 150.3; IR (KBr): ν˜=3201 (w), 2962 (w), 1603 (s), 1581 (s), 1489 (m), 1309 (m), 
1194 (m); HRMS (EI): m/z=308.1354 [M]+, calc. for C19H20N2S=308.1347. 
 
N-ethyl-6-(4-methoxyphenyl)-4-phenyl-6H-1,3-thiazin-2-amine (125d) 
The product was isolated as yellow oil. Yield: 56%; 1H NMR (400.13 MHz, CDCl3): 
δ=1.23 (t, J=7.3 Hz, 3H; CH3CH2), 3.57–3.60 (m, 2H; CH2), 3.78 (s, 3H; CH3O), 
4.88 (d, J=5.8 Hz, 1H; CHS), 5.71 (d, J=5.8 Hz, 1H; CHCHS), 6.84 (d, J=8.7 Hz, 
2H; Ph-H), 7.25–7.36 (m, 5H; Ph-H), 7.80 (d, J=7.4 Hz, 2H; Ph-H); 13C NMR 
(100.61 MHz, CDCl3): δ=14.9, 37.3, 43.9, 55.3, 99.9, 114.2 (2C), 125.6 (2C), 127.8, 128.1 (2C), 
128.9 (2C), 133.5, 139.4, 147.4, 152.4, 159.2; IR (NaCl): ν˜=3400 (w), 2969 (w), 1567 (s), 1510 (s), 
1249 (s); HRMS (EI): m/z=324.1310 [M]+, calc. for C19H20N2OS=324.1296. 
 
6-(4-methoxyphenyl)-4-phenyl-N-(1-phenylethyl)-6H-1,3-thiazin-2-amine (125e) 
The product was isolated as yellow oil as a 1:1 mixture of diastereomers. Yield: 
64%; 1H NMR (250.13 MHz, CDCl3): δ=1.54 (d, J= 7.2 Hz, 3H; CHCH3Ph), 1.56 
(d, J=7.5 Hz, 3H; CHCH3Ph), 3.79 (s, 3H; OCH3), 3.80 (s, 3H; OCH3), 4.85 (d, 
J=6.0 Hz, 1H; CHS), 4.88 (d, J=5.6 Hz, 1H; CHS), 5.38–5.41 (m, 2 × 1H; 
CHCH3Ph), 5.68 (d, J=5.6 Hz, 1H; CHCHS), 5.71 (d, J=6.0 Hz, 1H; CHCHS), 6.81–
7.60 (m, 28H; Ph-H); 13C NMR (400.13 MHz, CDCl3, 25 °C): δ=22.7, 22.8, 43.8, 44.1, 51.9 (2C), 
55.3, 55.4, 99.8, 100.3, 114.1 (2C), 114.2 (2C), 125.7 (4C), 126.0 (2C), 126.1 (2C), 127.0, 127.1, 
127.8 (2C), 128.0 (4C), 128.5 (2C), 128.6 (2C), 128.9 (4C), 133.3, 133.4, 139.1 (2C), 144.0, 144.1, 
150.3, 150.7, 159.2 (2C), 188.7 (2C); IR (NaCl): ν˜=3399 (w), 2929 (w), 1567 (s), 1509 (s), 1250 (s); 
HRMS (EI): m/z=400.1612 [M]+, calc. for C25H24N2OS=400.1609. 
 
Thiazines 125g, 125i and 125l have been prepared according to ref. 9c. 
Ethyl 2-(ethylamino)-4,6-diphenyl-6H-1,3-thiazine-5-carboxylate (125g). 
Yield: 71%; m.p. 135–137°C [i-propanol]; 1H NMR (360 MHz, CDCl3): δ=0.85 
(t, J=7.1 Hz, 3H; CH3CH2), 1.10 (t, J=7.1 Hz, 3H; CH3CH2), 3.46 (br s, 2H; 
CH2CH3), 3.83–3.96 (m, 2H; CH2CH3), 4.81 (br s, 1H; NH), 5.41 (s, 1H, CHS), 
7.22–7.40 (m, 8H; Ph-H), 7.47–7.51 (m, 2H; Ph-H); 13C NMR (90 MHz, CDCl3): 
δ=13.5, 14.8, 37.8, 43.7, 60.2, 126.8 (2C), 127.5 (2C), 128.0, 128.5, 128.6 (4C), 141.6, 141.9, 158.4, 
168.0;30 MS (pos APCI): m/z=368 (11, M+2), 367 (27, M+1), 366 (100, M), 334 (33, M–32), 279 (38, 
M–87). Anal. Calcd for C21H22N2O2S: C, 68.82; H, 6.05; N, 7.64. Found: C, 68.96; H, 5.95; N, 7.56. 
 
Ethyl 4-methyl-2-(methylamino)-6-p-tolyl-6H-1,3-thiazine-5-carboxylate (125i). 
Yield: 72%; m.p. 119–120°C [EtOH]; 1H NMR (360 MHz, CDCl3): δ=1.23 (t, J=7.1 
Hz, 3H; CH3CH2), 2.30 (s, 3H; CH3), 2.55 (s, 3H; CH3), 2.98 (s, 3H, CH3), 4.07–4.20 
(m, 2H, CH2CH3), 4.76 (br s, 1H; NH), 5.28 (s, 1H; CHS), 7.03–7.09 (m, 4H; Ph-H); 
13C NMR (90 MHz, CDCl3): δ=14.3, 21.1, 24.3, 42.5, 60.1, 126.7 (2C), 129.2 (2C), 


























Ethyl 2-amino-4,6-diphenyl-6H-1,3-thiazine-5-carboxylate (125l).  
Yield: 66%; m.p. 253-255°C (dec) [i-propanol]; 1H NMR (360 MHz, DMSO-d6): 
δ=0.74 (t, J=7.0 Hz, 3H; CH3), 3.56 (br s, 2H; NH2), 3.83 (q, J=7.0 Hz, 2H; CH2), 
5.75 (s, 1H; CHS), 7.33–7.55 (m, 10H; Ph-H); 13C NMR (90 MHz, DMSO-d6): 
δ=13.7, 41.8, 61.1, 127.2 (3C), 128.8 (3C), 129.4 (2C), 129.6 (2C), 130.6, 139.8, 
165.7;30 MS (pos APCI) m/z 338 (100, M),  304 (27, M–34), 279 (19, M–59). 
 
General Procedures for the Dimroth Rearrangement of 2-Amino-1,3-thiazines 125a–l into 
Dihydropyrimidine-2-thiones 123a–l. 
 
Method A (for compounds 125a–f): In a 5 mL pyrex microwave vial a sample of the corresponding 
thiazine (0.64 mmol) was dissolved in 1.5 mL of dry toluene. The vial was sealed and subjected to 
MW irradiation at 120 °C for 45–60 min. After the reaction was completed the solvent was removed 
under reduced pressure and the residue subjected to column chromatography (cyclohexane/EtOAc 
(19:1)) to obtain products 123a–f as pale yellow oils. 
 
3,4,6-Triphenyl-3,4-dihydropyrimidine-2(1H)-thione (123a).  
The product was isolated as a pale yellow oil. Yield: 74%; 1H NMR (250.13 MHz, 
CDCl3): δ=5.34 (d, J=4.9 Hz, 1H; CHC), 5.44 (dd, J=4.9 Hz, J=2.0 Hz, 1H; CHN), 
7.02–7.05 (m, 2H; Ph-H), 7.15–7.52 (m, 13H; Ph-H), 7.92 (s, 1H; NH); 13C NMR 
(50.32 MHz, CDCl3): δ=66.1, 101.0, 125.0 (2C), 127.5 (2C), 127.8, 128.2, 128.5 
(2C), 128.8 (2C), 129.0 (4C), 129.5, 133.0, 133.6, 141.1, 143.9, 176.7; IR (NaCl): ν˜=1698 (s), 1491 
(s), 1455 (s), 1230 (s); HRMS (EI): m/z = 342.1191 (M+), calc. for C22H18N2S = 342.1191. 
 
4-(4-Methoxyphenyl)-3,6-diphenyl-3,4-dihydropyrimidine-2(1H)-thione (123b). 
The product was isolated as a pale yellow oil. Yield: 67% yield; 1H NMR (400.13 
MHz, CDCl3): δ=3.81 (s, 3H; OCH3), 5.28 (d, J=4.9 Hz, 1H; CHC), 5.40 (dd, J=4.9 
Hz, J=2.2 Hz, 1H; CHN), 6.82 (d, J=8.7 Hz, 2H; Ph-H), 6.99–7.01 (m, 2H; Ph-H), 
7.13 (d, J=8.7 Hz, 2H; Ph-H), 7.26–7.36 (m, 3H; Ph-H), 7.41–7.45 (m, 5H; Ph-H), 
7.48–7.51 (m, 5H; Ph-H), 7.92 (s, 1H; NH); 13C-NMR (100.61 MHz, CDCl3): δ=55.7, 66.1, 101.8, 
114.6 (2C), 125.6 (2C), 128.3, 128.9 (2C), 129.4 (2C), 129.5 (4C), 130.0, 133.7, 133.8, 134.0, 144.5, 
160.2, 177.0; IR (NaCl): ν˜=1597 (s), 1509 (s), 1451 (s); HRMS (EI): m/z = 372.1287 (M+), calc. for 
C23H20N2OS = 372.1296 
 
6-Isopropyl-3,4-diphenyl-3,4-dihydropyrimidine-2(1H)-thione (123c).  
The product was isolated as a pale yellow oil. Yield: 59%; 1H NMR (250.13 MHz, 
CDCl3): δ=1.19 (d, J=6.8 Hz, 6H, (CH3)2CH), 2.32–2.42 (m, 1H; (CH3)2CH), 4.90 (d, 
J=4.5 Hz, 1H; CHC), 5.17 (d, J=4.5 Hz, 1H; CHN), 6.94–6.96 (m, 2H; Ph-H), 7.14–
7.17 (m, 8H; Ph-H), 7.60 (s, 1H; NH); 13C NMR (100.61 MHz, CDCl3): δ=20.1, 20.3, 30.4, 66.0, 
98.0, 127.5 (2C), 127.7, 128.3 (3C), 128.6 (2C), 128.9 (2C), 139.4, 141.8, 144.0, 176.4; IR (NaCl): 



























The product was isolated as a pale yellow oil. Yield: 70%; 1H NMR (250.13 MHz, 
CDCl3): δ=1.28 (t, J=7.1 Hz, 3H; CH3CH2), 3.32–3.40 (m, 1H; CH2), 3.84 (s, 3H; 
OCH3), 4.35–4.44 (m, 1H; CH2), 5.15–5.24 (m, 2H; CHC and CHN), 6.93 (d, J=8.7 
Hz, 2H; Ph-H), 7.28–7.31 (m, 2H; Ph-H), 7.38–7.47 (m, 5H; Ph-H), 7.59 (s, 1H, NH); 13C NMR 
(100.61 MHz, CDCl3): δ=11.6, 46.6, 55.3, 60.9, 100.5, 114.5 (2C), 125.0 (2C), 128.1 (2C), 128.9 
(2C), 129.4, 132.9, 133.2, 134.1, 159.7, 175.3; IR (NaCl): ν˜=1510 (s), 1462 (s), 1237 (s); HRMS 
(EI): m/z = 324.1290 (M+), calc. for C19H20N2OS = 324.1294. 
 
4-(4-Methoxyphenyl)-6-phenyl-3-(1-phenylethyl)-3,4-dihydropyrimidine-
2(1H)-thione (123e).  
Product isolated as a pale yellow oil in a 5:6 mixture of diastereomers. Yield: 55%; 
1H NMR (200.13 MHz, CDCl3): δ=1.20 (d, J=8.6 Hz, 3H; CH3CH), 1.65 (d, J=7.0 
Hz, 3H; CH3CH) 3.60 (s, 3H; OCH3), 3.72 (s, 3H; OCH3), 4.62 (d, J=6.1 Hz, 1H; 
CHN), 4.87 (d, J=6.2 Hz, 1H; CHN), 5.09 (dd, J=2.4 Hz, J=6.1 Hz, 1H; CHC), 5.23 (dd, J=2.4 Hz, 
J=6.2 Hz, 1H; CHC), 6.39 (d, J=8.7 Hz, 2H; Ph-H), 6.63 (d, J=8.7 Hz, 2H; Ph-H), 6.78–7.32 (m, 
26H; Ph-H and CHCH3), 7.75 (s, 1H; NH), 7.80 (s, 1H, NH); 13C NMR (400.13 MHz, CDCl3,): 
δ=15.9, 17.3, 29.7 (2C), 55.2, 55.3, 56.0 (2C), 58.9, 59.6, 101.6, 101.7, 113.6, 114.4, 125.0 (2C), 
125.2 (2C), 127.0 (2C), 127.2 (2C), 127.6 (4C), 127.9 (2C), 128.5 (2C), 128.7 (2C), 128.9 (4C), 129.3 
(2C), 132.9, 133.0 (2C), 133.5, 135.2, 136.2, 138.6, 139.3, 158.5, 159.4, 177.3, 177.4; IR (NaCl): 
ν˜=1510 (s), 1443 (s), 1249 (s); HRMS (EI): m/z = 400.1611 (M+), calc. for C25H24N2OS = 400.1609. 
 
3-Ethyl-4,6-diphenyl-3,4-dihydropyrimidine-2(1H)-thione (123f)  
The product was isolated as a pale yellow oil. Yield: 72%; 1H NMR (250.13 MHz, 
CDCl3): δ=1.22 (t, J=7.1 Hz, 3H; CH3CH2), 3.26–3.34 (m, 1H; CH2), 4.37–4.45 (m, 
1H; CH2), 5.18–5.21 (m, 2H; CHC and CHN), 7.35–7.67 (m, 10H; Ph-H); 13C NMR 
(50.32 MHz, CDCl3): δ=11.6, 46.8, 61.5, 100.3, 125.1 (2C), 126.7 (2C), 128.4, 128.9 
(2C), 129.2 (2C), 129.4, 133.1, 141.9, 175.6; IR (NaCl): ν˜=2973 (w), 2928 (w), 1520 (s), 1464 (s), 
1287 (s), 1124 (s); HRMS (EI): m/z = 294.1187 (M+), calc. for C18H18N2S = 294.1191. 
 
Method B (for compounds 125g–j): In a 5 mL Pyrex microwave vial a sample of the corresponding 
thiazine 125g–j (0.30 mmol) was dissolved in 1.5 mL of dry NMP. The vial was sealed and subjected 
to MW irradiation at 200°C for 35 min. After the reaction was completed the dark-colored solution 
was poured onto ice-water and stirred for 5-10 min. The solid precipitate was filtered and dried to 
give products 123g–j as solids. For the rearrangement of 125j an extractive work-up with diethyl 
ether and subsequent dry-flash chromatography (petroleum ether/EtOAc (1:1)) of the residue was 





Yield: 88%; m.p. 167–169°C [i-propanol]; 1H NMR (360 MHz, CDCl3) δ=0.85 (t, 
J=7.1 Hz, 3H; CH3CH2), 1.26 (t, J=7.1 Hz, 3H; CH3CH2), 3.44 (sextet, J=7.2 Hz, 
1H; CH2N), 3.82–3.96 (m, 2H; OCH2), 4.38 (sextet, J=7.2 Hz, 1H; CH2N), 5.95 (s, 























47.7, 60.3, 60.6, 102.8, 126.9 (2C), 128.3 (4C), 128.4, 129.0 (2C), 129.9, 134.0, 141.1, 143.8, 165.0, 
174.5; MS (pos APCI) m/z 367 (28, M+1), 366 (100, M), 334 (53, M–32), 279 (43, M–87). Anal. 
Calcd for C21H22N2O2S: C, 68.82; H, 6.05; N, 7.64. Found: C, 68.50; H, 6.01; N, 7.45. 
 
Ethyl 1,2,3,6-tetrahydro-1,4-dimethyl-6-phenyl-2-thioxopyrimidine-5-
carboxylate (123h).  
Yield: 95 %; m.p. 163–165°C [EtOH]; 1H NMR (360 MHz, CDCl3) δ=1.26 (t, J=7.1 
Hz, 3H; CH3CH2), 2.33 (s, 3H; CH3), 3.30 (s, 3H, CH3), 4.06–4.20 (m, 2H, CH2), 5.39 
(s, 1H; CHN), 7.28–7.34 (m, 5H, Ph-H), 8.09 (s, 1H; NH); 13C NMR (90 MHz, CDCl3) δ=14.2, 18.3, 
40.4, 60.4, 63.3, 102.4, 126.9 (2C), 128.4, 128.9 (2C), 140.4, 142.5, 165.3, 175.0; MS (pos APCI) m/z 
291 (19, M+1), 290 (100, M), 258 (43, M–32). Anal. Calcd for C15H18N2O2S: C, 62.04; H, 6.25; N, 
9.65. Found: C, 62.12; H, 6.13; N, 9.52. 
 
Ethyl 1,2,3,6-tetrahydro-1,4-dimethyl-2-thioxo-6-(p-tolyl)-pyrimidine-5-
carboxylate (123i).  
Yield: 95 %; m.p. 135–137°C [EtOH];  1H NMR (360 MHz, CDCl3) δ=1.25 (t, J=7.1 
Hz, 3H; CH3CH2), 2.33 (s, 6H, CH3N, CH3C), 3.31 (s, 3H; CH3Ph), 4.07–4.21 (m, 
2H; CH2), 5.36 (s, 1H; CHN), 7.13 (d, J=8.0 Hz, 2H; Ph-H), 7.19 (d, J=8.1 Hz, 2H; 




carboxylate (123j).  
Yield: 61%; m.p. 171–172°C [EtOH]; 1H NMR (360 MHz, CDCl3) δ=1.21 (t, 
J=7.1 Hz, 3H; CH3CH2), 2.43 (s, 3H; CH3C), 4.05–4.20 (m, 2H; CH2), 5.59 (s, 1H; 
CHN), 7.01–7.03 (m, 2H; Ph-H), 7.28–7.34 (m, 8H; Ph-H), 8.37 (s, 1H; NH); 13C NMR (90 MHz, 
CDCl3) δ=14.1, 18.3, 60.5, 65.2, 103.8, 127.4 (2C), 127.9 (2C), 128.2, 128.4, 128.7 (2C), 129.2 (2C), 
141.1, 142.7, 143.8, 165.1, 176.1; MS (pos APCI) m/z 352 (31, M+1), 353 (100, M), 320 (33, M–32). 
Anal. Calcd for C20H20N2O2S: C, 68.16; H, 5.72; N, 7.95. Found: C, 67.84; H, 5.82; N, 7.86. 
 
Method C (for 125k,l). In a 5 mL pyrex microwave vial a sample of the corresponding thiazine (0.30 
mmol) was dissolved in 1.5 mL of dry toluene. After the addition of a passive heating element31 the 
vial was sealed and subjected to microwave irradiation at 210°C for 40 min. After the reaction was 
completed, the solvent was removed under reduced pressure and the solid crude product recrystallised 




Yield: 67%; m.p. 200–202°C [acetonitrile] (lit. m.p. 201°C32); 1H NMR (360 MHz, 
DMSO-d6) δ=1.10 (t, J=7.1 Hz, 3H; CH3CH2), 2.29 (s, 3H; CH3C), 4.01 (q, J = 7.1 
Hz, 2H; CH2), 5.17 (d, J=3.4 Hz, 1H; CHN), 7.21 (d, J=7.2 Hz, 2H; Ph-H), 7.27 (t, J=7.3 Hz, 1H; Ph-
H), 7.34 (t, J=7.30 Hz, 2H; Ph-H), 9.64 (s,1H; NH), 10.32 (s, 1H, NH).  
 
Ethyl 1,2,3,4-tetrahydro-4,6-diphenyl-2-thioxopyrimidine-5-carboxylate (123l).  
Yield: 63%; m.p. 191–193 °C [EtOH] (lit. m.p. 192°C33); 1H NMR (360 MHz, 
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J=3.6 Hz, 1H; CHN), 7.29–7.45 (m, 10H; Ph-H), 9.76 (s, 1H; NH), 10.48 (s, 1H; NH); 13C NMR (90 
MHz, DMSO-d6) δ=13.8, 54.6, 59.9, 102.3, 126.9 (2C), 128.2 (2C), 128.3, 129.2 (4C), 129.6, 134.5, 
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Oxidation-hydrocyanation of γ,δ-unsaturated alcohols using (immobilised) TEMPO/PhI(OAc)2 in combination 
with HbHNL proceeds smoothly. After (in situ) protection, the resulting cyanohydrin derivatives were obtained in 
good overall yields and high ee’s. A mild TEMPO-catalysed oxidation protocol is described that yields β,γ-
unsaturated aldehydes without isomerisation of the double bond and that is compatible with a subsequent HbHNL-
catalysed hydrocyanation performed in the same solvent. 
 




Cyanohydrins are versatile chiral building blocks,1–3 which can be transformed into α-
aminonitriles,4–6 α-hydroxyesters,7 amino alcohols,8 2,3-disubstituted piperidines,9 and 3-
hydroxytetrahydropyridines.10 The cyanohydrins are conveniently accessed by hydroxy-
nitrile lyase (HNL) catalysed hydrocyanation of the corresponding aldehydes.11 These 
biocatalysts are well established and both the (R)- and (S)-enantiomer of the cyanohydrins 
can be prepared in high yields and ee values.12–14 During our studies towards a chemo-
enzymatic de novo synthesis of non-natural nucleosides (A) containing a 3’-deoxy ribose 
moiety we required a series of differently substituted, optically pure, γ,δ-unsaturated 
cyanohydrins 130 (Scheme 1). For this, a biocatalytic hydrocyanation of β,γ-unsaturated 




























































 130 131 132 
Scheme 5.1 Retrosynthesis of non-natural nucleosides containing a 3’-deoxyribose moiety 
Oxidation of γ,δ-unsaturated primary alcohols 132 to the corresponding aldehydes 131 is the 
most direct way to prepare the required substrates for the HNL-catalysed hydrocyanation. 
However, many of the most widely employed oxidations like, e.g., Swern-oxidation or 
chromium(VI)-based reagents (PDC, PCC, etc) require relatively alkaline conditions. Such 
conditions are not suitable for the transformation of primary alcohols 132 to yield the desired 
β,γ-unsaturated aldehydes 131 because they promote the isomerisation of the double bond and 
thus yield the α,β-unsaturated isomers, which are difficult to separate from the required 
product.15-19 Furthermore, the alkaline conditions would also promote the racemic chemical 
addition of HCN to the aldehydes 131 in the follow-up reaction, a reaction that should result 
in the desired enantiopure cyanohydrin derivatives 130. 
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The work described in this chapter aims at a mild oxidation–hydrocyanation protocol to 
produce optically pure γ,δ-unsaturated (S)-cyanohydrins 130 starting from readily available 
primary alcohols 132. Since enzymatic redox reactions tend to be difficult due to problems 
with co-factor regeneration, a chemical reagent is envisaged for the oxidation step. The 
enantioselective C-C bond formation under close to neutral conditions, however, is difficult 
to perform with a chemical catalyst, therefore the efficient and highly enantioselective 
HbHNL will be employed.20 
(R)-Cyanohydrins are accessible in good yields and ee’s using the hydroxynitrile lyase 
Prunus amygdalus (PaHNL) from almonds, which catalyses the hydrocyanation 
efficiently.12 In general, (S)-cyanohydrins are readily available using the hydroxynitrile 
lyase from the rubber tree Hevea brasiliensis (HbHNL).13,14,20-27 However, reports on the 
enantioselective synthesis of γ,δ-unsaturated cyanohydrins 130 from β,γ-unsaturated 
aldehydes 131 are scarce.15,28 Only two examples are known of (R)-130 produced by 
PaHNL, while no examples exist for the preparation of (S)-130 using (S)-selective enzymes 
such as HbHNL. 
5.2 Results and Discussion 
5.2.1  Homogeneous oxidation 
In initial experiments, the application of the very mild Dess–Martin periodinane (DMP) to 
oxidise 132a (Scheme 5.2) without isomerisation seemed feasible but following this 
procedure, we encountered a couple of practical disadvantages.29,30 Commercial DMP is 
relatively expensive while at the same time its preparation is not entirely trivial and its 
storage can lead to degradation.31 When oxidising primary alcohols of relatively low 










 132a 131a 
Scheme 5.2 DMP-oxidation of 3-butenol 
In our case, one gram (13.9 mmol) of alcohol 132a is converted to the corresponding 
aldehyde 131a almost quantitatively, but this can only be achieved by using twelve grams 
(28.3 mmol) of DMP. Thus the Dess–Martin oxidation suffers from poor atom efficiency 
and the reaction work-up is troublesome. Consequently, the use of DMP in larger scale 
production of β,γ-unsaturated aldehydes becomes less convenient. Furthermore, we found 
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that the filtration/evaporation procedure, which is necessary after the Dess–Martin 
oxidation, was accompanied by some isomerisation of the product aldehyde. Therefore we 
turned to another method to oxidise alcohols 132 to the corresponding aldehydes 131. The 
use of relatively stable organic nitroxyl radicals, like 2,2,6,6-tetramethylpiperidin-1-oxyl 
(TEMPO), as catalysts for the mild oxidation of alcohols has found widespread 
application.32,33 A range of different procedures is known using TEMPO, e.g. in 
combination with p-TsOH, oxygen and CuCl, KBr and sodium hypochlorite (NaOCl) or a 
hypervalent iodine species.34 The first procedure is an acid-promoted disproportionation 
using 2 equiv. TsOH and TEMPO, which makes it not a very elegant method for the 
oxidation of small molecules. Like the oxidation with DMP, large amounts of oxidant are 
necessary. The second approach, oxidation using oxygen and CuCl, is usually performed in 
DMF and is therefore not applicable for the synthesis of very volatile aldehydes. The 
oxidation with KBr and NaOCl was at first sight interesting to try in the oxidation of 3-
butenol, because it uses simple chemicals and is very mild. However not the alcohol was 
oxidised, but the double bond was epoxidised. The mechanism of this epoxidation can be 
envisioned as depicted in Scheme 5.3. NaOCl and KBr form in situ the highly reactive 










 132a 133 134 
Scheme 5.3 Formation of epoxide 134 in NaOCl/KBr/TEMPO reaction 
Finally the oxidation of sensitive primary alcohols that employs a catalytic amount of 





PhI + R1R2CHO + 2 AcOH
 
Scheme 5.4 Oxidation of alcohols with PhI(OAc)2/TEMPO 
In this reaction an equilibrium between the alcohol (ROH) and PhI(OAc)2 is responsible 
for the exchange of one or both acetate ligands around the iodine atom (OR). The acetic 
acid that is formed catalyses dismutation of TEMPO to hydroxyl amine and the 
corresponding oxoammonium salt. The latter species is responsible for the selective 
oxidation of the primary alcohol to the aldehyde while being reduced to hydroxyl amine. 
Then PhI(OAc)2 completes the catalytic cycle via regeneration of TEMPO (Scheme 5.5).34 
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Scheme 5.5 Proposed reaction pathway for the oxidation of alcohols using PhI(OAc)2/TEMPO. 
Initially the reaction was performed following the literature procedure34 by using a 0.2 M 
solution of 132a in CH2Cl2, 1.1 equiv. of PhI(OAc)2, and 0.1 equiv. of TEMPO (entry 
1,Table 5.1). After 2.5 h only 15% had been converted to the desired β,γ-unsaturated 
aldehyde 131a. Although more oxidising agent improved the conversion, still only an 
unsatisfactory 38 or 50 % conversion (entries 2 and 3,Table 5.1) was detected after 2.5 h. 
Prolonged reaction times did not result in a better conversion but instead isomerisation to 
the undesired α,β-unsaturated aldehyde occurred. Instead of using CH2Cl2, an attempt was 
made to change the solvent to a more environmentally friendly mixture of pentane and 
CH2Cl2. This also has the advantage that this mixture is more suitable for HbHNL.24 To our 
satisfaction, application of 132a dissolved in a 9:1 mixture of pentane and CH2Cl2, 
respectively, together with 1.1 equiv. of PhI(OAc)2, and 0.1 equiv. of TEMPO gave 
complete and selective conversion to 131a after 2.5 h (entry 4, Table 5.1).  
 





Solvent Conversiona (%)  
1 1.1 0.1 CH2Cl2 15 
2 1.1 0.2 CH2Cl2 38 
3 1.2 0.2 CH2Cl2 50 
4 1.1 0.1 Pentane/CH2Cl2 (9:1) 100 






A number of γ,δ-unsaturated primary alcohols 132 were treated under similar conditions 
(Scheme 5.6 and Table 5.2). Conditions were optimised towards a minimum degree of 
isomerisation and optimum conversion. As can be seen, homo-allylic primary alcohols 
132a–g were readily converted to the corresponding β,γ-olefinic aldehydes 131a–g. Only 
one of three homo-propargylic alcohols, 132i, could be oxidised with TEMPO/PhI(OAc)2, 
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Scheme 5.6 Oxidation of γ,δ-unsaturated alcohols to β,γ-unsaturated aldehydes 
It should be noted that the above TEMPO/PhI(OAc)2 oxidation protocol encountered 
some problems during reaction work-up. Even when the aldehyde was carefully co-distilled 
with diethyl ether under reduced pressure, a significant isomerisation of the aldehyde was 
observed. This provided an additional incentive to develop the planned reaction protocol.  
 
















132a 27.5 quant. 1.1 0.1 9:1 0.20 150 
132b 5.00 quant. 1.1 0.1 9:2 0.36 120 
132c 2.00 quant. 1.1 0.1 9:2 0.36 40 
132d 2.00 quant. 1.1 0.1 9:2 0.36 100 
132e 2.00 quant. 1.1 0.1 9:2 0.36 100 
132f 4.00 quant. 1.2 0.2 2:1 0.66 30 
132g 4.00 quant. 1.2 0.2 2:1 0.66 30 
132h 0.25 0 1.2 0.2 1:1 1 -- 
132i 0.50 41 1.8 0.2 3:2 1 70 
132j 1.00 0b 1.2 0.2 1:1 1 150 
a) Conversion of 132 determined by 1H NMR; b) Different concentrations, amounts of chemicals, and 
temperatures were tried, however oxidation was never observed. 
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However, during the oxidation two equivalents of acetic acid are formed. As this acid 
would cause an immediate deactivation of the HbHNL it had to be removed prior to the 
hydrocyanation reaction.36 By washing the reaction mixture at the end of the 
TEMPO/PhI(OAc)2 oxidation with a saturated solution of NaHCO3, all the acetic acid was 
removed completely. To our satisfaction no isomerisation was detected.  
5.2.2  Homogeneous HNL‐catalysed hydrocyanation of β,γ‐unsaturated aldehydes 
Since both the formation of cyanohydrins and the isomerisation of the aldehyde 131a are 
base-catalysed, the enzyme reaction should be performed in a mildly acidic buffer. A direct 
transfer of the conditions that were used in the PaHNL-catalysed synthesis of the (R)-
enantiomer of 130a is not possible. PaHNL and HbHNL are structurally not related and 
their optimum reaction conditions are different.37 Initially two different pH’s (4.0 and 5.0) 
and two different temperatures (0° and 25° C) were investigated for the HbHNL catalysed 
addition of HCN to the in situ generated aldehyde 131a following a general procedure.24 
The results are summarised in Table 5.3. 
 
Table 5.3 Selectivity at complete conversion of 131a in the HbHNL-catalysed hydrocyanation; 







 131a 130a 135a 
Entry pH Temp. (°C) ee of 135a 
1 4.0 0 82 
2 5.0 0 71 
3 5.0 25 66 
a) Initially, HbHNL and 3 equiv. of HCN were used but after 30 min the reaction stopped. Complete conversion 
was only achieved by the addition of extra HbHNL and 1.5 equiv HCN (see experimental section).  
 
When the enzymatic hydrocyanation was performed at 0 °C and pH 4.0 the desired γ,δ-
unsaturated cyanohydrin 130a was formed with reasonable enantioselectivity (ee = 82 % 
entry 1, Table 5.3). Even though this result is in line with ee’s obtained previously with 
other short-chain aldehydes1 it is still insufficient for synthetic use. The relatively low ee is 
not caused by chemical background reaction, as this is virtually absent under these 




The HbHNL catalysed hydrocyanation of 131a as described above stopped after 30 min 
(Table 5.3). Apparently the enzyme was deactivated and additional HbHNL and HCN were 
needed to allow the reaction to complete. After NaHCO3 neutralisation of the crude 
reaction mixture that results from the oxidation, part of the highly reactive TEMPO is still 
present. To minimise a potentially harmful effect of TEMPO on the activity and the 
selectivity of the HbHNL we investigated the influence of different immobilised variants of 
TEMPO in the oxidation-hydrocyanation protocol. This should allow for efficient removal 
of TEMPO from the reaction mixture just before addition of the HbHNL. Furthermore, 
such a procedure opens the way to a more atom-efficient protocol that enables recycling of 
the TEMPO-catalyst. 
5.2.3  Heterogeneous oxidation  
TEMPO was immobilised on colloidal silica according to a known procedure38 and 
compared with commercial TEMPO immobilised on silica gel. The TEMPO immobilisates 
were screened in the oxidation of 132a for optimal conversion and minimal isomerisation 
of the aldehyde product 131a (Table 5.4). The data in entry 1 of table 5.4 show that 
oxidation of 132a using TEMPO immobilised on colloidal silica proceeds about three times 
faster as compared to oxidation of 132a using soluble TEMPO (Table 5.2). After 40 min at 
room temperature the reaction was complete and no isomerisation was observed. The 
TEMPO on colloidal silica could easily be recovered (by filtration) and re-used at least 
once without any loss of activity. The commercial TEMPO on silica (entry 2, Table 5.4) 
gave, under similar reaction conditions, only a few percent of 3-butenal 131a. In the 1H 
NMR spectrum of the reaction mixture, the unreacted alcohol 132a was clearly identified 
together with signals that could only be attributed to the undesired isomer 2-butenal 
(crotonaldehyde).  
 
Table 5.4 Oxidation of 132a using TEMPO immobilised on colloidal silica and commercial TEMPO 
immobilised on silica.a 
Entry Structure Loading 
(mmol/g) 




0.27 0.16 >98 40 min. 
2d N OHNSi
 
0.61 0.35 0e 3.5 h 
a) 1.2 equiv of PhI(OAc)2 in a 0.2 M solution of 132a in a 9:1 pentane/CH2Cl2 mixture at room temperature; b) 
Conversion determined by 1H NMR spectroscopy; c) TEMPO immobilised on colloidal silica; d) Commercial 
TEMPO immobilised on silica, available from Sigma-Aldrich; e) The reaction yielded the unwanted isomer of 
131a, crotonaldehyde. 
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5.2.4  Heterogeneous HNL‐catalysed hydrocyanation of β,γ‐unsaturated aldehydes  
Finally, the oxidation of 132a catalysed by immobilised TEMPO was combined with the 
HbHNL catalysed hydrocyanation to arrive at the desired cyanohydrin 130a.39 After the 
oxidation reaction, the immobilised TEMPO was removed by filtration and the resulting 
mixture neutralised with a saturated NaHCO3 solution. The resulting solution is directly 
used in the HbHNL catalysed formation of γ,δ-unsaturated 130a. Compound 130a (ee = 93 
%; entry 1, Table 5.5) could be isolated as its TBDMS-ether 5a in 37 % overall yield40 
starting from the γ,δ-unsaturated primary alcohol 132a. Although, under these optimised 
conditions, the isolated yield of 130a is 5-10% lower compared to the yield obtained after 
the oxidation-hydrocyanation sequence using soluble TEMPO, the optical purity of 130a is 
considerably higher (93% versus 82%; entry 1, Table 5.5 versus entry 1, Table 5.3) when 
performing this protocol using immobilised TEMPO. The results indicate that TEMPO has 
a negative effect both on the activity and the selectivity of the enzyme. 
The above procedures were used to prepare γ,δ-unsaturated cyanohydrins 130b–e, starting 
from the corresponding primary alcohols 132b–e. The resulting cyanohydrins were directly 
protected as acetates. The results are summarised in Table 5.5. A similar trend with regard 
to isolated yield and optical purity that was observed for the synthesis of 5a is also found 
for the preparation of 135b–e. In general, the ee’s of 135b–e (Table 5.5) are significantly 
higher whereas their isolated yields (calculated from 132b–e) are somewhat lower if they 
are prepared by the immobilised TEMPO/HbHNL protocol compared to the ee’s and yields 
obtained by applying the same protocol by using soluble TEMPO. As the reactions were 
performed on a 100 mg scale and the compounds involved in this reaction are relatively 
polar and/or volatile some loss/low yields could not be avoided. 
When testing both pH 4.0 and 5.0 for aldehydes 131c–e pH 5.0 proved to be favourable 
and was therefore utilised. Finally, the γ,δ-unsaturated primary alcohols 132f and 132g 
were readily oxidised by the TEMPO/PhI(OAc)2 procedure to the corresponding aldehydes 
131f and 131g. However, both aldehydes proved unreactive towards HbHNL catalysed 
hydrocyanation. This can be attributed to the length of the alkyl chain, which is known to 










Table 5.5 The three-step protocol oxidation-hydrocyanation and protection reaction starting from  
132a–e using both homogeneous and heterogeneous TEMPO in combination with HbHNL.  










132a 136a 4.0 82 n.d 93 37 
132b 135b 4.0 92 54 97 43 
132b 135b 5.0 95 43 92 37 
132c 135c 5.0 78 48 95 23 
132d 135d 5.0 61 52 87 26 
132e 135e 5.0 72 51 91 7c 
a) Isolated yields over 3 steps; b) ee determined by chiral GC; c) very low yield due to isolation problems. 
5.3 Conclusions 
In summary, we have developed an efficient oxidation-hydrocyanation protocol that 
produces optically enriched γ,δ-unsaturated cyanohydrins in good yields starting from the 
corresponding primary alcohols. The oxidation of the alcohols with TEMPO and PhI(OAc)2 
is a mild and selective method to prepare β,γ-unsaturated aldehydes, which are otherwise 
difficult to access as they readily undergo isomerisation to the α,β-unsaturated analogues. 
The thus generated aldehydes can be used directly in the subsequent HbHNL-catalysed 
hydrocyanation to give the desired optically enriched γ,δ-unsaturated cyanohydrins. 
Moreover, when the HbHNL catalyst was used in combination with the TEMPO catalyst 
immobilised on colloidal silica ee’s up to 97% and overall yields up to 43% of the final 
cyanohydrin derivatives were obtained. The TEMPO-catalyst could be re-used at least once 
without any loss of catalytic activity. 
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5.5 Experimental section 
5.5.1 General 
1H and 13C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AC 200 (200.13 
and 50.32 MHz, respectively), a Bruker Avance 250 (250.13 and 62.90, respectively) or a Bruker 
MSL 400 (400.13 and 100.61 MHz respectively) spectrometer; chemical shifts (δ) are given in ppm, 
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internally referenced to residual solvent resonances (1H: δ 7.29 ppm, 13C: δ 77.0 ppm). Column 
chromatography was performed on Baker 7024-02 silica gel (40 μ, 60 Å) with petroleum ether (PE, 
boiling range 40-60 °C) and ethyl acetate (EA) as eluents. Thin-layer chromatography (TLC) was 
performed using silica plates from Merck (Kieselgel 60 F254 on aluminium with fluorescence 
indicator). Compounds on TLC were visualised by UV-detection or 5% (w/v) aqueous KMnO4. High-
resolution mass spectra (HRMS, EI) and mass spectra (MS) were recorded on a Finnigan Mat 900 
spectrometer at 70 eV.  IR spectra were recorded on a Mattson 6030 Galaxy spectrophotometer and 
are reported in cm-1. To follow the course of the reactions, samples were taken directly from the 
reaction mixtures, dissolved in CDCl3 and analysed by 1H NMR spectroscopy. For the oxidation and 
enzyme reaction, the conversion was determined by monitoring the H2C-O (δ 3.59–3.76) and the 
HC=O (δ 9.66–9.74) signal respectively. The racemic cyanohydrin acetates were prepared from the 
corresponding aldehydes according to literature.41 The enantiomeric excess of the acylated (S)-
cyanohydrins 135 was determined on a Shimadzu GC-17A, equipped with a β-cyclodextrin column 
(CP-Chirasil-Dex CB 25m×0.32 mm ID), a FID detector, and a Shimadzu Auto-injector AOC-20i. 
The carrier gas was He with a linear gas velocity of 75 cm/s at 155kPa. The GC-retention times are 
summarised in Table 5.6. Optical rotations were measured on an AA-10 automatic polarimeter from 
Optical Activity Ltd. Pro analysis grade γ,δ-unsaturated primary alcohols 132a–e and 3h–j were all 
commercially available and used without purification except for 3-butenol 132a, which was distilled 
and stored under nitrogen and over molecular sieves 4Å. Primary alcohols 132f and 132g were 
prepared by hydrogenation and LAH reduction, respectively, starting from 3-decynol following 
literature procedures.42,43 TEMPO immobilised on silica gel (70-120 mesh) was purchased from 
Sigma-Aldrich. The loading of the TEMPO on colloidal silica was determined by elemental analysis 
on an Elementar Vario EL III analyzer. The hydroxynitrile lyase from Hevea brasiliensis (HbHNL) 
was a generous gift from DSM (Wubbolts, NL). The activity of the HbHNL (13.1 U/mg protein 
solution) was determined according to standard procedures.44,45 
5.5.2  Synthetic Procedures and Physical Data 
Colloidal silica: A mixture of tetramethoxysilane (25 mL) and acidic water (50 mL, pH adjusted to 
2.8 by addition of HCl) was stirred until a homogeneous mixture was formed. After ageing at room 
temperature for 18 h, the gel was crushed to a fine powder and the water was removed by azeotropic 
distillation with toluene. The solid was collected by filtration and dried at 120ºC overnight to give a 
white glass like powder. The TEMPO was immobilised on the colloidal silica according to 
literature.38 
 
Table 5.6 Temperature program and retention times for the GC analysis of acetates 135a–e 
Compound Temperature (°C) Rt (R) 135a–e (min.) Rt (S) 135a–e (min.) 
135a 100 3.13 4.16 
135b 135 1.13 1.20 
135c 135 1.61 1.81 
135d 135 1.63 1.83 




General Oxidation-hydrocyanation procedure A, using homogeneous TEMPO and HbHNL: To 
a solution of γ,δ-unsaturated primary alcohol 3a–e in a pentane/CH2Cl2 mixture, PhI(OAc)2 and 
TEMPO were added, all quantities are according to Table 5.2. The reaction mixture was stirred at 
room temperature until full conversion of the alcohol was reached (according to 1H NMR). Then, 
saturated NaHCO3 solution was added at 0°C to the reaction mixture until the CO2 development 
ended. The aqueous layer was removed and hydroxynitrile lyase from Hevea brasiliensis (1.45 
KU/mmol 132a–e) dissolved in an equivolume of 0.1 M citrate buffer (pH 4.0 or pH 5.0) at 0°C to 
generate a 1:1 mixture (v/v) of organic phase to buffer was added. The mixture was stirred vigorously 
until a stable emulsion was obtained, after which HCN dissolved in MTBE was added. [The HCN-
solution was prepared by dissolving sodium cyanide (3.0 equiv.) in water (10 mL) and adjusting the 
pH of the solution to 4.8 by addition of citric acid. This aqueous solution was extracted with MTBE 
(3×8 mL) at 0°C]. After the hydrocyanation was complete (according to 1H NMR) the organic layer 
was isolated and dried over MgSO4. In the cases where the emulsion was too stable it was extracted 
with CH2Cl2 (5–10 mL). After evaporation of the solvents, the resulting oil was dissolved in CH2Cl2 
(2 mL/mmol substrate) and acetic anhydride (3 equiv.), pyridine (2 equiv.) and 4-DMAP were added 
to the solutions of (S)-cyanohydrins 135b–e. The reaction mixture was stirred overnight, washed with 
1% HCl (2×10 mL), water (2×10 mL), followed by washing with saturated NaHCO3 (2×10 mL) and 
water (2×10 mL). The organic layer was dried over Na2SO4 and concentrated under vacuum. The 
crude product was purified by column chromatography. In the case of 130a, starting from 6 mmol, 
only an analytical sample was derivatised in the same manner. This showed an ee of 82 %.  
 
(2S)-2-acetoxy-4-methyl-4-pentenenitrile (135b) 
The title compound was prepared from 132b (430 mg, 5 mmol) according to general procedure A, 
using pH 4.0. (S)-135b was obtained as a clear oil (414 mg, 54% yield, 92% ee). For characterisation, 
see (S)-135b obtained from general procedure B. 
 
(2S)-2-acetoxy-5-methyl-4-hexenenitrile (135c)  
The title compound was prepared from 132c (200 mg, 2 mmol) according to general procedure A, 
using pH 5.0. (S)-135c was obtained as a clear oil (161 mg, 48% yield, 78% ee). For characterisation, 
see (S)-135c obtained from general procedure B. 
 
(2S,4E)-2-acetoxy-4-heptenenitrile (135d)  
The title compound was prepared from 132d (200 mg, 2 mmol) according to general procedure A, 
using pH 5.0. (S)-135d was obtained as a clear oil (174 mg, 52% yield, 61% ee). For characterisation, 
see (S)-135d obtained from general procedure B. 
 
(2S,4Z)-2-acetoxy-4-heptenenitrile (135e)  
The title compound was prepared from 132e (200 mg, 2 mmol) according to general procedure A, 
using pH5.0. (S)-135e was obtained as a clear oil (173 mg, 51% yield, 72% ee). For characterisation, 
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General Oxidation-hydrocyanation procedure B using TEMPO immobilisates and HbHNL  
A 0.2 M solution of γ,δ-unsaturated primary alcohols 132a–e (1 equiv.) in pentane/CH2Cl2 (9:1) 
mixture, PhI(OAc)2 (1.1 equiv.) was mixed with immobilised TEMPO (TEMPO on colloidal silica: 
0.27 mmol/g, 0.16 equiv. or commercial TEMPO on silica gel: 0.61 mmol/g, 0.35 equiv.) and stirred 
at room temperature until completion (according to 1H NMR). After filtration of immobilised 
TEMPO, a saturated NaHCO3 solution was added to the reaction mixture at 0°C until the CO2 
development ended. The aqueous layer was removed and to the organic layer was added 
hydroxynitrile lyase from Hevea brasiliensis (1.45  /mmol 132a–e) dissolved in an equivolume of 0.1 
M citrate buffer (pH 4.0 or pH 5.0) at 0°C to generate a 1:1 mixture (v/v) of organic phase to buffer. 
The mixture was stirred vigorously until a stable emulsion was obtained, after which HCN (3 equiv.) 
dissolved in MTBE was added. [The HCN-solution was prepared by dissolving sodium cyanide (3.0 
equiv.) in water (10 mL) and adjusting the pH of the solution to 4.8 by addition of citric acid. This 
aqueous solution was extracted with MTBE (3×8 mL) at 0°C]. After the hydrocyanation was 
complete (according to 1H NMR) the organic layer was separated and dried over MgSO4. In the cases 
where the emulsion was too stable it was extracted with CH2Cl2 (5–10 mL). After evaporation of the 
solvents, the resulting oil was dissolved in CH2Cl2 (2 mL/mmol substrate) and acetic anhydride (3 
equiv.), pyridine (2 equiv.) and 4-DMAP were added to the solutions of (S)-cyanohydrins 130b–e. 
The reaction mixture was stirred overnight, washed with 1% HCl (2×10 mL), water (2×10 mL), 
followed by washing with saturated NaHCO3 (2×10 mL) and water (2×10 mL). The organic layer was 
dried over Na2SO4 and concentrated under vacuum. The crude product was purified by column 
chromatography. In the case of 130a, only an analytical sample was derivatised in the same manner to 
give the acetate with an ee of 95 %. The remaining solution was derivatised as the corresponding 
TBDMS-ether 136a (see below). 
 
(2S)-2-acetoxy-4-methyl-4-pentenenitrile (135b)  
The title compound was prepared from 132b (431 mg, 5 mmol) according to general 
procedure B, using pH 4.0. (S)-135b was obtained as a clear oil (330 mg, 43% yield, 97% ee); Rf 
(PE/EA, 95:5)= 0.27; [α]22D= –74 (c=1, CHCl3); 1H NMR (250.13 MHz): δ=1.83 (s, 3H; CH3C═C), 
2.16 (s, 3H; CH3C═O), 2.64 (d, J=7.1 Hz, 2H; CH2CHCN), 4.94 (s, 1H; H2C═CCH3), 5.02 (s, 1H; 
H2C═CCH3), 5.50 (t, J=7.1 Hz, 1H; CHCN); 13C NMR (62.90 MHz): δ=20.3, 22.3, 40.4, 59.7, 
116.10, 116.7, 137.6, 168.9; IR (NaCl): ν˜= 2975 (m), 1756 (s), 1376 (s), 1221 (s), 1053 (s), 907 (m); 
MS (C8H11O2N, m/z, relative intensity): 153 [M+, 2], 111 (4), 93 (100), 66 (68), 55 (32);  
 
(2S)-2-acetoxy-5-methyl-4-hexenenitrile (135c)  
The title compound was prepared from 132c (75 mg, 0.75 mmol) according to general 
procedure B, using pH 5.0. (S)-135c was obtained as a clear oil (29 mg, 23% yield, 95% ee); Rf 
(PE/EA, 95:5) = 0.27; [α]22D = – 46 (c=1, CHCl3); 1H NMR (250.13 MHz): δ=1.71 (s, 3H; CH3C═C), 
1.79 (s, 3H; CH3C═C), 2,18 (s, 3H; CH3C═O), 2.61–2.67 (m, 2H; CH2), 5.19 (t, J=7.2 Hz, 1H; 
C═CH), 5.30 (t, J=6.9 Hz, 1H; CHCN); 13C NMR (100.61 MHz): δ=17.9, 20.3, 25.7, 31.1, 60.9, 
114.9, 116.7, 138.5, 168.9; IR (NaCl): ν˜= 2966 (m), 1755 (s), 1375 (m), 1220 (s), 1036 (s), 801 (s); 










(2S,4E)-2-acetoxy-4-heptenenitrile (135d)  
The title compound was prepared from 132d (75 mg, 0.75 mmol) according to 
general procedure B, using pH 4.0. (S)-135d was obtained as a clear oil (32.6 mg, 26% yield, 87% 
ee); Rf (PE/EA, 95:5) = 0.35; [α]22D = –32 (c=1, CHCl3); 1H NMR (250.13 MHz): δ=1.02 (t, J=7.4 
Hz, 3H; CH3), 2.03–2.12 (m, 2H; CH3CH2), 2.15 (s, 3H; CH3C═O), 2.56–2.62 (m, 2H; CH2CHCN), 
5.30–5.45 (m, 2H; CH═CH), 5.71–5.82 (m, 1H; CHCN); 13C NMR (100.61 MHz): δ=13.2, 20.1, 
25.4, 35.4, 60.9, 116.4, 119.5, 139.0, 168.9; IR (NaCl): ν˜= 2965 (m), 1755 (s), 1373 (m), 1222 (s), 
1037 (s), 970 (m); MS (C9H13O2N, m/z, relative intensity): 167 [M+, 16], 149 (52), 142 (24), 106 
(48), 83 (52), 69 (100);  
 
(2S,4Z)-2-acetoxy-4-heptenenitrile (135e)  
The title compound was prepared from 132d (75 mg, 0.75 mmol) according to general 
procedure B, using pH 4.0. (S)-135d was obtained as a clear oil (8.8 mg, 7% yield, 
91% ee); Rf (PE/EA 95:5) = 0.35; [α]22D = – 46 (c=1, CHCl3); 1H NMR (250.13 MHz,): δ=1.02 (t, 
J=7.4 Hz, 3H; CH3), 2.05–2.11 (m, 2H; CH3CH2), 2.15 (s, 3H; CH3C═O), 2.64–2.69 (m, 2H; 
CH2CHCN), 5.29–5.41 (m, 2H; CH═CH), 5.66–5.76 (m, 1H; CHCN); 13C NMR (62.90 MHz): 
δ=13.3, 19.1, 20.3, 30.1, 59.8, 116.6, 118.8, 137.8, 169.0; IR (NaCl): 2964 (m), 1715 (s), 1558 (m), 
1259 (s), 1211 (s), 800 (s); MS (C9H13O2N, m/z, relative intensity): 168 [M++1, 2], 142 (16), 106 
(84), 80 (64), 69 (100).  
 
(2S)-2-(t-butyldimethylsilanyloxy)-4-pentenenitrile (136a)  
A solution of recrystallised imidazole (0.87 g, 12.8 mmol) and t-
butyldimethylsilylchloride (2.11 g, 14 mmol) in 70 mL DMF was stirred at 0°C for 20 
min. The crude solution of 130a, prepared from 132a (844 mg, 11.7 mmol) according to general 
procedure B using pH 4 was added, the mixture was allowed to warm to room temperature and stirred 
overnight. The reaction mixture was diluted with 70 mL of water and extracted with diethyl ether 
(3×110 mL). The combined organic layers were washed with water (2×100 mL) and then with brine 
(1×100 mL). The organic layer was dried over Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by column chromatography on silica (PE/EA, 98:2) yielding 5a as a clear 
oil (659 mg, 37% yield, 95% ee); Rf (PE/EA, 95:5) = 0.74; [α]22D = –60 (c=1, CHCl3); 1H NMR (250 
MHz): δ=0.17 (s, 3H; CH3Si), 0.22 (s, 3H; CH3Si), 0.94 (s, 9H; (CH3)3C), 2.53–2.59 (m, 2H; 
CH2CHCN), 4.47 (t, J=6.5 Hz, 1H; CHCN), 5.23–5.30 (m, 2H; CH═CH2), 5.84 (ddt, J=17.4 Hz, 
J=9.8 Hz and J=7.0 Hz, 1H; CH=CH2); 13C NMR (62.90 MHz): δ= -4.9, -4.7, 18.5, 25.9 (3C), 41.1, 
62.3, 120.0, 120.5, 131.4; IR (NaCl): ν˜= 2956 (s), 2860 (s), 1652 (m), 1558 (m), 1259 w), 1114 (m); 
HRMS (EI): m/z = 211.1392 (M+), calc. for C11H21NOSi = 211.1392; MS (C11H21NOSi, m/z, relative 
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A chemical study has been performed on the synthesis of a lactone precursor of 3’-deoxy-5’-hexylribose. Starting 
from a simple homopropargylic alcohol via oxidation, hydrocyanation, reduction, epoxidation and finally 
hydrolysis-induced lactonisation a 3’-deoxy-5’-hexyllactone has been synthesised. This rather efficient and 
flexible 5-step approach was applied for the stereoselective synthesis of 3’-deoxylactone 176. The stereocenter 
was introduced selectively via HNL-catalysed hydrocyanation. The subsequent epoxidation and hydrolysis-




Deoxysugars are an important class of carbohydrates that occur widely in nature. They 
are commonly defined as monosaccharides with one or more hydroxyl group(s) replaced by 
e.g. hydrogen(s). Many biologically active natural products are glycosylated by one or more 
deoxysugar saccharide chains. These include important antibiotics (erythromycin)1, 
antifungals (amphotericin B)2, antiparasites (avermectins)3 and anticancer drugs 
(doxorubicin).4 3’-Deoxysugars also appear in nucleosides that since their discovery about 
sixty years ago cover some interesting compounds. Cordycepin (3’-deoxyadenosine) 
possesses several pharmacological activities like antitumour,5 antifungal,6 or antiviral 
activity.7 Other 3’-deoxy nucleosides, AZT and 3TC,8e are known as AIDS therapeutics, 
which inhibit reverse transcriptases involved in HIV-replication.8 Due to the lack of the 3’-
hydroxy group, these nucleosides act as chain terminators by blocking elongation of 
nascent DNA, leading to inhibition of viral replication.8c 3’-Deoxy nucleosides can be 
interesting as building block for the synthesis of other pharmaceutically important 
nucleosides as well, e.g. regulators of both the immune system and blood pressure via an 
agonist-antagonist effect on the G-protein coupled P2-receptors.9 Selective agonists are 
believed to be useful as hypotensive agents or in the treatment of diabetes, while selective 
antagonists may be useful as antithrombotic agents. Furthermore, oligonucleotides like, 
2’,5’-linked nucleic acids can prevent the expression of specific genes. 2’, 5’-Linked 
nucleic acids possess interesting physiological properties,10 e.g. they show a remarkable 
preference for complexation with complementary RNA.10a Finally, the 3’-deoxysugar 

























Figure 6.1 Three biologically active 3’-deoxynucleosides 
Thus, general and convenient methods for the stereoselective synthesis of rare and/or non-
natural carbohydrates and their corresponding nucleosides are of importance and 
widespread interest. Conventional syntheses of modified carbohydrates and nucleosides are 
usually based on chiral pool starting materials. The advantage is that the stereochemistry is 
already set, however natural sugars can only result in targeted molecules with the 
configurations and standard functionalities provided by nature. This limits the 
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configurational and functional flexibility. Furthermore, these synthetic routes are often 
lengthy, include difficult separations and are inherently inefficient because the 
multifunctional and sensitive starting materials limit the synthetic methodology that can be 
used. Consequently, extensive protection and deprotection reactions are often necessary to 








Figure 6.2 Starting material for several 3’-deoxylactones 
Alternative approaches to access non-natural chiral carbohydrates and their analogues are 
known, however these syntheses are mostly directed to one specific target molecule. An 
interesting precursor for the synthesis of 3’-deoxysugars that has been used by others is 
depicted in Figure 6.2. For example, for the synthesis of 3’-deoxylactone 140 a precursor 
with a chiral auxiliary attached to 137 was used. The hemiacetal N-glyoxyloyl-(2R)-
bornane-10,2-sultam (138)11 was reacted with allyltrimethylsilane in the presence of a 
Lewis acid and resulted in compound 139. This homo-allylalcohol was then 
acetoxylactonised, which resulted in a 1:1 diastereomeric mixture of lactone 140. Although 


















95 % 70 %
CF3SO3H, 70 oC
   
 138 139 (84 % ee) 140 (1:1) 
Scheme 6.1 Synthesis of 3’-deoxylactone according to Jurczak.11,12 
Another approach starts from γ,δ-unsaturated hydroxyl esters 141 as common precursor. 
The key steps for the asymmetric synthesis of 3’-deoxylactones 144-147 are depicted in 
Scheme 6.2. Epoxidation of the double bond with m-chloroperbenzoic acid afforded 
mixtures containing two stereoisomeric epoxides. Opening of the oxirane ring and 
lactonisation of the resulting aldonic acids upon treatment with aqueous acetic acid, 
followed by acetylation, yielded mixtures of arabino (144) and ribo (145) configurations in 
50-60 % yield. The other pair of stereoisomers was obtained by direct cis-hydroxylation of 
the double bond in 141, followed by lactonisation and acetylation. This led to a mixture of 
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 144 145 146 147 
Scheme 6.2 Synthesis of lactones 144–147 
We envisioned a de novo synthesis of 3’-deoxycarbohydrates starting from simple 
chemicals using stereoselective enzyme reactions (Scheme 6.3).  Unsaturated aldehydes, 
either commercially available or easily obtained via oxidation from the corresponding 
alcohols (e.g. see chapter 5) can be used as starting materials for the synthesis of 3’-
deoxycarbohydrates. Subsequent hydrocyanation catalysed by HNL provides optically pure 
cyanohydrins 148. Next, epoxidation and hydrolysis-induced lactonisation (either 
chemically or enzymatically) results in lactones 149-151. Finally, reduction of the lactones 
results in 3’-deoxycarbohydrates 152-154. Depending on the carbon chain between the 
unsaturated bond and the cyanohydrin functional group 5-, 6-, or 7- membered lactones can 
be obtained.  In this way, the synthetic routes are straightforward and ensure efficient and 
stereoselective access to a broad spectrum of differently functionalised 3’-
deoxycarbohydrates. As displayed in the former chapter a (S)-selective HNL enzyme can be 
applied for the synthesis of cyanohydrins 148. When used in combination with chemical 
cascade reactions optimal stereo- and regiocontrol can be achieved.  
 
 
Synthetic Studies towards the 3’-Deoxyribose Moiety 
135 









a = HNL-catalysed hydrocyanation
b
c = reduction
= epoxidation; hydrolysis-induced lactonisation
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Scheme 6.3 De novo approach to 3’-deoxycarbohydrates 
6.2 Synthesis of 3’‐deoxylactone 161 
First we studied the chemical feasibility of the general approach discussed above. For 
practical reasons aldehyde 157 was chosen as starting molecule. The route depicted in 
Scheme 6.4 should then lead to the 3’-deoxy lactone 161. At a later stage chiral building 
blocks from chapter 5 could be transformed in a similar fashion to the corresponding 
optically active 3’-deoxyribose moieties.   
6.2.1  Chemical strategy 
Thus, the racemic synthesis starts from aldehyde 157. This aldehyde can either be 
synthesised from a diacetal14 155 or an alcohol 156.15 Via acidic cleavage of 155 using a 
4/1/1 solvent mixture of DCM/TFA/H2O aldehyde 157 was obtained in 95 % yield.16 
Alternatively, oxidation of the alcohol using 2 equiv. Dess-Martin periodinane (DMP) gave 
157 in quantitative yield. Subsequently, aldehyde 157 is transformed into cyanohydrin 158 
via Greenlee’s method17 using TBSCN, KCN and 18-crown-6 ether in 85 % yield. After the 
triple bond of cyanohydrin 158 is hydrogenated with Lindlar catalyst18 in ethanol in 93 % 
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yield, the resulting cis-alkene 159 was epoxidised. To achieve this, 5 equiv. oxone® were 
added to a three-phase system containing alkene 159, 18-crown-6 ether and NaHCO3.19 
This resulted in a 1:1 mixture of two diastereomers 160 in 91 % yield, which could be 







































61 %  
 159 160 161 
Scheme 6.4 Chemical synthesis of model compound  
At this point the key transformation, a hydrolysis-induced lactonisation of epoxides 160 
to form the desired lactones 161 was planned. In an initial attempt to achieve this, the 
epoxides 160 were reacted with 20 equiv. of 25 % HCl at room temperature. According to 
1H NMR the diols 162 and 163 were formed in 50 % and 47 % yield, respectively. This 
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Scheme 6.5 Hydrolysis of epoxide 160 
To the best of our knowledge no precedent exists in literature for the hydrolysis-induced 
lactonisation, starting from a TBS-protected epoxy cyanohydrin like 160. However, 
conditions similar to those we tried (see Scheme 6.5) led to efficient hydrolysis-induced 
lactonisation of TMS-protected cyanohydrin derivative 164 and affords the desired 
corresponding lactones 166 efficiently (Scheme 6.6).20  



















91 %  
 164 165 166 (3:1) 
Scheme 6.6 Hydrolysis-induced Lactonisation by Bacher et al.20 
In a further test reaction, 160 was allowed to react with excess HCl (25 %) in refluxing 
ethanol for 6 hours. After work-up and purification, it was possible to obtain in about 20 % 
yield a pure product with a characteristic signal at 1779 cm-1 in the IR-spectrum. This 
indicates the formation of stable lactones 161, which can only be the result of a cascade 
reaction including 4 succesive steps starting from 160 (Scheme 6.7). After extensive 
spectroscopic analysis (see section 6.2.2) the structure of the lactones 161 could be 
confirmed. The order of events are summarised in Scheme 6.7. Acid catalysed epoxide ring 
opening of 160, results in threo diols 162 via an anti addition of water. Bulky silyl 
protective groups are more stable than epoxides, so under highly acidic conditions they will 
be hydrolysed after the oxirane moiety to give the triols 163. At this stage, the cyano-group 
is still intact but under reflux conditions this will be hydrolysed as well, resulting in the 
carboxylic acids 167. These will undergo an intramolecular esterification through 
nucleophilic attack of the C4-hydroxyl group to the electrophilic carbon of the carboxylic 























































 167 161 
Scheme 6.7 Lactonisation of epoxide 160 
The cascade reaction leading to lactones 161 was further optimised. Thus, in the presence 
of 5 equiv. of acid, the solvent and reaction temperature were varied. In Table 6.1 the 
results are summarised. In dioxane only small amounts of side products were formed 
according to GC, and an optimal yield of ∼ 84 % was found. An additional advantage of the 
hydrolysis-induced lactonisation reaction performed in dioxane is that the reaction can be 
followed visually by the formation of a white pricipitate, which is the NH4Cl salt. The 
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precipitation of NH4Cl may drive the reaction to completion and additional work-up is 
easier as compared to the reaction in ethanol and t-butanol. When the optimised conditions 
were used for the hydrolysis-induced lactonisation of 160 the lactones 161a-d were 
obtained in a ratio of 1:5:6:1 in 61 % isolated yield. The formation of four diastereomeric 
lactones may be explained by little temperature-induced epimerisation or by non-optimal 
regioselectivity in the first epoxide-hydrolysis step of the cascade process (9% 161a and d). 
However, no 6-membered ring lactone formation was observed. 
 
Table 6.1 Optimisation of the cascade reaction using 25 % HCl in different solvents. 




a) Yield was determined by GC. 
 
The cis-alkene 159 was employed, which leads to cis-epoxides 160 and in principle to 
only four of the eight possible stereoisomers of 161. However, the route is easily modified 
to yield the corresponding trans-alkenes, e.g. by reduction of the triple bond using metal 
hydride reducing agents instead of hydrogenation. Subsequent analogous transformation 
should then afford the corresponding trans-epoxides. These then lead to the other four 
stereoisomers of 161. In this way all eight possible stereoisomers of lactone 161 are 
accessible. 
6.2.2 Structure of lactones 161 
Even after extensive crystallisation efforts it was not possible to obtain single crystals 
suitable for X-ray analysis. This would, of course, have unambiguously proven the structure 
of the lactones 161. Our structural elucidation had, consequently, to rely on alternative 
spectroscopic considerations, which are discussed in the following section. 
Kinetics of lactone formation 
Many examples of intramolecular reactions leading to ring closure have served to 
establish a correlation between the rate of a reaction and the ring size of the ring being 
formed. Intramolecular lactonisation from carboxylic acid intermediate 167 may result in 
two possible products, a five- or a six-membered ring lactone (Scheme 6.8). Illuminati et al. 
have investigated the lactonisation of ω-bromoalkanoic acids with strong bases in 99 % 
aqueous DMSO to determine the rate constants for ring formation in order to obtain deeper 
understanding of the factors involved in ring closure.21 




















 167  161 
Scheme 6.8 Mechanism for 5- and 6-membered lactone formation 
The experiments showed first-order rates, which are collected in Table 6.2. Formation of 
5-ring lactones are approximately 100 times faster, compared to formation of corresponding 
6-ring lactones under these conditions. Although the conditions are not directly comparable 
to the hydrolysis-induced lactonisation reaction described here, it shows that formation of 
5-ring lactones like 161 is fairly easy as compared to the corresponding 6-ring lactones. 
 
Table 6.2 Relative rates for the formation of lactones21 
Ring size Relative rate 
4 2.4 ⋅ 102 
5 2.9 ⋅ 104 
6 2.6 ⋅ 102 
7 1 
IR absorption frequency of lactones 
Lactones have been extensively studied on their characteristic frequencies in the infrared 
spectra. Rasmussen22 found that a γ-valerolactone (five-membered ring) has a characteristic 
frequency of 1770 cm-1 and Jones23 found 1780–1778 cm-1 for steroid γ-lactones. 
Generally, saturated five-membered ring lactones show a C=O stretch frequency between 
1780–1760 cm-1. For six-membered rings (δ-lactones) and also the open-chain analogues 
characteristic C=O stretch frequencies are observed between 1750–1735 cm-1. This can be 
attributed to the lack of strain in the ring.23 The order of the C=O stretch frequency for 
lactones is: 4-ring > 5-ring > 6-ring = acyclic (1818, 1775, 1740cm-1 respectively). Bartlett 
and Stiles explained this effect in terms of the hybridisation of the carbon atom of the 
carbonyl group, rather than strain in the ring.24 As the ring is contracted, the bonds to this 
carbon atom have more p-character, which confers more s-character to the C=O bond. This 
strengthening of the carbonyl bond will be reflected in a higher force constant and hence in 
a higher C=O stretch frequency.25 
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The above considerations show that for lactones the IR C=O stretch frequencies are a 
reliable tool for characterisation. Upon comparison of the C=O stretch frequencies of the IR 
spectra of lactones 161a-d with those reported for lactones in general (see above) the data 
confirm that these indeed are 5-ring lactones.  
 
Table 6.3 IR absorption frequencies of lactone 161 




five-membered ring 1780-176023 
six-membered ring 1750-173523 
a) 161b+d was measured as a mixture, which could not be separated by CC. 
NMR studies on lactone 161 
Additional evidence for the structure of 161 was collected as well. Thus, the 13C signals 
of the lactone C=O of 161a-c were compared with 13C NMR data from literature (Table 
6.4). These data also support the proposed 5-ring lactone structure for 161. 
 
Table 6.4 13C NMR data of lactones 




five-membered ring 178.726 and 178.127 
six-membered ring 172.426 and 171.227 
 
The conformational behaviour of 5-memberered ring lactones is more complex and less 
well understood than that of 6-membered ring lactones. It is thought that the reason for this 
is associated with the flexible nature of five-membered rings, which permits rapid 
pseudorotation involving interconversion of numerous conformations of similar energies. 
However, in 2,4-disubstituted-γ-butyrolactones, pseudorotation is probably severely 
impaired by either the presence of substituents on C2 and C4, and/or the resonance 
demands of the C-CO-O-C group for planarity.28 Although this is an oversimplification, 
qualitative conclusions can be drawn. 2,4-Disubstituted-γ-butyrolactones can exist in a 
conformation in which both substituents are quasi-equatorial (cis-isomer; 169) or in a 
conformation where one of the two substituents is quasi-axial. (trans-isomer; 170 and 171). 

























 169 170 171 
Figure 6.3 Possible conformations of 2,4-disubstituted -γ-butyrolactones 
Although calculation of specific torsional angles in flexible systems from vicinal 
constants are a dangerous procedure and is to be avoided, the relative magnitudes 
characterise the different diastereomers. When the vicinal coupling constants of lactones 
161a-d are compared with other 2,4-disubstituted-γ-butyrolactones,28 one can conclude that 
161a is similar to 161b and this corresponds to the trans conformation because the pattern 
of vicinal couplings is: 2 – 3β > 2 – 3α and 3α – 4 > 3β – 4. Lactone 161c is similar to 
161d, being the cis-isomers, because: 2 – 3α > 2 – 3β and 3α – 4 > 3β – 4. 
 
Table 6.5 Coupling constants of all 4 stereoisomers  
3JHH 161a (Hz) 161b (Hz) 161c (Hz) 161d (Hz) 
2 – 3α 7.0 7.5 10.6 10.7 
2 – 3β 8.8 9.2 8.7 8.7 
3α – 4 8.5 9.0 10.5 9.8 
3β – 4 3.6 3.1 5.6 5.6 
6.3 Synthesis of lactones 176 
From the previous section it becomes clear that 5-membered ring lactones can be 
synthesised in 5 steps from a simple alcohol in 44 % overall yield. The key step in this 
sequence is the four-reaction hydrolysis-induced lactonisation cascade. The results 
described in chapter 5 show that optically active cyanohydrins can be obtained from the 
corresponding alcohols by TEMPO/PhI(OAc)2 mediated oxidation followed (in situ) by a 
stereoselective HNL-catalysed hydrocyanation. Via this protocol the γ,δ-unsaturated TBS-
protected cyanohydrins (S)-136a can be obtained by employing an (S)-selective HNL (see 
chapter 5; p. 115-118). Further elaboration of this material via the general route described 
in the previous section would lead to optically active 3’-deoxylactones. After reduction, 
these yield 3’-deoxyribose derivatives, which are useful as chiral building blocks for the 
synthesis of mureidomycin analogs (see also scheme 1.4 in chapter 1). Thus, (R)-136a and 
(S)-136a29 were epoxidised with oxone® resulting in epoxides 172a-d in 94 or 92 % yield, 
Chapter 6 
142 
respectively. Both diastereomers are formed in about a 1:1 ratio. When (R)-136a was 




























 (S)-136a 172c 172d 
Scheme 6.9 Synthesis of epoxides 172 
The subsequent hydrolysis induced lactonisation, was performed following the procedure 
described for epoxide 160. Epoxides 172a and b were separately treated in this four-step 
cascade reaction. However, not the expected lactones (174) with a 5’-OH substituent, but 
the lactones with a 5’-chloro substituent were formed (176). This is confirmed with LRMS 
and HRMS. The formation of this chlorolactone 176, is the result of attack of the chloride 
at the primary carbon and not at the secondary carbon of the epoxide, resulting in retention 
of the stereochemistry. Additional hydrolysis of the TBS-protected cyanohydrin results in 
intermediates 175a and b, which upon ring-closure result in chlorolactones 176a and b. 
Similar 5’-iodolactones have been synthesised before.30 However, never an enantiopure 
starting material was used for the lactonisation. Thus always resulting in either a racemic 
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 (2R, 4S)-172b 175b (2R, 4S)-176b 
Scheme 6.10 Synthesis of lactones 
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6.4 Conclusions 
The synthesis of 3’-deoxylactones can be accomplished starting with simple chemicals, 
like β,γ-unsaturated aldehydes. 5’-Hexyl 3’-deoxylactone 161 can be synthesised in 5 steps 
from the commercially available 3-decyn-1-ol in 44 % overall yield. This strategy is also 
used for the steroeselective synthesis of 3’-deoxylactones 176. With this we developed an 
interesting straightforward and stereoselective synthesis of 3’-deoxylactones, which can be 
elaborated to 3’-deoxycarbohydrates as displayed in Scheme 6.3.   
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6.6  Experimental section and physical data 
6.6.1  General part 
1H and 13C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AC 200 (200.13 
and 50.32 MHz, respectively), a Bruker Avance 250 (250.13 and 62.90, respectively) or a Bruker 
MSL 400 (400.13 and 100.61 MHz respectively) spectrometer; chemical shifts (δ) are given in ppm, 
internally referenced to residual solvent resonances (1H: δ 7.29 ppm, 13C: δ 77.0 ppm). Column 
chromatography was performed with Baker 7024-02 silica gel (40 μ, 60 Å) with solvents petroleum 
ether (PE, boiling range 40-60 °C), ethyl acetate (EA) or diethyl ether (DEE). Thin-layer 
chromatography (TLC) was performed using silica plates from Merck (Kieselgel 60 F254 on 
aluminium with fluorescence indicator). Compounds on TLC were visualised by UV-detection and/or 
coloured with MOP solution (14g phosphomolybdic acid in 125 ml EtOH), anisaldehyde solution or 
CERMOP solution (5g phosphomolybdic acid, 2g Ce(SO4)2 and 16 ml sulphuric acid in 185 ml of 
demiwater) followed by heating to 150˚C.  High-resolution mass spectra (HRMS, EI) were recorded 
on a Finnigan Mat 900 spectrometer at 70 eV. IR spectra are recorded on a Mattson-6030 Galaxy 
spectrophotometer and are reported in cm-1. Optical rotation was determined with an AA-10 
automatic polarimeter from Optical Activity. Gas Chromatography was performed on INTERSMAT 
IGC 121 (3% CP-SIL-8, 3m ¼ CHROM-W-HP 100-120 mesh) equipped with a FID. Injector and 
Detector temperature was 200˚C and flow was 30 ml/min of H2. Integration was performed with a 
LDC/Milton Roy CI-10B integrator. Temperature programme is as follows: [Tstart (˚C) ─ tconstant (min.) 
─G (˚C/min.) ─ Tend (˚C)]. Diethyl ether was distilled from potassium and sodium. THF was distilled 
from sodium/benzophenone. Dichloromethane was distilled from P2O5. Methanol was dried over 
molecular sieves. Other commercially available chemicals were used as purchased. When necessary 






To a vigorously stirred solution of 1-octyne (7.00 mL, 83.5 mmol) in THF 
(150 mL) was slowly (approx. 1.5 h) added a 1.6 M nBuLi in hexanes 
solution (43.75 mL, 70.0 mmol) under nitrogen at -65˚C. Subsequent a catalytic amount of HMPA 
(2.00 mL) and bromoacetaldehyde diethyl acetal (7.65 mL, 50.9 mmol) were slowly added. After the 
reaction mixture was warmed to room temperature, it was refluxed for three more days, until the 
reaction was finished (the reaction was followed by GC and TLC). The reaction mixture was washed 
with a saturated NH4Cl solution (3×150 mL) and water (3×100 mL). The organic layer was dried over 
MgSO4, purified with norit, filtered over a layer of high-flow and concentrated under reduced 
pressure to give a yellow oil. The product was purified by CC (PE/EA 40:1) and obtained as a yellow 
oil. Yield: 11.1 g, 48.9 mmol, 96 %; Rf (PE/EA 40:1) = 0.30; 1H NMR (200.13 MHz, CDCl3): δ=0.82 
(t, J=6.9 Hz, 3H; CH3CH2), 1.15 (t, J=7.1 Hz, 6H; CH3CH2O), 1.21-1.41 (m, 8H; CH3(CH2)4), 2.01-
2.09 (m, 2H; CH2C), 2.44-2.49 (m, 2H; CH2CH), 3.45-3.73 (m, 4H; OCH2), 4.54 (t, J=5.7 Hz, 1H; 
CHCH2); 13C NMR (50.32 MHz, CDCl3): δ=13.9, 15.1 (2C), 18.6, 22.4, 24.9, 28.4, 28.7, 31.2, 61.5 
(2C), 74.9, 81.8, 101.1; IR (NaCl): ν˜= 2931 (m), 2860 (m), 1456 (m), 1373 (m), 1344 (m), 1119 (s), 
1065 (s), 1022 (s); HRMS (EI): m/z=227.2007 [M]+, calc. for C14H27O2=227.2011; GC programme 
[90-3-20-200] tr =10.4 min. 
  
3-decynal (157) 
A) From 1,1-diethoxy-3-decyne 155: 1,1-diethoxy-3-decyne 155 (2.26 g, 10.0 
mmol) was slowly added to a vigorously stirred two-phase system of DCM/TFA/H2O (100/25/25 mL) 
at room temperature. To protect the reaction mixture from daylight and in this way prevent side 
reactions, the flask was covered with a sheet of aluminium. After the reaction ran to completion (5.5 
h, according to GC), the excess of TFA was carefully neutralised with a saturated NaHCO3 solution. 
The organic layer was separated, dried over MgSO4, purified with norit and filtered over a layer of 
high-flow to give a yellow solution of 3-decynal 157 in dichloromethane. Yield: ~ 95% (according to 
GC). Due to the sensitive nature of 157, the organic layer was not concentrated or purified by CC.  
B) From 3-decynol 156 with DMP: 3-Decynol 156 (1.71 mL, 1.4 mmol) was added under nitrogen to 
a solution of DMP (1.19 g, 2.8 mmol) in DCM (6 mL) at room temperature. The reaction was stirred 
for 45 min. until full conversion was reached (according to 1H NMR). 3-Decynal 157 was not purified 
because of its sensitivity. 1H NMR (250. 13 MHz): δ= 0.92 (t, J=6.7 Hz, 3H; CH3(CH2)4), 1.31–1.55 
(m, 8H; CH3(CH2)4), 2.20–2.24 (m, 2H; CH2C), 3.25 (d, J=1.9 Hz, 2H; CH2CHO), 9.63 (t, J=1.9 Hz, 
1H; CHO); GC programme [180˚C iso] tr =1.4 min. 
  
2-(tert-butyldimethylsilyloxy)undec-4-ynenitrile (158) 
To a solution of TBSCN (0.56 g, 4.0 mmol) KCN (0.02 g, 0.3 mmol), 18-
crown-6 (0.13 g, 0.5 mmol) in DCM (10 mL) was slowly added a solution of 3-decynal 157 (2.0 
mmol) in DCM at room temperature under nitrogen. After addition was complete, the reaction 
mixture was stirred for 24 h at room temperature. The reaction mixture was washed with a saturated 
NH4Cl solution. The organic layer was separated, dried over MgSO4, purified with norit, filtered over 
a layer of high-flow and concentrated to give a yellow oil. Purification by CC (PE/EA 40:1) gave a 
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CDCl3):  δ=0.10 (s, 3H; SiCH3), 0.21 (s, 3H; SiCH3), 0.86–0.95 (m, 12H; SiC(CH3)3, CH3(CH2)5), 
1.15–1.56 (m, 8H; (CH2)4CH3), 2.16–2.18 (m, 2H; (CH2)4CH2), 2.65–2.67 (m, 2H; CH2CHCN), 4.52 
(t, J=7.1 Hz, 1H; CHCN); 13C NMR (50.32 MHz, CDCl3): δ= -5.5, -5.4, 13.9, 18.5 (2C), 22.4, 25.3 
(3C), 27.4, 28.4, 28.5, 31.2, 61.7, 72.8, 84.4, 119.4;  IR (NaCl): ν˜= 2932 (s), 2859 (s), 2235 (w), 
1472 (w), 1256 (w), 1117 (s); GC programme [100-2-20-200] tr =13.0 min. 
 
(Z)-2-(tertbutyldimethylsilyloxy)undec-4-enenitrile (159) 
A suspension of Lindlar’s catalyst (0.15 g) in EtOH (5 mL) was degassed and 
subsequently flushed with nitrogen (three times). This was repeated with a balloon of 
H2-gas. Subsequently 158 (1.11 g, 3.8 mmol) was added dropwise. After 30 min the 
reaction was completed (according to TLC and GC). Thereafter, the solution was dried over MgSO4, 
filtered over a layer of high-flow and concentrated. Purification by CC (PE/DEE 20:1) resulted in a 
yellow oil of 159. Yield: 1.04 g; 3.5 mmol; 93%; Rf (PE/DEE 20:1) = 0.39; 1H NMR (250.13 MHz, 
CDCl3): δ=0.11 (s, 3H; CH3Si), 0.16 (s, 3H; CH3Si), 0.82–0.90 (m, 12H; SiC(CH3)3 and CH3CH2), 
1.25 (br s, 8H; (CH2)4CH3), 2.01-2.05 (m, 2H; CH2C), 2.48–2.55 (m, 2H; CH2CH), 4.36 (t, J=6.7 Hz, 
1H; CHCN), 5.29-5.67 (m, 2H; CHCH); 13C NMR (50.32 MHz, CDCl3): δ=-5.5, -5.4, 13.9, 17.9, 
22.5, 25.3, 27.4 (3C), 28.8, 29.3, 31.6, 34.2, 61.9, 119.4, 121.2, 135.0; HRMS (EI): m/z=296.2418 
[MH]+, calc. for C17H34NOSi=296.2410; MS (EI) m/z (%): 281 (45), 221 (10), 147 (20), 115 (30), 83 
(100); GC programme [180˚C iso], tr =11.0 min. 
 
cis-1-(TBDMSO)-1-cyano-3,4-epoxydecane (160) 
To a solution of cis-alkene 159 (1.49 g, 5.1 mmol) in DCM (145 mL), acetone (145 
mL), water (45 mL), NaHCO3 (12.6 g, 150.0 mmol) and 18-crown-6 ether (0.11 g, 
0.4 mmol) were successively added. The resulting three-phase system was cooled to 
0˚C and oxone® (23.3 g, 37.9 mmol) dissolved in water (100 mL) was added dropwise (1drop/sec.). 
After overnight stirring, the reaction was complete (according to GC and TLC) and a Na2S2O5-
solution (5%, 80 mL), a saturated NaHCO3 solution (80 mL) were added. The reaction mixture was 
salted with NaCl. The organic layer was separated and the aqueous layer was extracted with DCM 
(2×100 mL) and DEE (2×100 mL). The combined organic layer were dried (MgSO4), purified with 
norit, filtered over high-flow and concentrated to give a colourless oil. Purification by CC (PE/DEE 
15:1) gave a 1:1 mixture of diastereomers 160a and b. Yield: 1.44 g, 4.61 mmol, 91 %;  
160a Rf (PE/DEE 9:1) = 0.45; 1H NMR (400.13 MHz, CDCl3): δ=0.16 (s, 3H; CH3Si), 0.21 (s, 3H; 
CH3Si), 0.87 (s, 3H; CH3CH2), 0.92 (s, 9H; (CH3)3C), 1.25-1.59 (m, 10H; (CH2)5CH3), 1.92 (ddd, 
J=5.8 Hz, J=7.5 Hz, J=14.2 Hz, 1H; CHCHCN), 2.12 (ddd, J=4.5 Hz, J=7.8 Hz, J=14.2 Hz, 1H; 
CHCHCN), 2.98 (dt, J=4.3 Hz, J=6.6 Hz, 1H; CHO (epoxide)), 3.11 (dt, J=4.5 Hz, J=7.5 Hz, 1H; 
CHO (epoxide)), 4.61 (dd, J=5.8 Hz, J=7.8 Hz, 1H; CHCN); 13C NMR (100.61 MHz, CDCl3): δ= -
5.4, -5.2, 14.0, 18.0, 22.5, 25.5 (3C), 26.5, 28.0, 29.1, 31.7, 35.3, 52.4, 56.6, 60.4, 119.4;  
160b Rf (PE/DEE 9:1) = 0.53); 1H NMR (400.13 MHz, CDCl3): δ=0.18 (s, 3H; CH3Si), 0.23 (s, 3H; 
CH3Si), 0.89 (s, 3H; CH3CH2), 0.93 (s, 9H; (CH3)3C), 1.25-1.59 (m, 10H; (CH2)5CH3), 1.81 (ddd, 
J=3.5 Hz, J=8.1 Hz, J=14.1 Hz, 1H; CHCHCN), 2.12 (ddd, J=4.0 Hz, J=9.5 Hz, J=14.1 Hz, 1H; 
CHCHCN), 2.98 (dt, J=4.3 Hz, J=7.5 Hz, 1H; CHO (epoxide)), 3.11 (dt, J=4.0 Hz, J=8.1 Hz, 1H; 
CHO (epoxide)), 4.61 (dd, J=3.5 Hz, J=9.5 Hz, 1H; CHCN); 13C NMR (100.61 MHz, CDCl3): δ= -
5.5, -5.3,14.0, 18.1, 22.5, 25.5 (3C), 26.4, 28.0, 29.1, 31.7, 35.1, 52.4, 57.6, 59.6, 119.7; IR (NaCl): 









m/z=312.2312 [MH]+, calc. for C17H34NO2Si=312.2359; GC programme [200˚C iso], tr 160a = 7.0 
min. and tr 160b = 7.4 min. 
 
Diols 162 and Triols 163 
To a solution of cis-1-(TBDMSO)-1-cyano-3,4-epoxydecane 160 
(0.16 g, 0.50 mmol) in EtOH (1mL) was added dropwise HCl (1 
mL 25 %) at room temperature. After 90 min. the reaction was 
stopped via neutralisation with NH3 (25% in water) and extracted 
with PE (3×10 mL). The combined organic layer was dried over MgSO4, filtered over high-flow and 
concentrated to give a yellow oil. Purification by CC (PE/DEE 9:1) gave a 1:1 mixture of diols 162 
and triols 163. Yield: (162: 83 mg; 0.25 mmol; 50% and 163: 51 mg; 0.24 mmol; 47%). 1H NMR and 
13C NMR spectra revealed that the products were the diols and triols, however the triols contained too 
many isomers to be interpreted. 162: 1H NMR (400.13 MHz, CDCl3): δ=0.17 (s, 3H; CH3Si), 0.18 (s, 
3H; CH3Si), 0.21 (s, 3H; CH3Si), 0.22 (s, 3H; CH3Si), 0.87-0.94 (m, 6H; CH3CH2), 0.93 (s, 9H; 
C(CH3)3), 0.94 (s, 9H; C(CH3)3), 1.28-1.60 (m, 16H; CH3(CH2)4), 1.75-1.90 (m, 4H; CH2(CH2)4), 
2.01-2.13 (m, 4H; CHCHCN), 2.16 (d, J=4.1 Hz, 1H, OH), 2.28 (d, J=4.1 Hz, 1H, OH), 3.87-3.95 (m, 
4H, CHOH), 4.68-4.75 (m, 2H; CHCN); 13C NMR (100.61 MHz, CDCl3): δ= -5.6, -5.4, -5.3, -5.2, 
14.0 (2C), 18.0 (2C), 22.5 (2C), 25.5 (6C), 26.4 (2C), 28.7 (2C), 31.6 (2C), 34.3, 34.7, 40.7, 41.1, 




To a solution of epoxide 160 (0.33 g, 1.1 mmol) in dioxane (4 mL) was 
added dropwise 25 % HCl (0.6 mL, 6 mmol) at room temperature. 
After 15 min, the mixture was warmed to 50˚C, and kept at this temperature for 30 min., subsequently 
the reaction mixture is refluxed for 2 h. After separating the organic layer, the aqueous layer was 
extracted with PE/EE (1:1) (3×5 mL). The combined organic layer was dried over MgSO4, filtered 
over high-flow and concentrated to give a viscous, brown oil. Purification by CC (PE/DEE 1:1) gave 
a mixture of 161a, 161b+d and 161c in 60 % total isolated yield.31   
161a: Yield: 11 mg; 1H NMR (400.13 MHz, CDCl3): δ= 0.91 (t, J=6.7 Hz, 3H; CH3CH2), 1.25-1.50 
(m, 7H; CH2), 1.55–1.89 (m, 3H, CH2), 2.33 (ddd, J=7.0 Hz, J=8.5 Hz, J=13.9 Hz, 1H; CH2 (ring)), 
2.61 (ddd, J=3.7 Hz, J=8.8 Hz, J=13.9 Hz, 1H; CH2 (ring)), 3.02 (br s, 1H; OH), 4.02–4.08 (m, 1H; 
CHOH), 4.63 (dd, J=7.0 Hz, J=8.8 Hz, 1H; CHOH (ring)), 4.70 (ddd, J=3.7 Hz, J=5.0 Hz, J=8.5 Hz, 
1H; CH (ring)); 13C NMR (100.61 MHz, CDCl3): δ= 14.0, 22.5, 26.0, 28.6, 31.5, 31.7, 34.0, 63.7, 
67.2, 79.7, 176.8; IR (NaCl): ν˜= 3407 (br s), 2928 (s), 1777 (s), 1458 (m), 1192 (m), 1117 (m). 
 161b: Yield: 50 mg;32 1H NMR (400.13 MHz, CDCl3): δ=0.90 (t, J=6.6 Hz, 3H; CH3CH2), 1.25-1.60 
(m, 7H; CH2), 1.52–1.62 (m, 1H, CH2), 1.75–1.92 (m, 2H, CH2CHOH), 2.39 (ddd, J=7.5 Hz, J=9.0 
Hz, J=13.8 Hz, 1H; CH2 (ring)), 2.59 (ddd, J=3.1 Hz, J=9.2 Hz, J=13.7 Hz, 1H; CH2 (ring)), 2.86 (br 
s, 1H; OH), 3.95 (ddd, J=2.4 Hz, J=5.4 Hz, J=9.0 Hz, 1H; CHOH), 4.73 (dd, J=7.5 Hz, J=9.2 Hz, 1H; 
CHOH (ring)), 4.81 (ddd, J=2.4 Hz, J=3.1 Hz, J=9.0 Hz, 1H; CH (ring)); 13C NMR (100.61 MHz, 
CDCl3): δ= 13.9, 22.4, 26.5, 28.4, 31.4, 33.4, 34.3, 64.7, 66.7, 78.9, 177.1; IR (NaCl): ν˜= 3403 (br s), 
2928 (s), 1773 (s), 1194 (m), 1119 (m). 
161c: Yield: 58 mg; 1H NMR (400.13 MHz, CDCl3): δ=0.90 (t, J=6.3 Hz, 3H; CH3CH2), 1.27–1.40 
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1.86 (m, 2H; CH2CHOH), 2.23 (ddd, J=10.5 Hz, J=10.5 Hz, J=12.7 Hz, 1H, CH2 (ring)), 2.69 (ddd, 
J=5.6 Hz, J=8.7 Hz, J=12.7, 1H, CH2 (ring)), 3.06 (br s, 2H; OH), 3.97 (dt, J=4.5 Hz, J=9.1 Hz, 1H; 
CHOH), 4.54 (ddd, J=4.5 Hz, J=5.6 Hz, J=10.1, 1H; CH (ring)), 4.58 (dd, J=8.7 Hz, J=10.5 Hz, 1H; 
CHOH (ring)); 13C NMR (100.61 MHz, CDCl3): δ= 14.0, 22.5, 26.3, 28.6, 31.5, 33.4, 33.5, 62.2, 
68.2, 77.9, 176.2; IR (NaCl): ν˜=3447 (br s), 2928 (s), 1757 (s), 1213 (m), 1144 (m), 1003 (m). 
161d: Yield: 12 mg.32 
Products 161a-d: MS (EI) m/z (%): 235 (100), 219 (60), 203 (30); GC programme [100-0-4-200], tr 
161a = 25.33 min.; tr 161b = 25.97 min.; tr 161c = 25.60 min.; tr 161d = 25.57 min. 
 
2-(tbutyldimethylsilyloxy)pent-4-enenitrile (136a) 
A solution of TBSCN (0.44 g, 3.10 mmol) KCN (0.015 g, 0.23 mmol), 18-crown-6 (0.10 
g, 0.37 mmol) in DCM (2 mL) was slowly added to a solution of 3-butenal (131a) (1.0 mmol) in 
DCM and DEE at room temperature under nitrogen atmosphere. After addition was complete, the 
reaction mixture was stirred for 71 h at room temperature. The reaction mixture was washed with a 
saturated NH4Cl solution (5×20 mL), and the resulting aqueous layer was extracted with DCM (4×20 
mL). The combined organic layer was dried over MgSO4, purified with norit and concentrated under 
reduced pressure. Purification by CC (PE/DEE = 94:6) gave a light yellow liquid. According to 1H 
NMR, the remaining product consisted of a mixture of TBSCN, TBSOAc and 2-(t-butyldimethyl-
silanyloxy)-pent-4-enenitrile in the molar ratio 0.12:0.62:1.0 (estimated 63 % w/w 
2-(t-butyldimethylsilanyloxy)-pent-4-enenitrile; 0.14 g; 0.66 mmol; 65 %). 1H NMR (250 MHz, 
CDCl3): δ=0.17 (s, 3H; CH3Si), δ 0.22 (s, 3H; CH3Si), δ 0.94 (s, 9H; SiC(CH3)3), 2.53–2.59 (m, 2H; 
CH2CH), 4.47 (t, J= 6.5 Hz, 1H; CHCN), 5.23–5.30 (m, 2H; =CH2), 5.84 (ddt, J=17.4 Hz, J=9.8 Hz, 
J=7.0 Hz, 1H; CH=CH2); 13C NMR (62.9 MHz, CDCl3): δ= -4.9, -4.75, 18.5, 25.9 (3C), 41.1, 62.3, 
120.0, 120.5, 132.0; IR (NaCl): ν˜= 2956 (s), 2860 (s), 1652 (m), 1558 (m), 1259 w), 1114 (m); 
HRMS (EI): m/z = 211.1392 (M+), calc. for C11H21NOSi = 211.1392. 
 
Epoxides 172a-b  
To a solution of (R-136a) (99 % ee; 0.19 g; 0.9 mmol) in DCM (13 mL), 
acetone (13 mL), water (3.8 mL), NaHCO3 (2.20 g, 26 mmol) and 18-
crown-6 ether (0.019 g, 0.07 mmol) were successively added. The resulting three-phase system was 
cooled to 0˚C and oxone® (3.15 g, 5.1 mmol) dissolved in water (17 mL) was added dropwise over 30 
min. After stirring overnight, a second portion of DCM (13 mL), acetone (13 mL), H2O (3.8 mL) and 
NaHCO3 (2.20 g, 26 mmol) were added. The system was cooled again to 0 oC and oxone® (3.15 g, 5.1 
mmol) in H2O (17 mL) was added over 30 min. After stirring overnight, a third identical portion of 
DCM, acetone, H2O, NaHCO3 and oxone was added. To the three-phase system a saturated NaHCO3 
solution (20 mL) and 5 % Na2S2O5 solution (20 mL) was added dropwise, followed by extraction 
with DEE (20 mL), DCM (2×20 mL) and DEE (2×20 mL). The combined organic layer was dried 
over MgSO4 and concentrated under reduced pressure. Purification by CC (gradient starting from 
DEE/pentane=1:14 ending with Et2O/pentane=1:2) gave two different diastereomers. Total yield of 
the diastereomers is 94 % (194 mg; 0.86 mmol). 
Product (2R,4R)-172a: [α]30D = + 55.0 o (c =1.0; CHCl3); 1H NMR (250 MHz, CDCl3): δ=0.21 (s, 3H; 
CH3Si), 0.26 (s, 3H; CH3Si), 0.96 (s, 9H; SiC(CH3)3), 1.85 (ddd, J=14.1 Hz, J=7.4 Hz, J=3.7 Hz, 1H; 
CH2), 2.21 (ddd, J=14.1 Hz, J=8.9 Hz, J=4.2 Hz; 1H; CH2), 2.63 (dd, J=4.9 Hz, J=2.6 Hz, 1H; 
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Hz, 1H; CHO), 4.67 (dd, J=8.9 Hz, J=3.7 Hz, 1H; CHCN); 13C NMR (62.9 MHz, CDCl3): δ= -5.1, -
4.9, 18.5, 25.9 (3C), 40.0, 48.0, 48.3, 59.8, 119.9. 
Product (2R,4S)-172b: [α]34D= + 35.9 o (c = 1.0; CHCl3);33 1H NMR (250 MHz, CDCl3): δ=0.19 (s, 
3H; CH3Si), 0.24 (s, 3H; CH3Si), 0.95 (s, 9H; SiC(CH3)3), 1.96–2.15 (m, 2H; CH2), 2.60 (dd, 
J=4.9 Hz, J=2.6 Hz, 1H; CH2O), 2.87 (dd, J=4.9 Hz, J=4.0 Hz, 1H; CH2O), 3.11–3.18 (m, 1H; CHO), 
4.65 (dd, J=7.0 Hz, J=5.9 Hz, 1H; CHCN); 13C NMR (62.9 MHz, CDCl3): δ= -5.0, -4.8, 18.4, 25.9 
(3C), 40.0, 47.1, 48.3, 60.3, 119.7.  
Products (2R,4R)-172a and (2R,4S)-172b: IR (KBr): ν˜= 3057 (m), 2959 (m), 2932 (m), 2859 (m), 
1472 (s), 1258 (s), 1111 (s), 1015 (s), 899 (s); MS (EI) m/z (%): 199 (6), 170 (18), 143 (29), 115 
(100). 
 
Epoxides 172c-d  
To a solution of (S-136a) (93 % ee; 0.85 g; 4.0 mmol) in DCM (60 mL), 
acetone (60 mL), water (16.8 mL), NaHCO3 (10.0 g, 119 mmol) and 18-
crown-6-ether (0.09 g, 0.34 mmol) were successively added. The resulting three-phase system was 
cooled to 0˚C and oxone® (14.0 g, 22.8 mmol) dissolved in water (60 mL) was added dropwise over 2 
h. After stirring overnight, a second portion of DCM (60 mL), acetone (60 mL), H2O (16.8 mL) and 
NaHCO3 (10.0 g, 119 mmol) were added. The system was cooled again to 0 oC and oxone® (14.0 g, 
22.8 mmol) in H2O (60 mL) was added over 2 h. After stirring overnight, a third identical portion of 
DCM, acetone, H2O, NaHCO3 and oxone was added. To the three-phase system a saturated NaHCO3 
solution (90 mL) and 5 % Na2S2O5 solution (90 mL) was added dropwise, followed by extraction 
with DEE (90 mL), DCM (2×90 mL) and DEE (2×90 mL). The combined organic layer was dried 
over MgSO4 and concentrated under reduced pressure. Purification by CC (gradient starting from 
DEE/pentane=1:14 ending with DEE/pentane=1:2) gave two different diastereomers in a 1:1 ratio.  
Product (2S,4R)-172c and (2S, 4S)-172d: Yield: 92 % (0.85 g; 3.68 mmol); [α]23D = – 40.0 o, (c =1.0; 
CHCl3);34 1H NMR (250 MHz, CDCl3): δ=0.06 (s, 3H; CH3Si), 0.08 (s, 3H; CH3Si), 0.11 (s, 3H; 
CH3Si), 0.13 (s, 3H; CH3Si), 0.82 (s, 9H; SiC(CH3)3), 0.83 (s, 9H; SiC(CH3)3), 1.86–2.10 (m, 4H, 
CH2), 2.46–2.53 (m, 2H; CH2O), 2.73–2.80 (m, 2H; CH2O), 3.02–3.03 (m, 2H; CHO), 4.49–4.57 (m, 
2H; CHCN); 13C NMR (62.9 MHz, CDCl3): δ=-5.6, -5.5, -5.4, -5.3, 17.9 (2C), 25.4 (6C), 39.5 (2C), 
46.5, 47.4, 47.7, 47.8, 59.3, 59.8, 119.2, 119.4; IR (NaCl): ν˜= 2958 (m), 2933 (m), 2860 (m), 1473 
(s), 1257 (s), 1124 (s), 839 (s); Products (2S,4R)-172c and (2S,4S)-172d: IR (KBr): ν˜= 3056 (m), 
2959 (m), 2931 (m), 2859 (m), 1472 (s), 1258 (s), 1111 (s), 1015 (s), 899 (s); MS (EI) m/z (%): 170 
(18), 143 (29), 115 (100), 75 (25). 
 
(2R, 4R)-Lactone 176a 
To a solution of epoxide (2R,4R)-172a (0.049 g, 0.22 mmol) in dioxane (0.9 mL) was 
added dropwise 25 % HCl (0.12 mL, 1.2 mmol) at room temperature. After 15 min, the 
mixture was warmed to 50˚C, and kept at this temperature for 30 min., subsequently the reaction 
mixture is refluxed for 2.5 h. After separating the organic layer, the aqueous layer was extracted with 
pentane/DEE (1:1) (3 x 1 mL). The combined organic layer was dried over Na2SO4 and concentrated 
to give a viscous yellow oil of product (2R,4R)-176a (0.030 g; 0.20 mmol; 92%). [α]31D = + 16.9 o (c 
=0.83; CHCl3); 1H NMR (400 MHz, CDCl3): δ=2.14 (ddd, J=12.8 Hz, J=10.2 Hz, J=9.9 Hz, 1H; 
CH2CHOH), 2.76 (ddd, J=12.8 Hz, J=8.6 Hz, J=5.6 Hz, 1H; CH2CHOH), 3.72 (dd, J=11.8 Hz, J=5.4 
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CHOH), 4.62 (ddt, J=9.9 Hz, J=5.6 Hz, J=5.4 Hz, 1H; CHCH2Cl); 13C NMR (62.9 MHz, CDCl3): 
δ=34.7, 45.3, 68.6, 75.7, 176.7; IR (KBr): ν˜= 3370 (m), 2959 (m), 1775 (s), 1192 (s), 1128 (s); MS 
(EI) m/z (%): 150/152 (1) [M+], 149/151 (8), 131/133 (10), 101 (27), 73 (100), 57 (82); HRMS (EI): 
m/z= 150.0063; calc. for C5H7ClO3=150.0084.  
 
(2R, 4S)-Lactone 176b 
Prepared by the same procedure as described for (2R,4R)-176a. In this reaction (2R,4S)-
172b (0.053 g, 0.23 mmol) was used. After work up a viscous yellow oil of product 
(2R,4S)-176b was obtained (0.025 mg; 0.17 mmol; 71 %). ; [α]31D = + 41.8 o (c =1.1; CHCl3); 1H 
NMR (400 MHz, CDCl3): δ=2.41 (ddd, J=13.7 Hz, J=8.6 Hz, J=7.6 Hz, 1H; CH2CHOH), 2.57 (ddd, 
J=13.7 Hz, J=8.8 Hz, J=3.3 Hz, 1H; CH2CHOH), 3.66 (dd, J=12.1 Hz, J=3.5 Hz, 1H; CH2Cl), 3.77 
(dd, J=12.1 Hz, J=4.5 Hz, 1H; CH2Cl), 4.67 (dd, J=8.8 Hz, J=7.6 Hz, 1H; CHOH), 4.91 (ddt, J=8.6 
Hz, J=4.4 Hz, J=3.4 Hz, 1H; CHCH2Cl); 13C NMR (50.3 MHz, CDCl3): δ=32.9, 46.2, 66.9, 76.0, 
176.8; IR (KBr): ν˜= 3408 (m), 2959 (m), 1771 (s), 1186 (s), 1117 (s); MS (EI) m/z (%): 150/152 (1) 
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The syntheses of the three building blocks of the peptide backbone of mureidomycin A are described. A model 
study on the synthesis of dihydropyrimidine nucleosides resulted in the formation of an ortho-ester and a 




The synthesis of a small library of dihydropyrimidine (DHPM) nucleosides as potential 
antibiotic agents was one of the primary goals of this research. In addition, a first study on 
the total synthesis of mureidomycin A (MRD A) was envisioned. To realise this, the 
synthesis of the peptide backbone of MRD A is essential. In the first section of this chapter 
our initial studies to access the required building blocks are described. Further, for the 
synthesis of the DHPM nucleoside library flexible synthetic methodologies were developed 
(chapters 3 and 4) for the construction of DHPMs and DHPM analogues. In the second 
section of this chapter our efforts to prepare nucleosides from riboses and a DHPM-
heterocycle as nucleobase are described, which brings the realisation of the DHPM-
nucleoside library closer to reality. 
7.2 Synthesis of the peptide backbone of mureidomycin A 
The synthesis of the peptide backbone of MRD A (BB7) is envisioned as depicted in Scheme 
7.1. The synthess of BB1 (protected m-tyrosine), BB2 (protected 2-amino-3-




























































Scheme 7.1 Peptide part of the retrosynthetic analysis of mureidomycin A 
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 7.2.1  Synthesis of unsymmetrical urea (BB6)  
The unsymmetrical urea moiety in MRD A consists of two different amino acids: m-
tyrosine and methionine. Although the exact stereochemistry of MRD A is not known, it is 
assumed that the amino acids have the natural (S)-configuration. To confirm this, we 
wished to develop a general synthetic methodology to access all possible isomers of the 
unsymmetrical urea.  
Initially, the unsymmetrical urea from L-methionine and D,L-m-tyrosine was prepared. L-
methionine is commercially available, while D,L-m-tyrosine was easily synthesised via the 
classical Erlenmeyer condensation reported by Schweet et al.1 Starting with an 
intramolecular condensation of acetylglycine (177) in the presence of acetic anhydride 
resulted in intermediate 178, which was subsequently reacted with m-hydroxybenzaldehyde 
to yield azlactone 179 in 83%. This compound can be readily converted to m-tyrosine (180) 
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Scheme 7.2 Synthesis of m-tyrosine 
In general, in the synthesis of unsymmetrical ureas, successful coupling between the 
amino acids is only efficient when the carboxylic acids are protected as esters. In the 
literature, different esters are used for this varying from methyl, ethyl to benzyl esters and 
even the trimethylsilyl protecting group is used.2 To deduce which protecting group is most 
suitable for the synthesis of unsymmetrical urea 181, the final step in the synthesis of the 
peptide backbone of MRD A has to be considered. During this step, it was planned that, 
unsymmetrical urea 182 is coupled with the AMBA-derivative 183 (Scheme 7.3). To assure 
that this reaction will take place at the methionine side, 182 has to be a half acid/half ester 
urea. Therefore protecting group 4 (PG4) must be more easily removable than protecting 
group 3 (PG3). A procedure that proved successful in the literature is the use of the 
combination of a benzyl and a methyl-protecting group.3 The benzyl protecting group can 
easily be removed by reduction (H2, Pd/C in methanol), while the methyl ester is unreactive 
under these conditions. Therefore, it was decided to protect m-tyrosine (180) as a methyl 
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Scheme 7.3 Synthetic plan for peptide backbone of MRD A. 
For the protection of m-tyrosine as a methyl ester, the procedure of Rachele was followed,4 
using 2,2-dimethoxypropane and HCl resulting in m-tyrosine methyl ester hydrochloride salt 
185 in 72% yield (Scheme 7.4). L-Methionine is protected as its benzyl ester via a procedure 
reported by Okada et al.5 Refluxing a mixture of L-methionine (186), p-toluenesulfonic acid 
monohydrate, benzyl alcohol in toluene under Dean-Stark conditions resulted in L-methionine 
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Scheme 7.4 Esterification of the amino acids m-tyrosine and L-methionine 
The most direct way to synthesise unsymmetrical ureas starts with phosgene. The use of 
the very toxic phosgene is highly undesirable, therefore analogues were developed that are 
less toxic.6,7 Triphosgene has been used for the synthesis of other unsymmetrical ureas 
bearing amino acid derivatives.7 Under mild conditions after a short reaction time, in a 
facile ‘one-pot’ fashion unsymmetrical ureas can be synthesised. For example, Randad et 
al. reported the synthesis of 188 with triphosgene as coupling reagent using benzyl- and 
methyl ester protected amino acids.7 Therefore, we decided to use this reagent for the 
synthesis of unsymmetrical urea 181. 












Figure 7.1 Unsymmetrical urea synthesised by using triphosgene 
L-Methionine benzyl ester p-toluenesulfonium salt 187 is reacted with triphosgene under basic 
conditions resulting in intermediate 189. Subsequent reaction with the second amino acid m-
tyrosine methyl ester hydrochloride salt 185 yields unsymmetrical urea 181a-b in a 1:1 mixture 
of diastereomers in 70%. These diastereomers can be partially separated by column 
chromatography. The precise mechanism of the formation of unsymmetrical ureas with 
triphosgene is not reported in literature. However, it is known that triphosgene converts into 
phosgene in the presence of a nucleophile.8 In addition, phosgene is a known reagent for the 
formation of isocyanates.9 A possible mechanism is that the methionine benzyl ester p-
toluenesulfonium salt (187) initiates the formation of phosgene. The anionic p-toluenesulfonium 
ion can attack the carbonyl carbon of triphosgene giving tosyl 1,1,1-trichloromethyl carbonate 
and phosgene. This reaction yields the more nucleophilic chloride ions which can react further 
with triphosgene to yield more phosgene. The chloride ion is only needed in a catalytic amount, 
since it is not consumed during the reaction. Subsequently, phosgene can react with methionine 
benzyl ester, to form the reactive isocyanate 189, which can react with m-tyrosine methyl ester 
(185) yielding the unsymmetrical urea’s 181a and b. Thus, with m-tyrosine and L-methionine 
the formation of unsymmetrical urea proved successful. To arrive at the optically pure analogues 
of 181, the synthesis of the unsymmetrical urea must be repeated with enantiopure m-tyrosine. 
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2-Amino-3-methylaminobutanoic acid  (AMBA, 190; Scheme 7.1) is a peptidyl building 
block that is not only important for the synthesis of MRD A. AMBA is also part of other 
uridyl peptide antibiotics, like pacidamycins10 and napsamycins.11 AMBA is an aza 
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Figure 7.2 Possible isomers of AMBA 
In literature there are two routes reported for the synthesis of AMBA.3,13 The first 
reported synthesis employed the method of Janda et al.14 and completed the synthesis 
starting from the achiral starting material, trans-crotonyl chloride (191; Scheme 7.6). This 
approach is considered very flexible and in principle all four stereoisomers of AMBA (190) 
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Scheme 7.6 Synthesis of AMBA via Janda’s route 
The first step, synthesis of t-butyl trans crotonyl ester (192) from trans crotonyl chloride 
(191) worked in 61% yield, however the purification was troublesome. The large amount of 
benzene that is necessary for the reaction could not be removed quantitatively by 
evaporation/distillation without loss of a large amount of product. Several test reactions 
were carried out with different quantities of benzene, cyclohexene or diethyl ether to 
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improve the yield, but to no avail. Thus, using cyclohexene as medium, similar purification 
problems arose as compared to the reaction in benzene. Using only minimal amounts of 
benzene or diethyl ether, the reaction proved unselective and not quantitative, with yields of 
only 9% of pure product. Alternative syntheses, like the classical esterification using 
sulphuric acid16 or DCC and DMAP17 did not result in good yields of 192. The use of a 
differently substituted crotonyl ester could be envisioned. A benzyl protection group would 
make synthesis via the same procedure possible, however the synthesis of benzyl trans 
crotonyl ester was also not quantitative and removal of residual benzyl alcohol led to 
decomposition of the product. Therefore we turned our attention to the route of Boojamra.3 
He started the synthesis of 2S,3S-AMBA (190b) using the amino acid L-threonine (198).3 
This route worked very well and 190b could be prepared in 20% overall yield in 6 steps. 
First L-threonine is protected with Boc2O and converted into the O-benzylhydroxamate 199 
in 60% yield with (O-benzylhydroxyl)-amine and 1-ethyl-3-(3-(dimethyl-amino)propyl)-
carbodiimide (WSC). Treatment of 199 with Ph3P, CCl4 and Et3N leads to the hydroxamate 
nitrogen anion that cyclises, forming 200 in 54% yield.18 The azetidinone ring in 200 is 
then hydrolysed using NaOH, providing compound 201 in 84% yield.3 Then, the N-methyl 
group was introduced by reductive amination with formaldehyde and NaCNBH3 resulting 
in compound 202 in 94% yield. The last step in this procedure is deprotection of the N-
methylated amino group. This was done by hydrogenation with H2, Pd/C to provide the 
required product 190b in 82% yield (Scheme 7.7). In the same manner Boojamra et al. proved 
that 190a can be synthesised from D-threonine.3 The synthesis of the syn-AMBA isomers 
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The synthesis of dihydropyrimidine 3’-deoxynucleosides was one of the primary goals of 
this research (Scheme 7.8). In order to get general insight on the coupling of DHPMs to 
riboses, we start to investigate whether the free nitrogen (N1) of DHPMs is reactive at all. 
From bottom-up, we first explored whether DHPMs can be methylated at N1. In order not 
to use the valuable 3’-deoxy ribose precursor (176) we started to examine the coupling of 
























Scheme 7.8 Coupling of DHPMs to 3’-deoxyriboses 
7.3.1 Alkylation of DHPMs 
The alkylation of four DHPMs (204a-d) was investigated. Via deprotonation of the 
DHPM with NaH at 0°C and subsequent reaction with methyl iodide, N1-methylated 
DHPMs (205a-d) could be synthesised in good yields (72–95%). In addition, when 
deprotonation was performed at 50°C with DHPM 204d, not the N1-methylated DHPM 
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Scheme 7.9 Methylation of DHPMs 204a-d 
Thus, a higher reaction temperature during deprotonation does not lead to a faster 
reaction, but to ring opening resulting in a more stable anion. Therefore, during the 
deprotonation the temperature may not exceed room temperature. The high yields of the 
N1-methylated DHPMs 205a-d indicate that deprotonation with sodium hydride and 
subsequent reaction with methyl iodide works very well. It seemed therefore appropriate to 
react 1’-halogenated riboses deprotonated DHPMs in order to synthesise DHPM the 
analogous nucleosides. 
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7.3.2  Coupling of DHPMs to ribose 
The synthesis of DHPM nucleosides is envisioned via deprotonation of the base and 
subsequent reaction with a halogenated ribose or using the Vorbrüggen condensation 
(Scheme 7.10).20 Like in the synthesis of N1-methylated DHPMs, the DHPM is first 
deprotonated with sodium hydride. Subsequent reaction with a brominated ribose should 
then lead to DHPM-nucleosides. In the Vorbrüggen condensation the DHPM is first 
silylated, for example with hexamethyldisilazane (HMDS) or bis(trimethylsilyl)acetamide 
(BSA), which is then followed by Lewis acid catalysed condensation with a protected 


























1) HMDS or BSA
2)                               , Lewis acid
or
208 209  
Scheme 7.10 Proposed synthesis of DHPM nucleosides 
Under these conditions several attempts to couple DHPM 204b-c and 206 to riboses 208 
and 209 did not result in clear product formation. Table 7.1 summarises the applied 
conditions and outcome. With LC-MS the correct mass is sometimes observed, however in 
such a small amount that isolation was not attempted.  
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Figure 7.3 Reactants for the coupling reactions 
Therefore we decided to use 207 as the heterocyclic base, which is aromatic and in this way 
resembles more natural nucleobases. First, 207 and 209 are dissolved in dry acetonitrile. BSA 
is added and the reaction mixture is refluxed for three hours resulting in silylation of 207. 
Subsequently, TMSOTf or SnCl4 is added and the reaction mixture is stirred overnight. In the 
reaction of 207 with SnCl4 all starting ribose 209 was consumed (entry 10; Table 7.1), while 
with TMSOTf only marginal consumption of 209 was observed (entry 11; Table 7.1). 
Therefore the reaction of 207 with TMSOTf was heated for an additional 3 hours at 60°C 
(entry 12; Table 7.1) which resulted in total consumption of 209. In all reactions of 207 with 
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Figure 7.4 Nucleosides 210 and 211 
In the SnCl4 mediated reaction 210 was the only product that could be isolated. Although 
no other product could be identified, only a moderate yield of 36% was achieved. The two 
TMSOTf mediated reactions also yielded ortho-ester 210. Depending on the reaction 
temperature either a very small amount (2%, entry 11; Table 7.1) or a moderate amount 
(21%, entry 12; Table 7.1) of ortho-ester 210 was formed. 
  
Table 7.1 Attempts to couple DHPMs to riboses 
Entry DHPM Ribose Conditions Results 
1 204b 208 NaH, rt, DMF or CH3CN - 
2 204b 209 rt, DCM - 
3 204b 209 HMDS, (NH4)2SO4, DCM, TMSOTf -a 
4 204b 209 NaH, (NH4)2SO4, DCM, TMSOTf -a 
5 206 209 HMDS, (NH4)2SO4, DCM, TMSOTf -b 
6 206 209 NaH, (NH4)2SO4, DCM, TMSOTf -b 
7 204c 209 BSA, CH3CN, TMSOTf -b 
8 204c 209 NaH, CH3CN, TMSCl, TMSOTf -b 
9 204c 209 SnCl4 - 
10 207 209 BSA, CH3CN, SnCl4 (rt) 36% 210 
11 207 209 BSA, CH3CN, TMSOTf (rt) 7% 211 + 2% 210b 
12 207 209 BSA, CH3CN, TMSOTf (60 °C) 21% 210c 
a) With LC-MS the correct mass of the nucleoside is observed; b) most of the starting material is recovered; c) 
12% of an unknown coupling product was also formed 
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The reaction mediated by TMSOTf at room temperature resulted next to 210 in another 
coupling product: the nucleoside 211. Although, a nucleoside analogue, this is not the 
desired product, since the heterocyclic base is attached via N3 to the ribose. Nevertheless, 
coupling between a ribose and 207 is achieved via the Vorbrüggen condensation. Besides 
formation of 210 and 211 predominantly starting material was recovered. Longer reaction 
times or heating of the reaction mixture could lead to higher yields. Therefore, the coupling 
reaction using TMSOTf was heated for 3 hours at 60 °C (entry 12; Table 7.1), which 
resulted in a higher yield of ortho-ester 210. However, formation of nucleoside 211 was no 
longer observed. In addition the formation of an unknown coupling product was observed. 
So far, we were not able to determine the structure of this product, which according to 
NMR data consists of the nucleobase, the ribose and two TMS-groups. The formation of 
ortho-ester 210 and nucleoside 211 can be rationalised by the mechanism of the 




















































 209 210 
Scheme 7.11 Mechanism of formation of ortho-ester 210 
Silylation of 207 with BSA results in intermediate A, while reaction of ribose 209 with a 
Lewis acid (SnCl4 or TMSOTf) results in intermediate B. Two different reaction pathways 
are thus responsible for the formation of ortho-ester 210 and nucleoside 211. Formation of 
210 starts with the attack of the anionic residue of the reaction between the Lewis acid and 
ribose 209 to the silyl group of intermediate A. This results, via isomerisation, in attack of 
the exocyclic double bond to the ortho-position of intermediate B, giving ortho-ester 210 
after basic work-up. (Scheme 7.11). The formation of an ortho-ester is a common side 
reaction of the Vorbrüggen condensation and the formation of an analogous ortho-ester was 
reported recently.21 In Scheme 7.12 the mechanism of the formation of nucleoside 211 is 
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depicted. Attack of the triflate anion on the silyl group and subsequent nucleophilic attack 
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Scheme 7.12 Mechanism of formation of nucleoside 211 
7.4 Conclusion 
The synthesis of the protected building blocks of the peptide-backbone of MRD A, m-
tyrosine BB1), AMBA (BB2) and unsymmetrical urea (BB6) has been accomplished. 
Protected m-tyrosine can be synthesised via the classical Erlenmeyer procedure, protected 
AMBA via a procedure reported by Boojamra et al.3 in 20% overall yield starting from L-
threonine and the unsymmetrical urea (181) can be synthesised in a 1:1 diastereomeric 
mixture in 70% yield. The model study on the synthesis of DHPM nucleosides resulted in 
the formation of a nucleoside, which is connected via N3 of the pyrimidine to the ribose 
moiety. Depending on the Lewis acid different side products are formed. Further studies are 
currently performed to direct this reaction towards the correctly N1-connected nucleoside 
derivatives.    
7.5 Acknowledgements 
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7.6 Experimental section and physical data  
7.6.1  General part 
1H and 13C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AC 200 (200.13 
and 50.32 MHz, respectively), a Bruker Avance 250 (250.13 and 62.90, respectively) or a Bruker 
MSL 400 (400.13 and 100.61 MHz respectively) spectrometer; chemical shifts (δ) are given in ppm, 
internally referenced to residual solvent resonances (1H: δ 7.29 ppm, 13C: δ 77.0 ppm). Column 
chromatography was performed with Baker 7024-02 silica gel (40 μ, 60 Å) with cyclohexane (c-
Synthetic Studies towards Mureidomycin A and Dihydropyrimidine Nucleosides 
163 
hexane), ethyl acetate (EA), chloroform and methanol as eluents. Thin-layer chromatography (TLC) 
was performed using silica plates from Merck (Kieselgel 60 F254 on aluminium with fluorescence 
indicator). Compounds on TLC were visualised by UV-detection and/or coloured with anisaldehyde 
solution followed by heating to 150˚C. High-resolution mass spectra (HRMS, EI) were recorded on a 
Finnigan Mat 900 spectrometer at 70 eV. IR spectra are recorded on a Mattson-6030 Galaxy 
spectrophotometer and are reported in cm-1. Melting points were measured on a Stuart Scientific 
SMP3 melting point apparatus and are uncorrected. Tetrahydrofuran (THF), toluene, acetonitrile and 
dichloromethane were dried and distilled before use. Sodium hydride was prior to use, washed with 
dry hexane (2 times 5mM). Commercial chemicals were used as such. Reactions were performed 
under nitrogen or argon when necessary. AMBA (190b),3 DHPMs 206-20722 were synthesised 
according to literature procedure and NMR data were in accordance with those reported.    
7.6.2 Synthetic procedures and Physical Data 
2-Methyl-4-(3’-actetoxybenzal)-5-oxazolone (179)1  
m-Hydroxybenzaldehyde (8.78 g, 72.0 mmol), acetylglycine (8.42 g, 72.0 mmol), 
anhydrous sodium acetate (5.91 g, 72.0 mmol) and acetic anhydride (20.4 mL, 
216.0 mmol) where thoroughly mixed and heated at 100 °C for 6 h. Hereafter the 
reaction mixture was allowed to come to room temperature with the resultant formation of a solid 
mass, at which point 45 mL of ice-cold water was gradually added to the mixture. After storage in the 
refrigerator (3 oC) overnight, the product was separated by filtration and thoroughly washed portion 
wise (4x) with ice-cold water. The obtained air-dried material was a brown solid, which was pure 
enough to use in the following reaction. Yield: 13.89 g, 60 mmol, 83%; m.p. 119-120 °C [H2O]; 1H 
NMR (250.13 MHz, CDCl3): δ=2.33 (s, 3H; CH3CO), 2.41 (s, 3H; CH3CN), 7.10 (s, 1H; CH=), 7.17 
(ddd, J = 8.2 Hz, J = 2.4 Hz, J = 1.0 Hz, 1H; Ph-H), 7.45 (dd, J = 8.0 Hz, J = 7.9 Hz, 1H; Ph-H), 7.85 
(dt, J = 7.8 Hz, J = 1.0 Hz, 1H; Ph-H), 7.92–7.94 (m, 1H; Ph-H); 13C NMR (62.90 MHz, CDCl3): 
δ=15.1, 20.1, 124.4, 124.7, 129.7 (2C), 130.0, 133.3, 134.5, 150.9, 166.6, 167.5, 169.2; IR (KBr): 
ν˜=3431 (w), 1804 (s), 1763 (s), 1657 (s), 1597 (w), 1213 (s), 1167 (s). 
 
m-Tyrosine (180)1  
Azlactone (179) (10.03 g, 43 mmol) was mixed with glacial acetic acid (54 mL), 
hydroiodic acid (54 mL) and red phosphorus (4.00 g, 129 mmol) and heated at reflux 
temperature (117 oC) for 3 h. The hot mixture was filtered over a 3-cm plug of silica, 
after which the solvents were evaporated. To remove the remaining hydroiodic acid, 
three times 4 mL water was added and evaporated. The remaining solid amino acid hydroiodide was 
dissolved in 25 mL hot water and treated with norit. The mixture was neutralised with concentrated 
ammonia to a pH of 5.0 to 5.5. Absolute ethanol (20 mL) was added and the mixture was allowed to 
stand overnight in the refrigerator (3 oC). The obtained brown solid was filtered and dried. Yield: 5.25 
g, 29 mmol, 67%; analytical data were in accordance with literature data.  
 
m-Tyrosine methyl ester hydrochloride (185)4  
m-Tyrosine (180) (0.37 g, 2.0 mmol) was suspended in 2,2-dimethoxypropane (25 mL) 
and concentrated hydrochloric acid (2 mL) was added. The mixture was kept at room 
temperature overnight resulting in a dark brown solution. The solvents were 
evaporated and the residue was dissolved in warm THF. Overnight standing in the 















1.5 mmol, 73%; 1H NMR (250.13 MHz, D2O): δ=3.23 (dd, J = 14.5 Hz, J = 7.5 Hz, 1H; CH2), 3.29 
(dd, J = 14.5 Hz, J = 6.0 Hz, 1H; CH2), 3.88 (s, 3H; CH3), 4.46 (dd, J = 7.2 Hz, J = 6.0 Hz, 1H;  
CHN), 6.81 (s, 1H; Ph-H), 6.85–6.91 (m, 2H; Ph-H), 7.31 (dd, J = 8.0 Hz, J = 7.8 Hz, 1H; Ph-H); 13C 
NMR (62.9 MHz, CDCl3): δ= 35.9, 54.0, 54.4, 115.4, 116.8, 121.8, 131.1, 136.0, 156.5, 170.5. 
 
L-Methionine Benzyl ester p-toluenesulfonate (187)23  
A mixture of L-methionine (7.02 g, 46.9 mmol), p-toluenesulfonic acid 
monohydrate (11.60 g, 61.0 mmol), benzyl alcohol (25 mL, 234.5 mmol) and 
toluene (50 mL) was refluxed for 5 h under Dean-Stark conditions to remove all 
water that is formed during the reaction. Then, the solution was concentrated and the organic layer 
was extracted three times with water (50 mL). The combined water layer was washed three times with 
90 mL diethyl ether after which the pH was adjusted to 10 with 20% Na2CO3. The resulting 
precipitate was extracted with ethyl acetate (3×90 mL) and the ethyl acetate layer was dried with 
Na2SO4. The solvent was evaporated and the resulting syrupy residue was dissolved in diethyl ether. 
A saturated ethereal solution of p-toluenesulfonic acid was added and the resulting precipitate was 
collected by filtration washed with diethyl ether and dried. More product precipitated by allowing the 
first organic layer to stand, resulting in L-methionine benzyl ester p-toluenesulfonate as a white solid. 
Yield: 6.61 g, 16 mmol, 34%; [α]34D = + 1.8 (c = 1.1 in MeOH); m.p. 127-129 °C; 1H NMR (250 
MHz, CDCl3): δ=1.85 (s, 3H; Ph-CH3), 2.10–2.14 (m, 2H; CH2CH2S), 2.31 (s, 3H; SCH3), 2.42–2.47 
(m, 2H; CH2S), 4.14 (t, J = 6.0 Hz, 1H; CHN), 5.02 (d, J = 12.3 Hz, 1H; CH2O), 5.14 (d, J = 12.3 Hz, 
1H; CH2O), 7.09 (d, J = 7.8 Hz, 2H; m-CH(Ts)), 7.25–7.29 (m, 5H; Ph-H)), 7.74 (d, J = 7.8 Hz, 2H; 
o-CH(Ts)), 8.35 (br s, 3H; NH3); 13C NMR (62.9 MHz, CDCl3): δ=14.8, 21.3, 29.0, 29.5, 52.2, 67.9, 
126.1 (2C), 128.5 (5C), 128.9 (2C), 134.7, 140.4, 141.3, 169.0; IR (KBr): ν˜= 3158 (w), 3034 (w), 
2918 (w), 1746 (s), 1524 (s), 1213 (s), 1125 (s), 1036 (s).  
 
Unsymmetrical urea 181  
Triphosgene (0.11 g, 0.37 mmol) was dissolved in dry CH2Cl2 (2 mL) under 
a dry argon atmosphere. A mixture of L-methionine benzyl ester p-
toluenesulfonate salt (187) (0.17 g, 1 mmol) and diisopropyl-ethylamine 
(DIPEA, 0.38 mL, 2.2 mmol) in CH2Cl2 (3.5 mL) was slowly added to the 
stirred solution of triphosgene over a period of 30 min at room temperature using a syringe pump. 
After a further 5 min stirring, a solution of (D,L)-m-tyrosine methyl ester hydrochloride (185) and 
DIPEA (0.38 mL, 2.2 mmol) in CH2Cl2 (2 mL) was added in one portion. The reaction mixture was 
stirred for an additional 10 min at room temperature, evaporated to dryness, solved in ethyl acetate, 
washed with 10% aqueous KHSO4 (5 mL), 5% aqueous NaHCO3 (5 mL), and brine (5 mL), dried 
over MgSO4, and evaporated to give the crude product. In the first experiment purification by CC 
(methanol/CHCl3 1:100) yielded a 1:1 mixture of diastereomers in 70% yield. Data of 1:1 mixture of 
diastereomers: 1H NMR (400.13 MHz, CDCl3): δ=1.71–2.12 (m, 4H; CH2CH2S), 1.96 (s, 3H; SCH3), 
2.00 (s, 3H; SCH3), 2.38–2.47 (m, 4H; CH2S), 2.90–3.19 (m, 4H; CH2CHCO2Me), 3.65 (s, 3H; 
CO2CH3), 3.70 (s, 3H; CO2CH3), 4.52–5.21 (m, 8H; CH(CH2)2S, CHCO2Me and CH2Ph), 5.50–5.78 
(m, 4H; NH); 6.46–6.73 (m, 6H; Ph-H), 7.02–7.12 (m, 2H; Ph-H), 7.31–7.51 (m, 10H; CH2Ph-H); 13C 
NMR (100.61 MHz, CDCl3): δ=15.4 (2C), 29.9, 30.0, 31.9, 32.1, 37.9, 38.7, 52.2 (2C), 52.4 (2C), 
53.5, 54.0, 67.5, 68.1, 114.4, 114.7, 116.3, 116.5, 120.4, 121.2, 128.3 (2C), 128.5 (4C), 128.6 (2C), 
128.7 (2C), 129.8 (2C), 134.8, 135.1, 136.9, 137.7, 156.3, 156.9 (2C), 157.7, 172.4 (2C), 173.4 (2C).  
In a second experiment purification by CC (methanol/CHCl3 1:100) yielded one of the two isomers in 
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2.00 (s, 3H; SCH3), 2.40–2.50 (m, 2H; CH2S), 3.02–3.08 (m, 2H; CH2CHCO2Me), 3.66 (s, 3H; 
CO2CH3), 4.57 (dt, J=7.6 Hz, J=5.1 Hz, 1H; CH(CH2)2S), 4.72 (dt, J=7.7 Hz, J= 6.2 Hz, 1H; 
CHCO2Me), 5.07 (d, J=12.2 Hz, 1H; CH2Ph), 5.15 (d, J=12.2 Hz, 1H; CH2Ph), 5.26 (d, J=7.9 Hz, 
1H; NH), 5.54 (d, J=7.7 Hz, 1H; NH), 6.60–6.62 (m, 2H; Ph-H), 6.68-6.70 (m, 1H; Ph-H), 7.10 (dd, 
J=7.6 Hz, J=7.8 Hz, 1H;  Ph-H), 7.30–7.45 (m, 5H; CH2Ph-H); 13C NMR (62.90 MHz, CDCl3): 
δ=15.3, 29.8, 32.2, 38.1, 52.3, 52.5, 54.3, 67.4, 114.3, 116.4, 121.0, 128.4 (2C), 128.5, 128.6 (2C), 
129.6, 135.2, 137.5, 156.5, 157.0, 173.1, 173.3. 
 
1-(3-(4-methoxyphenyl)-1-phenylallylidene)-3-methyl-3-tosylurea (203) 
DHPM 204d (0.152 g, 0.35 mmol) is added to a suspension of sodium hydride 
(0.013 g, 0.53 mmol) in DMF (2 mL) at 0°C. The suspension is stirred for 30 min at 
0°C, 2 h at room temperature and 1 h at 50°C. After cooling down to room 
temperature, methyl iodide (0.043 mL, 0.69 mmol) is added and the reaction 
mixture is stirred overnight at room temperature. The crude product is concentrated under reduced 
pressure and purified by CC (c-hexane/EA 4:1), which resulted in a light yellow oil of 203. Yield: 75%; 
1H NMR: (250.13 MHz, CDCl3): δ=3.46 (s, 3H, NCH3), 3.87 (s, 3H; CH3O), 6.83–7.80 (m, 15H; Ph-H 
and CH=CH); 13C NMR (100.61 MHz, CDCl3): δ=21.6, 33.3, 55.4, 114.3 (2C), 127.5, 128.1 (2C), 128.3 
(2C), 129.0 (2C), 121.3, 129.3 (2C), 129.9 (2C), 130.7, 136.4, 136.5, 144.3, 145.3, 160.5, 161.5. 
 
General procedure for the synthesis of N1-methylated DHPMs 205a-d 
To a suspension of sodium hydride (1.0 equiv) in DMF (0.08 M) at 0°C DHPM 204 (1 equiv) is 
added. The suspension is stirred for 75 min at 0°C. Then methyl iodide (1 equiv) is added and the 
solution is allowed to warm-up overnight. The crude product is concentrated under reduced pressure 




Yield: 72%; 1H NMR: (250.13 MHz, CDCl3): δ=3.06 (s, 3H; CH3N), 3.83 (s, 3H; 
CH3O), 5.20–5.27 (m, 2H; CH), 6.88 (d, J=8.6 Hz, 2H; Ph-H), 7.14–7.40 (m, 12H; 
Ph-H); 13C NMR (100.61 MHz, CDCl3): δ=33.3, 55.2, 62.3, 105.0, 114.1 (2C), 
126.2, 127.0 (2C), 127.8 (2C), 128.3 (2C), 128.4 (2C), 128.6, 128.7 (2C), 134.3, 135.4, 140.4, 142.4, 




Yield: 95%; 1H NMR: (250.13 MHz, CDCl3): δ=3.06 (s, 3H; CH3N), 3.82 (s, 
3H; CH3O), 5.34–5.40 (m, 2H; CH), 6.92 (d, J=8.7 Hz, 2H; Ph-H), 7.19–7.44 
(m, 9H; Ph-H), 8.16 (d, J=7.2 Hz, 2H; Ph-H); 13C NMR (100.61 MHz, CDCl3): 
δ=33.5, 55.3, 60.7, 105.6, 114.6 (2C), 124.2 (2C), 125.1 (2C), 126.9 (2C), 128.1 (2C), 128.5 (2C), 





Yield: 95%; 1H NMR: (250.13 MHz, CDCl3): δ=3.00 (s, 3H; CH3N), 3.84 (s, 3H; 
























Hz, 1H; Ph-H), 7.42–7.66 (m, 12H; Ph-H); 13C NMR (100.61 MHz, CDCl3): δ=33.6, 53.2, 55.2, 
109.0, 114.2 (2C), 127.6 (2C), 127.9 (2C), 128.1 (2C), 128.2 (2C), 128.7 (2C), 129.2, 131.1 (2C), 





Yield: 85%; 1H NMR: (250.13 MHz, CDCl3): δ=2.94 (s, 3H; CH3N), 3.87 (s, 3H; 
CH3O), 5.42 (d, J=6.9 Hz, 1H; CHC), 6.07 (d, J=6.9 Hz, 1H; CHN), 6.89 (d, 
J=8.7 Hz, 2H; Ph-H), 7.14 (d, J=8.2 Hz, 2H; Ph-H), 7.26–7.53 (m, 9H; Ph-H); 
13C NMR (62.90 MHz, CDCl3): δ=21.6, 33.2, 55.4, 57.1, 107.2, 114.4 (2C), 128.2 (2C), 128.5 (2C), 
128.6 (2C), 128.8 (2C), 128.9 (2C), 129.1, 132.4, 134.2, 139.9, 144.0, 151.3, 159.8.  
 
Procedure for pyrimidine nucleoside synthesis 
Ribose 209 (0.13 g, 0.26 mmol) and pyrimidine 207 (0.20 g, 0.78 mmol) are co-evaporated three 
times with anhydrous CH3CN (3 mL) under argon. Dry CH3CN (3 mL) and BSA (0.19 mL, 0.78 
mmol) are added at room temperature. The mixture was stirred at 65°C for three h. After cooling 
down to room temperature, TMSOTf or SnCl4 (1.5 equiv) is added and the reaction mixture is stirred 
overnight at room temperature. One of the reactions with TMSOTf (entry 12; Table 7.1) is heated 
three more hours at 60°C. The other two reactions are worked up immediately via the following 
procedure: the reaction mixture is diluted with DCM (20 mL) and washed with sat. NaHCO3 sol. (10 
mL) and water (2×10 mL). The combined organic layer is dried over Na2SO4 and concentrated under 
reduced pressure. The crude product is purified by CC (c-hexane/EA 2:1 → EA). 
 
Ortho ester 210 
1H NMR: (400.13 MHz, CDCl3): δ=0.77 (t, J=7.1 Hz, 3H; CH3), 3.45–
3.49 (m, 1H; H-4’), 3.57 (d, J= 13.7 Hz, 1H; CH2CN), 3.61 (d, J= 13.7 
Hz, 1H; CH2C), 3.80 (dd, J=7.1 Hz, J=10.8 Hz, 1H; CH2CH3), 3.88 (dd, 
J=7.1 Hz, J=10.8 Hz, 2H; CH2CH3), 4.09 (dd, J=4.1 Hz, J=12.3 Hz, 1H; 
H-5’), 4.31 (dd, J=3.3 Hz, J=12.3 Hz, 1H; H-5’), 4.85 (dd, J=5.5 Hz, 
J=9.3 Hz, 1H; H-3’), 5.09 (dd, J=4.2 Hz, J=5.5 Hz, 1H; H-2’), 6.03 (d, J=4.1 Hz, 1H; H-1’), 7.26–
7.59 (m, 16H; Ph-H), 7.83 (d, J= 7.8 Hz, 2H; Ph-H), 7.90 (d, J= 7.7 Hz, 2H; Ph-H); 13C NMR (100.61 
MHz, CDCl3): δ=13.2, 44.0, 61.5, 62.7, 72.8, 76.5, 79.1, 105.6, 112.8, 113.8, 125.8 (2C), 128.0 (2C), 
128.1 (2C), 128.3 (4C), 128.5 (2C), 128.8, 128.9, 129.5, 129.6 (2C), 129.9 (2C), 130.7, 133.1, 133.6, 
141.0, 157.1, 165.2, 165.8, 166.1;24 MS (EI) m/z (%): 322 (12), 218 (36), 105 (100), 77 (50). 
 
Nucleoside 211 
1H NMR: (400.13 MHz, CDCl3): δ=0.81 (t, J=7.1 Hz, 3H; CH3CH2), 2.52 (s, 
3H; CH3), 3.86 (q, J=7.1 Hz, 2H; CH2), 4.54–4.60 (m, 1H; H-4’), 4.69–4.90 
(m, 2H; H-5’), 5.44 (d, J=2.2 Hz, 1H; H-’1), 6.15 (dd, J=7.1 Hz, J=8.1 Hz, 
1H; H-’3), 6.23 (dd, J=2.2 Hz, J=7.1 Hz, 1H; H-’2), 7.20–7.52 (m, 14H; Ph-
H), 7.68 (d, J=7.2 Hz, 2H; Ph-H), 7.90 (d, J=7.6 Hz, 2H; Ph-H), 8.06 (d, 
J=7.3 Hz, 2H; Ph-H); 13C NMR (100.61 MHz, CDCl3): δ=13.4, 24.7, 61.4, 
64.3, 72.4, 74.3, 80.5, 94.0, 113.8, 128.2–133.4 (24C)25, 153.6, 157.7, 165.0, 165.4, 165.5, 166.3, 
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The naturally occurring mureidomycin A (MRD A) shows potent antibiotic activity and is 
up to now only isolated from the bacterium Streptomyces flavidovirens SANK 60486. It is 
built-up from two moieties: a 3’-deoxy-nucleoside moiety, which is linked via an unusual 
enamide bond to a peptide moiety. This peptide consists of non-natural amino acids, like m-
tyrosine and 2-amino-3-methylaminobutanoic acid (AMBA) and possesses also an 
unsymmetrical urea function (Figure 8.1). In chapter 1 we summarised structure-activity 
relationship (SAR) studies and the possible mode of action of mureidomycin A. For more 
dedicated biological studies we decided to synthesise analogous dihydropyrimidine 
nucleosides (A) that include the unusual enamide bond (Figure 8.1). These nucleoside 
analogues themselves could be biologically active as well. An overview of a large range of 
biologically active nucleoside analogues with 5-or 6-membered nucleobases was discussed in 
chapter 2. Many therapeutic activities are indeed connected to these nucleoside analogues, 
which stimulated our further research in this area.  
The synthesis of an analogue of MRD A, dihydropacidamycin D, showed that this type of 
uridyl peptide compounds without the enamide bond, can be obtained from chiral pool 
starting materials.1 For example, the 3’-deoxyuridine moiety can be prepared via a rather 
lengthy route starting from uridine. However, we aim at a more versatile approach for the 
synthesis of dihydropyrimidine nucleosides A. Therefore, disconnection between the sugar 
and the base resulting in 3’-deoxyribose moiety B and dihydropyrimidine (DHPM) C seemed 


























































Figure 8.1 Mureidomycin A and dihydropyrimidine nucleosides 
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In order to prepare these moieties a stereoselective chemo-enzymatic cascade reaction for the 
synthesis of 3’-deoxyribose moiety B and a multi-component approach for the synthesis of 
dihydropyrimidines C were investigated in detail (chapters 3-6).  
The synthesis of dihydropyrimidines C can be achieved via a four-component reaction 
(4CR) of phosphonates, nitriles, aldehydes and isocyanates under basic conditions. The 
scope and limitations of this reaction have been explored. While the nitrile and aldehyde 
input can be varied extensively, the phosphonate input is rather restricted. When 
phosphonates other than diethyl methylphosphonate are used, phosphoramidates are 
observed predominantly. However, differently substituted phosphonates may lead to other 
C5-functionalised DHPMs, which can be used for further manipulations. Further research 
in this direction is currently in progress in our group. Variation of the isocyanate input 
results in the formation of several products: dihydropyrimidines, imines and triazinane 
diones (Scheme 8.1). The application of a chiral aldehyde led to the diastereoselective 
formation of a dihydropyrimidine in over 80 % de, which is promising for a first small 
study. Chiral inputs with the stereocenter close to the newly formed stereocenter may be 
better candidates to induce chirality. Furthermore, the application of chiral catalysis is 
another possibility of introducing chirality.  
The synthesis of thio-dihydropyrimidines C was envisioned via the same 4CR using 
isothiocyanates as input. However under the conditions of the 4CR, thiazines were formed 
(Scheme 8.1). In a study thiazines with or without an ester functionality at C5 showed easy 
isomerisation to thio-dihydropyrimidines under microwave heating. Whereas the thiazines 
without an ester function already rearranged at 120°C, the thiazines with an ester group did 



















































Scheme 8.1 Different outcomes of 4CR 
The synthesis of the second part of dihydropyrimidine nucleoside A, the 3’-deoxyribose 
moiety B, was planned via a de novo chemo-enzymatic cascade starting from simple 
alcohols. First a model study has been performed resulting in 3’-deoxy-5’-hexylribolactone 
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in 44 % overall yield starting from 3-decyn-1-ol (Scheme 8.2). Analogous treatment of 3-
buten-1-ol resulted in 3’-deoxy-5’-chlororibolactone. The use of HCl in the last step, the 
hydrolysis induced lactonisation, led to the formation of a 5’-chlorolactone, which makes 
further synthetic manipulations easier since differentiation between the 2’- and 5’-position 
is already realised in this way (Scheme 8.2). Finally, the route was adapted to a chemo-
enzymatic route, which introduces the stereocenter at C2. A general protocol was 
developed for the oxidation-hydrocyanation of γ,δ-unsaturated alcohols using 
(immobilised) TEMPO/PhI(OAc)2 in combination with Hevea Brasiliensis hydroxynitrile 
lyase (HbHNL) and led to high ee’s of the cyanohydrin precursors. To finish the synthesis 
of the 3’-deoxyribose moiety B the 3’-deoxy-5’-chlorolactone must be reduced; similar 





























Scheme 8.2 Synthesis of 3’-deoxylactones 
To fulfil the primary goal of this research, the synthesis of dihydropyrimidine nucleosides 
A, a model study on the coupling of protected natural riboses to our dihydropyrimidines 
was performed. Both the Vorbrüggen condensation and a nucleophilic substitution did not 
give the desired nucleoside yet. The use of a close, but aromatic, pyrimidine analogue as 
the base (Scheme 8.3) in the Vorbrüggen condensation did result in the formation of a 
nucleoside, which is connected via N3 to the ribose moiety (Scheme 8.3). In addition, 
depending on the Lewis acid different side products were formed (Scheme 8.3). The 
formation of the ortho-ester may be prevented by the use of a differently protected ribose, 
for example a pivaloyl-protected ribose. Furthermore, the application of different 
equivalents, solvent, temperature or Lewis acid could promote formation of 
dihydropyrimidine nucleosides A. Currently, further experiments to achieve this are being 
performed.     
































Scheme 8.3 Vorbrüggen condensation of pyrimidine with ribose 
Finally, studies toward the total synthesis of mureidomycin A were initiated. The 
synthesis of the building blocks of the peptide backbone has been accomplished. In the near 
future the building blocks will be linked, which should be straightforward and will be done 
via standard peptide coupling. Still our original strategy holds to first synthesise the 
complete peptide moiety and the 3’-deoxuridine and in the final step generate the enamide 
linkage, since this enamide linkage is the most sensitive part of mureidomycin A.  
The synthesis of the enamide linkage is planned via coupling of a vinyl iodide nucleoside 
with an amide, which is catalysed by Cu(I) in the presence of base, a promoter in a polar 
aprotic solvent.3 Alternatively, the method of Bugg et al,4 using an aza-Wittig reaction for 
the synthesis of the enamide linkage can be considered. However in this method no 
selective E- or Z- enamide is formed and the yield is rather low (13 %). Our future attention 
will be focused on the synthetic methodology to synthesise the crucial enamide function in 
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De eerste antibiotica werden ongeveer vijfenzeventig jaar geleden ontwikkeld. Dit zorgde 
er voor dat tot dan toe ongeneeslijke ziekten behandeld konden worden. In de loop der jaren 
echter hebben misbruik en verkeerde doseringen van antibiotica geleid tot resistente 
bacteriën. Hierdoor is er een vraag ontstaan naar nieuwe antibiotica. Deze kunnen worden 
ontwikkeld door de modificatie van bestaande middelen, maar een mogelijk betere aanpak 
is de ontwikkeling van antibiotica met een nieuw werkingsmechanisme. Een voorbeeld van 
een potentieel antibioticum met een nieuw werkingsmechanisme is Mureidomycine A.  
De natuurstof Mureidomycine A (MRD A) bezit een hoge antibiotische activiteit die 
waarschijnlijk kan worden teruggevoerd op de bijzondere chemische structuur. MRD A 
bestaat uit twee delen, namelijk een 3’-deoxynucleoside deel dat via een ongebruikelijk 
enamide binding verbonden is met een peptide deel. Het peptide deel bevat naast een 
opvallende niet symmetrische ureum functionaliteit o.a. de niet proteogene 
aminozuurresiduen m-tyrosine en 2-amino-3-methylaminobutaan zuur (AMBA). In 
hoofdstuk 1 worden de verschillende studies naar de structuur-activiteits relatie en het 
werkingsmechanisme van mureidomycine A samengevat.  
Tot nu toe kon MRD A slechts geïsoleerd worden uit de bacterie Streptomyces 
flavidovirens SANK 60486. Om zelf gerichtere biologische studies te kunnen doen, is 
besloten om analoge dihydropyrimidine nucleosiden (A) te synthetiseren op basis van de 
bijzondere enamide binding (Figuur 8.1). Daarbij is het niet ondenkbaar dat deze 
nucleoside analoga mogelijk zelf ook een biologische activiteit bezitten. Om dit te 
onderzoeken wordt in hoofdstuk 2 een literatuurstudie beschreven naar biologisch actieve 
nucleoside analoga die opgebouwd zijn uit een vijf- of zes-ring nucleobase die via het 
stikstofatoom aan een ribose suikereenheid zijn verbonden. Het enorme spectrum aan 
verbindingen en bijbehorende biologische activiteiten die dit opleverde, vormde een 
stimulans voor de voortzetting van het onderzoek.  
De synthese van dihydropacidamycine D, een analoog van MRD A, zonder de karakteristieke 
enamide binding, laat zien dat dit type verbindingen verkregen kan worden uit de koppeling 
van de verschillende afzonderlijke chirale bouwstenen. Zo werd bijvoorbeeld de 3’-
deoxyuridine functie via een relatief lange route gesynthetiseerd uit het nucleoside uridine.1  
In dit onderzoek wordt getracht dihydropyrimidine nucleosiden A via een veelzijdigere 
benadering te synthetiseren. Hiervoor wordt het nucleoside A opgedeeld in een 3’-
deoxyribose fragment B en een dihydropyrimidine (DHPM) fragment C. Getracht wordt 
het 3’-deoxyribose fragment B via een stereoselective chemo-enzymatische cascade reactie 
te synthetiseren en voor de synthese van het dihydropyrimidine (DHPM) fragment C 
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gebruik te maken van een multi-component benadering. Beide strategieën leveren een 
enorme flexibiliteit in de synthese van dihydropyrimidine nucleosiden op en worden 



























































Figuur 8.1 Mureidomycin A en dihydropyrimidine nucleosides 
Dihydropyrimidines C kunnen gesynthetiseerd worden via een vier-componenten reactie 
(4CR) waarbij fosfonaten, nitrillen, aldehydes en isocyanaten onder basische condities met 
elkaar reageren. De mogelijkheden en de beperkingen van deze multicomponent reactie zijn 
uitgebreid beschreven in hoofdstuk 3, waarbij variatie van alle vier de componenten 
onderzocht is. De variatiemogelijkheid in het nitril en aldehyde is zeer uitgebreid, terwijl 
variatie in het fosfonaat beperkt is. Het gebruik van andere fosfonaten dan diethyl 
methylfosfonaat leidde in de meeste gevallen tot een omleggingsreactie waarbij 
fosforamidaten gevormd werden. Variatie van het isocyanaat leidde tot de vorming van 
verscheidene producten: dihydropyrimidines, imines en triazinane dionen (Schema 8.1). 
Verder resulteerde de toepassing van een chiraal aldehyde in de vorming van een 
dihydropyrimidine met een de van 80 %, hetgeen veelbelovend is voor een eerste studie 
met chirale startmaterialen.  
Wanneer in plaats van isocyanaten, isothiocyanaten gebruikt werden in de 4CR, leidde dit 
niet tot de verwachte thio-dihydropyrimidines C, maar werden er thiazines gevormd 
(Schema 8.1). In een studie met vergelijkbare thiazines met een ester op de C5-positie is 
aangetoond dat de thiazines omgezet konden worden in thio-dihyropyrimidines C middels 
verwarming in een magnetron. De omlegging van de thiazines zonder ester functie op de 
C5-positie bleek reeds plaats te vinden bij 120°C, terwijl de thiazines met een ester groep 





















































Schema 8.1 Verschillende producten van de 4CR 
Het tweede deel van de dihydropyrimidine nucleoside A, het 3’-deoxyribose deel B, kan 
gesynthetiseerd worden via een de novo chemo-enzymatische cascade reactie uitgaande van 
een eenvoudige alcohol. Om inzicht te krijgen in de mogelijkheden van deze snelle selectieve 
chemo-enzymatische reactie, is eerst een chemische model studie uitgevoerd. Daarin is 
begonnen met een relatief gemakkelijk te hanteren alcohol: 3-decyn-1-ol, dat omgezet is in 
































Schema 8.2 Synthese van 3’-deoxylactonen 
Vervolgens is op een zelfde wijze 3-buten-1-ol, dat veel vluchtiger en isomerisatie gevoeliger 
is, omgezet in 3’-deoxy-5’-chloorlacton ((2) in Schema 8.2). In de laatste stap van de synthese, 
de door hydrolyse geinduceerde lactonisatie, is gebruik gemaakt van HCl, wat leidde tot de 
vorming van een 5’-chloorlacton. De invoering van een chloor atoom op de 5’-positie zorgt 
ervoor dat er geen verschil meer gemaakt hoeft te worden tussen 2’- en de 5’-positie, waardoor 
vervolg reacties gemakkelijker uitgevoerd zullen kunnen worden (Schema 8.2).  
Tenslotte, is deze chemische route omgezet naar een chemo-enzymatische route, waarbij een 
stereocentrum op C2 geïntroduceerd wordt. Een algemene procedure is ontwikkeld voor de 
synthese van γ,δ-onverzadigde cyanohydrinen vanuit γ,δ-onverzadigde alcoholen waarbij een 
(geimmobiliseerde) TEMPO/PhI(OAc)2 oxidatie is gecombineerd met een Hevea Brasiliensis 
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hydroxynitrile lyase (HbHNL) gekatalyseerde hydrocyanering. Dit leidde tot hoge ee’s van de 
cyanohydrine producten.  
Om tenslotte het hoofddoel van dit onderzoek te voltooien, de synthese van 
dihydropyrimidine nucleosiden A, is er een model studie uitgevoerd naar de koppeling van 
natuurlijke ribosen aan de in hoofdstuk 3 gesynthetiseerde dihydropyrimidines. Helaas 
leidden tot nut toe, noch de Vorbrüggen condensatie, noch een nucleofiele substitutie tot de 
vorming van de gewenste dihydropyrimidine nucleosiden. Wanneer in de Vorbrüggen 
condensatie echter een overeenkomstig pyrimidine gebruikt werd, leidde dit wel tot de 
vorming van een nucleoside (Schema 8.3). De nucleobase is echter niet verbonden via N1, 
maar via N3 aan de ribose. Bij het gebruik van TMSOTf als Lewis zuur werd afhankelijk 
van de reactietemperatuur ook bijproducten gevormd, een daarvan is een ortho-ester 
(Schema 8.3). Op dit moment worden verder studies uitgevoerd om wel tot de N1 gebonden 































Schema 8.3 Vorbruggen condensatie van pyrimidine met ribose 
Uiteindelijk is er ook een begin gemaakt met de synthese van mureidomycine A. De 
synthese van de verschillende aminozuur bouwstenen van het peptide deel is voltooid. Het 
niet-symmetrisch ureum kon verkregen worden uit de trifosgeen koppeling van m-tyrosine 
met L-methionine. 2-Amino-3-methylaminobutaan zuur (AMBA) kon gesynthetiseerd worden 
via een 6 staps synthese waarbij gestart werd met threonine. De synthese van MRD A staat 
echter nog in de kinderschoenen en in de toekomst zullen de verschillende aminozuren aan 
elkaar gekoppeld moeten worden. De verwachting is dat dit gedaan kan worden via 
standaard peptide koppelingen. Tenslotte, wordt op dit moment onderzocht hoe de enamide 
binding in MRD A het beste gesynthetiseerd kan worden, waarmee de totaalsynthese van 
MRD A steeds dichterbij komt.     
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En dan zitten de vier jaar er al weer op! Daarover een boekje schrijven is een hele klus, 
maar het meest gelezen deel schrijven zonder typefouten en niemand te vergeten is ook niet 
gemakkelijk. Want alleen had ik dit niet allemaal kunnen doen. 
Ten eerste Romano, ontzettend bedankt dat je me de kans gegeven hebt om bij jou te 
promoveren. Mijn schrijfkamer voor die van jou, maakte een babbeltje over het werk, vrije 
tijd enz. erg gemakkelijk. Altijd stond je deur voor me open, ook naarmate je meer 
promovendi kreeg en dus ook de tijd schaarser werd. Na een overleg met jou, wilde ik altijd 
meteen alles proberen wat we besproken hadden. Je stimulerende adviezen en enthousiasme 
hebben gezorgd dat ik veel geleerd heb en ik een hele leuke tijd heb gehad bij jou. Prof. 
Marinus Groen, wat ontzettend fijn dat u bij ons kwam als bijzonder hoogleraar. Tijdens 
werkbesprekingen waren uw suggesties vaak erg nuttig en droegen wezenlijk bij aan het 
vervolg van het onderzoek. Ik ben erg blij dat u nu mijn promotor bent en dat u met uw 
nauwkeurigheid mijn manuscripten gecontroleerd heeft.   
De heren van de lees- en/of promotiecommissie, prof.dr. F. Bickelhaupt, prof.dr. G. van 
der Marel, dr. U. Hanefeld en dr. R. Pieters, bedankt voor jullie correctie van mijn 
proefschrift en de aanwezigheid tijdnes de verdediging. In addition, the foreign referees, 
prof.dr. O. Kappe and Dr. M. Elliott thank you for reading and correcting this thesis.  
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proefschrift. Rob, dankjewel voor al je hulp bij het zoeken naar en opbouwen van de meest 
ongebruikelijke opstellingen en de analyse van menig HPLC monster. Je gezellige lach en 
discussies en anekdotes (vroeger….) tijdens de koffiepauze mis ik nu al! Manoe, tijdens de 
laatste periode van mijn promotie werden jouw hand- en spandiensten veelvuldig gebruikt 
en daardoor zijn de laatste details van twee publicaties uitgewerkt. Ontzettend bedankt voor 
de synthese van verschillende thiazines, dihydropyrimidine-2-thionen en lactonen. Frans, 
voor jouw nauwkeurige analyse van vele NMR samples, met name op het einde de 
nucleosiden, ben ik je zeer erkentelijk. Heel erg bedankt! Marek, bedankt dat je mijn 
HRMS samples altijd zo snel kon meten. En tenslotte de secretaresses, ten eerste Judith: 
voor van alles kon ik bij je terecht. Zelfs voor heerlijk eten bij jou thuis! Het stokje werd na 
Judith overgenomen door Miep, jouw hulp met name bij het printen van het manuscript 
voor de leescommissie heb ik zeer gewaardeerd. 
Naast de hulp “binnenshuis” zijn de verschillende samenwerkingen ook zeer vruchtbaar 
geweest. Lars en Ulf, bedankt voor jullie goede samenwerking. Jullie expertise hebben we 
uiteindelijk toegepast in de synthese van de 3’-deoxylacton. Oliver and Toma, thank you 
very much for the great collaboration on the thiazine-dihydropyrimidinethiones 
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rearrangement of chapter 4. Within a very short period a nice paper was written, although 
Toma and I had never met before. Carel, helaas heeft onze samenwerking tot nu toe niet tot 
een publicatie geleid, maar hopelijk is er in de toekomst weer mankracht om het toch nog 
op te pakken.     
Ook de vele studenten die voorbij gekomen zijn, wil ik natuurlijk hartelijk bedanken 
voor hun bijdrage aan dit onderzoek. Bastian, mijn eerste student toen ik zelf nog maar drie 
maanden aio was. Het begeleiden heb ik door/met jou kunnen leren. Altijd in voor een 
gezellig praatje, borrel bezoeken en dan met name de BBB met kasteelbier… Sander, van te 
voren was ik voor je gewaarschuwd, omdat je tijdens het practicum niet altijd de meest 
handige zou zijn geweest. Hier heb ik niets van gemerkt en je hebt je bij mij in drie 
maanden voorbereid op je buitenlandse stage in Berlijn. Helen, jij hebt aan een zijproject, 
de synthese van de bouwstenen van mureidomycine A, gewerkt. In de synthese van 
AMBA, zoals in hoofdstuk 7 beschreven, bleek achteraf dat we de verkeerde keuzes hebben 
gemaakt. Gelukkig was de synthese van het niet-symmetrisch ureum succesvoller… Veel 
succes met je eigen promotieonderzoek! Renske, een ijverige student die wist wat ze deed! 
Je hebt dan ook een wezenlijke bijdrage geleverd aan de synthese van het 3’-deoxylacton 
zoals beschreven in hoofdstuk 6. Anass, je bleef maar terugkomen, ook al was ik 
vertrokken bij OAC. Twee keer heb je bij mij stage gelopen, nu bij Rachel om maar liefs 
twee Master diploma’s te behalen. Het was altijd erg gezellig met je op het lab, want wat 
kan jij kletsen zeg! Michiel, drie vrouwen op een lab en een vierde erbij, dan zou toch echt 
een te groot kippenhok worden. En dus kwam jij bij mij stage lopen, nou toen was het 
kippenhok op zijn hoogtepunt! Helaas werden de oorspronkelijke drie maanden wat langer, 
desondanks heb je het met succes afgerond. Kanar, hoofdstuk 5 van dit proefschrift is 
grotendeels jouw werk. Samen cyanohydrine reacties doen, zorgde voor een hele dag 
keihard werken met een resultaat dat er mag wezen. Samen met Marien moest je op het 
eind een zuurkast delen en dat deden jullie op geheel eigen wijze. Een streep door het 
midden van de zuurkast met daarnaast een bufferzone! Stond er iets in de bufferzone dan 
werd dat wel duidelijk gemaakt aan de ander. Marien, last but not least… Je kreeg een van 
de moeilijkste projecten, maar aan het eind van je stage zei je dat je wel een potje met 
mureidomycine A op mijn bureau zou zetten. Helaas is het niet zover gekomen….  
Naast studenten, waren er ook de vele collega’s die mijn promotietijd erg aangenaam 
maakten. Robin, Bas en Mieke, samen hebben we vele keren op een borrel op de VU, in de 
stad of bij een van ons thuis een of meerdere drankjes gedronken. Een ontzettend leuke tijd 
waarvan ik erg heb genoten. Robin, altijd was het gezellig met je, en voor menig vrouw ook 
wel gevaarlijk… Bas met jou heb ik menig keer bij Achmed gezeten (na een borrel) om 
toch maar telkens weer te proberen of ze nu wel sito-sticks hadden. Mieke, een paar jaar 
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geleden stond ik naast jou als paranimf, nu ben ik zelf aan de beurt. Wat is dat snel gegaan. 
Nu toch wel fijn om te weten wat er straks gaat gebeuren. Rachel, je zit nog niet zo lang bij 
OAC, maar ondertussen kennen we elkaar al aardig! Samen (elke week) sporten op de VU 
bevalt me erg goed en wat mij betreft kunnen we dit nog wel even volhouden! Maurice, een 
bezig bijtje naast het werk, waar ik ook van heb mogen genieten in Paradiso. Was erg gaaf! 
Andre, ook al zat je bij prof. Lammertsma, toch heb ik je in de afgelopen jaren goed leren 
kennen. De schrijfperiode heb ik nl. bij jou op de kamer doorgebracht. De schrijfmomenten 
en onze word-micropauzes vormden een goede omgeving om dit proefschrift af te maken. 
Niels, bedankt dat jij wel handig bent met computers. Het omzetten van mijn word-
documenten naar PDF was voor jou geen probleem. Ook de andere collega’s en studenten 
van de bio-organische en fosforgroep ontzettend bedankt voor jullie bijdrage aan de 
gezelligheid op de vakgroep: prof. Lammertsma, Marius, Andreas, Alessia, Lisette, 
Monica, Guido, Bart, Bart, Edith, Erik, Chris, Mark, Helen, Rosa, Fedor, Arjan, Bas de J, 
Sander, Niels, Wannes, en iedereen die ik nog vergeten ben!  
Naast het werk was er ook nog een ander leven, al stond dat de laatste periode wat op 
een laag pitje! Meiden uit “Helvoirt” het is altijd gezellig om met (een van) jullie weer af te 
spreken en bij te kletsen. Lin, ik vind het ontzettend fijn om jou als paranimf naast me te 
hebben. Ook al zien en spreken we elkaar niet meer zo vaak als vroeger, toch betekent onze 
vriendschap nog steeds ontzettend veel voor mij! Viva-vriendinnen, ook met jullie is het 
altijd weer gezellig om samen op pad te gaan en een keer per jaar op kamp te gaan. Dit jaar 
kwam het alleen wat ongelukkig uit, maar gelukkig is het allemaal goed afgelopen en ligt 
dit boekje nu voor je. Anette, dankjewel dat je mee hebt gedacht over de omslag van mijn 
boekje en je op het laatste toch nog even wat hebt veranderd.  
Hans en Marij, dankjewel voor jullie interesse en gezelligheid bij jullie thuis! Pap & 
mam, Debby & Jack, bedankt voor jullie steun, interesse en liefde. Mam, volgens mij weet 
jij vaak nog beter dan ik wat ik zou moeten doen. Deb, ook jij, mijn (kleine) zusje als 
paranimf naast me, betekent heel veel voor me.  
En tenslotte, lieve Remco, wat ontzettend blij ben ik met je. Waar een symposium toch 
al niet goed voor is geweest. Jouw relativeringsvermogen heeft me vaak aan het nadenken 
gezet en me geholpen om de juiste beslissingen te nemen. Dankjewel voor je liefde en 











De auteur van dit proefschrift werd geboren op 30 augustus 1979 te Tilburg. Na het 
behalen van het Atheneum diploma in juni 1997 aan het Maurick College te Vught, werd 
begonnen met een studie Chemie aan de Hogeschool West Brabant in Etten-Leur. Van 
februari 2000 tot oktober 2000 werd in het kader van stage/afstuderen en doorstuderen aan 
de Vrije Universiteit onderzoek gedaan bij de sectie organische en anorganische chemie 
(prof.dr. K. Lammertsma) van de Vrije Universiteit naar de reactie van fosfinidenen met 
imines.  
Na het afleggen van het ingenieurs examen in februari 2001 werd de studie Scheikunde 
voortgezet aan de Vrije Universiteit te Amsterdam. Van augustus 2001 tot januari 2002 
werd tijdens een hoofdvakstage onderzoek gedaan aan de Westfälische-Wilhelms 
Universität Münster (prof.dr. G. Erker) op het gebied van  zirkonium-fosfor chemie. Het 
doctoraal examen werd in mei 2002 behaald. In diezelfde maand werd gestart met het 
promotieonderzoek in de Bio-Organische Synthese onder leiding van dr. ir. R. V. A. Orru 
en later prof.dr. M. B. Groen, hetgeen heeft geresulteerd in het voor u gelegen proefschrift. 
Tijdens deze periode van vier jaar werden de behaalde resultaten gepresenteerd op 
nationale en internationale congressen in binnen- en buitenland, zoals het 2nd Multi 
Component Reaction conference in Genua, Italië en Biotrans in Delft, Nederland. Vanaf 
augustus 2006 is Danielle werkzaam als post-doc bij het radionucliden centrum en de KNO 
afdeling van het VUmc (prof.dr. G. A. M. S. van Dongen) in samenwerking met Philips.      
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